England and Wales
|
98‑1373159
|
(State or other jurisdiction
|
(I.R.S. Employer Identification No.)
|
of incorporation or organization)
|
|
Title of each class
|
|
Name of each exchange on which registered
|
Ordinary Shares, $0.001 Par Value per Share
|
|
New York Stock Exchange
|
Large accelerated
filer
þ
|
Accelerated
filer
¨
|
Non-accelerated
filer
¨
|
Smaller reporting
company
¨
|
Emerging growth
company
¨
|
|
|
Page
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
•
|
volatile global economic conditions;
|
•
|
cyclical and volatile TiO
2
product applications;
|
•
|
highly competitive industries and the need to innovate and develop new products;
|
•
|
our ability to successfully transfer production of certain specialty and differentiated products from our Pori, Finland manufacturing facility to other sites within our manufacturing network;
|
•
|
economic conditions and regulatory changes following the likely exit of the United Kingdom (the “U.K.”) from the EU;
|
•
|
increased manufacturing regulations for some of our products, including the outcome of the pending potential classification of TiO
2
as a carcinogen in the European Union (“EU”) or any increased regulatory scrutiny;
|
•
|
disruptions in production at our manufacturing facilities and our ability to cover resulting costs, including construction costs, and lost revenue with insurance proceeds;
|
•
|
fluctuations in currency exchange rates and tax rates;
|
•
|
price volatility or interruptions in supply of raw materials and energy;
|
•
|
our ability to realize financial and operational benefits from our business improvement plans and initiatives;
|
•
|
changes to laws, regulations or the interpretation thereof;
|
•
|
significant investments associated with efforts to transform our business;
|
•
|
differences in views with our joint venture participants;
|
•
|
high levels of indebtedness;
|
•
|
EHS laws and regulations;
|
•
|
our ability to obtain future capital on favorable terms;
|
•
|
seasonal sales patterns in our product markets;
|
•
|
our ability to successfully defend legal claims against us, or to pursue legal claims against third parties;
|
•
|
our ability to adequately protect our critical information technology systems;
|
•
|
our ability to comply with expanding data privacy regulations;
|
•
|
failure to maintain effective internal controls over financial reporting and disclosure;
|
•
|
our indemnification of Huntsman and other commitments and contingencies;
|
•
|
financial difficulties and related problems experienced by our customers, vendors, suppliers and other business partners;
|
•
|
failure to enforce our intellectual property rights;
|
•
|
our ability to effectively manage our labor force;
|
•
|
conflicts, military actions, terrorist attacks and general instability; and
|
•
|
our ability to realize the expected benefits of our separation from Huntsman.
|
|
|
Rutile TiO
2
|
|
Anatase TiO
2
|
|
Nano TiO
2
|
Characteristics
|
|
Most common form of TiO
2
. Harder and more durable crystal
|
|
Softer, less abrasive pigment, preferred for some specialty applications
|
|
Very small particles of either rutile or anatase TiO
2
(typically less than 100nm in diameter)
|
Applications
|
|
Coatings, printing inks, PVC window frames, plastic masterbatches
|
|
Cosmetics, pharmaceuticals, food, polyester fibers, polyamide fibers
|
|
Catalysts and cosmetics
|
|
|
Barium and Zinc Additives
|
Characteristics
|
|
Specialty pigments and fillers based on barium and zinc chemistry
|
Applications
|
|
Coatings, films, paper and glass fiber reinforced plastics
|
|
|
Iron Oxides
|
|
Ultramarines
|
|
Specialty Inorganic
Chemicals
|
|
Driers
|
Characteristics
|
|
Powdered, granulated or in liquid form are synthesized using a range of feedstocks
|
|
Range of ultramarine blue and violet and also manganese violet pigments
|
|
Complex inorganic pigments and cadmium pigments
|
|
A range of metal carboxylates and driers
|
Applications
|
|
Construction, coatings, plastics, cosmetics, inks, catalyst and laminates
|
|
Predominantly used in plastics, coatings and cosmetics
|
|
Coatings, plastics and inks
|
|
Predominantly coatings
|
|
|
Annual Capacity (metric tons)
|
||||||||||
|
|
|
|
North
America
|
|
|
|
|
||||
Product Area
|
|
EAME
(1)
|
|
|
APAC
(2)
|
|
Total
|
|||||
TiO
2
|
|
517,000
|
|
|
75,000
|
|
|
60,000
|
|
|
652,000
|
|
|
|
(1)
|
“EAME” refers to Europe, Africa and the Middle East.
|
(2)
|
“APAC” refers to the Asia-Pacific region including India.
|
|
|
Annual Capacity (metric tons)
|
||||||||||||
|
|
|
|
North
America
|
|
|
|
|
|
|
||||
Site
|
|
EAME
(1)
|
|
|
APAC
|
|
Total
|
|
Process
|
|||||
Greatham, U.K.
|
|
150,000
|
|
|
|
|
|
|
|
|
150,000
|
|
|
Chloride TiO
2
|
Uerdingen, Germany
|
|
107,000
|
|
|
|
|
|
|
|
|
107,000
|
|
|
Sulfate TiO
2
|
Duisburg, Germany
|
|
100,000
|
|
|
|
|
|
|
|
|
100,000
|
|
|
Sulfate TiO
2
|
Huelva, Spain
|
|
80,000
|
|
|
|
|
|
|
|
|
80,000
|
|
|
Sulfate TiO
2
|
Scarlino, Italy
|
|
80,000
|
|
|
|
|
|
|
|
|
80,000
|
|
|
Sulfate TiO
2
|
Lake Charles, Louisiana
(2)
|
|
|
|
|
75,000
|
|
|
|
|
|
75,000
|
|
|
Chloride TiO
2
|
Teluk Kalung, Malaysia
|
|
|
|
|
|
|
|
60,000
|
|
|
60,000
|
|
|
Sulfate TiO
2
|
Total
|
|
517,000
|
|
|
75,000
|
|
|
60,000
|
|
|
652,000
|
|
|
|
|
|
(1)
|
Excludes a sulfate plant in Umbogintwini, South Africa, which closed in the fourth quarter of 2016, our TiO
2
finishing plant in Calais, France which was closed in the fourth quarter of 2017, and our TiO
2
plant in Pori, Finland, closure of which was announced in the third quarter of 2018 and which currently has an annual finishing capacity of up to 25,000 metric tons.
|
(2)
|
This facility is owned and operated by Louisiana Pigment Company L.P. (“LPC”), a manufacturing joint venture that is owned 50% by us and 50% by Kronos Worldwide, Inc. (“Kronos”). The capacity shown reflects our 50% interest in LPC.
|
|
|
Annual Capacity (metric tons)
|
||||||||||
|
|
|
|
North
America
(1)
|
|
|
|
|
||||
Product Area
|
|
EAME
|
|
|
APAC
|
|
Total
|
|||||
Functional additives
|
|
100,000
|
|
|
|
|
|
|
100,000
|
|
||
Color pigments
|
|
85,000
|
|
|
40,000
|
|
|
20,000
|
|
|
145,000
|
|
Timber treatment
|
|
|
|
|
140,000
|
|
|
|
|
|
140,000
|
|
Water treatment
|
|
140,000
|
|
|
|
|
|
|
|
|
140,000
|
|
Total
|
|
325,000
|
|
|
180,000
|
|
|
20,000
|
|
|
525,000
|
|
|
|
(1)
|
Excludes color pigments plants in St. Louis, Missouri, Easton, Pennsylvania, and Beltsville, Maryland which were closed in the fourth quarter of 2017, second quarter of 2018, and fourth quarter of 2018, respectively.
|
|
|
Functional
Additives
|
|
Color Pigments
|
|
Timber
Treatment
|
|
Water
Chemicals
|
Primary raw materials
|
|
Barium and zinc based inorganics
|
|
Iron oxide particles, scrap iron, copperas, alkali
|
|
DCOIT, copper, monoethanolamine
|
|
Aluminum oxide
|
Name
|
|
Age
|
|
Position(s) at Venator
|
Simon Turner
|
|
55
|
|
President and Chief Executive Officer
|
Kurt Ogden
|
|
50
|
|
Executive Vice President and Chief Financial Officer
|
Russ Stolle
|
|
56
|
|
Executive Vice President, General Counsel and Chief Compliance Officer
|
Mahomed Maiter
|
|
57
|
|
Executive Vice President, Business Operations
|
Rob Portsmouth
|
|
53
|
|
Senior Vice President, EHS, Innovation and Technology
|
•
|
in the event of new customs operations being implemented, there is a strong likelihood of border delays both within and outside of the U.K.;
|
•
|
duties will become payable on goods traded between the U.K. and the EU, and customs, excise and indirect tax procedures will change to those currently applicable to goods traded between the EU and non-EU countries;
|
•
|
transportation availability is expected to be impacted for a period, especially if there are delays at borders between the U.K. and EU; and
|
•
|
new product registration requirements are expected to apply.
|
•
|
diversion of management time and attention away from existing operations;
|
•
|
requiring capital investment that could otherwise be used for the operation and growth of our existing businesses;
|
•
|
disruptions to important business relationships;
|
•
|
increased operating costs;
|
•
|
limitations imposed by various governmental entities;
|
•
|
use of limited investment and other baskets under our debt covenants;
|
•
|
difficulties realizing projected synergies;
|
•
|
difficulties due to lack of or limited prior experience in any new markets we may enter; and
|
•
|
difficulty integrating acquired businesses or products with our existing businesses.
|
•
|
we may be more vulnerable to business, industry or economic downturns, making it more difficult to respond to market conditions;
|
•
|
cash flow available for other purposes, including the growth of our business, may be reduced;
|
•
|
our ability to refinance or obtain additional financing may be constrained, particularly during periods when the capital markets are unsettled;
|
•
|
our competitors with lower debt levels may have a competitive advantage relative to us; and
|
•
|
part of our debt is subject to variable interest rates, which makes us more vulnerable to increases in interest rates (for example, assuming all commitments were available and all loans under the ABL Facility were fully drawn, a 1% increase in interest rates, without giving effect to interest rate hedges or other offsetting items, would increase our annual interest rate expense by approximately $6 million).
|
•
|
the failure of securities analysts to cover our ordinary shares or changes in financial estimates by analysts;
|
•
|
our inability to meet the financial estimates of analysts who follow our ordinary shares;
|
•
|
our strategic actions;
|
•
|
our announcements of significant contracts, acquisitions, joint ventures or capital commitments;
|
•
|
general economic and stock market conditions;
|
•
|
changes in conditions or trends in our industry, markets or customers;
|
•
|
future sales of our ordinary shares or other securities; and
|
•
|
investor perceptions of the investment opportunity associated with our ordinary shares relative to other investment alternatives.
|
Location
(2)
|
|
Business
Segment
(4)
|
|
Description of Facility
|
Duisburg, Germany
|
|
Various
|
|
TiO
2
, Functional Additives, Water Treatment Manufacturing and Research Facility and Administrative Offices
|
Greatham, U.K.
|
|
TiO
2
|
|
TiO
2
Manufacturing Facility
|
Huelva, Spain
|
|
TiO
2
|
|
TiO
2
Manufacturing Facility
|
Lake Charles, Louisiana
(3)
|
|
TiO
2
|
|
TiO
2
Manufacturing Facility
|
Pori, Finland
(5)
|
|
TiO
2
|
|
TiO
2
Manufacturing Facility
|
Scarlino, Italy
|
|
TiO
2
|
|
TiO
2
Manufacturing Facility
|
Teluk Kalung, Malaysia
(1)
|
|
TiO
2
|
|
TiO
2
Manufacturing Facility
|
Uerdingen, Germany
(1)
|
|
TiO
2
|
|
TiO
2
Manufacturing Facility
|
Augusta, Georgia
|
|
Additives
|
|
Color Pigments Manufacturing Facility
|
Birtley, U.K.
|
|
Additives
|
|
Color Pigments Manufacturing Facility
|
Comines, France
|
|
Additives
|
|
Color Pigments Manufacturing Facility
|
Dandenong, Australia
(1)
|
|
Additives
|
|
Color Pigments Manufacturing Facility
|
Freeport, Texas
|
|
Additives
|
|
Timber Treatments Manufacturing Facility
|
Harrisburg, North Carolina
|
|
Additives
|
|
Timber Treatments Manufacturing Facility
|
Ibbenbueren, Germany
(1)
|
|
Additives
|
|
Water Treatment Manufacturing Facility
|
Kidsgrove, U.K.
|
|
Additives
|
|
Color Pigments Manufacturing Facility
|
Los Angeles, California
|
|
Additives
|
|
Color Pigments Manufacturing Facility
|
Schwarzheide, Germany
(1)
|
|
Additives
|
|
Water Treatment Manufacturing Facility
|
Sudbury, U.K.
|
|
Additives
|
|
Color Pigments Manufacturing Facility
|
Taicang, China
|
|
Additives
|
|
Color Pigments Manufacturing Facility
|
Turin, Italy
|
|
Additives
|
|
Color Pigments Manufacturing Facility
|
Walluf, Germany
(1)
|
|
Additives
|
|
Color Pigments Manufacturing Facility
|
Everberg, Belgium
|
|
Various
|
|
Shared Services Center and Administrative Offices
|
Kuala Lumpur, Malaysia
(1)
|
|
Various
|
|
Shared Services Center and Administrative Offices
|
The Woodlands, Texas
(1)
|
|
Various
|
|
Headquarters & Administrative Offices
|
Wynyard, U.K.
(1)
|
|
Various
|
|
Headquarters & Administrative Offices, Research Facility and Shared Services Center
|
|
|
(1)
|
Leased land and/or building.
|
(2)
|
Excludes plant in Umbogintwini, South Africa, which was closed in the fourth quarter of 2016, plants in St. Louis, Missouri and Calais, France which were both closed in 2017, and plants in Easton, Pennsylvania and Beltsville, Maryland, which were both closed in 2018.
|
(3)
|
Owned by LPC, our unconsolidated manufacturing joint venture which is owned 50% by us and 50% by Kronos.
|
(4)
|
Solely for the purposes of this column, “TiO
2
” and “Additives” represent the Titanium Dioxide and Performance Additives segments, respectively.
|
(5)
|
The Pori, Finland plant closure was announced in the third quarter of 2018 and is anticipated to be completed in 2022.
|
|
|
Total
number of
shares
purchased
(1)
|
|
Average price
paid per
share
(1)
|
|
Total number of
shares purchased
as part of publicly
announced plans
or programs
|
|
Maximum number (or
approximate dollar value) of
shares that may yet be
purchased under the plans or
programs
|
||||||
October
|
|
—
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
—
|
|
November
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||
December
|
|
24,021
|
|
|
4.19
|
|
|
—
|
|
|
—
|
|
||
Total
|
|
24,021
|
|
|
$
|
4.19
|
|
|
—
|
|
|
$
|
—
|
|
|
|
(1)
|
Represents shares purchased from employees to satisfy the tax withholding obligations in connection with the vesting of restricted stock units.
|
(in millions, except per share amounts)
|
|
2018
|
|
2017
|
|
2016
|
|
2015
|
|
2014
|
||||||||||
Statements of Operations Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Revenues
|
|
$
|
2,265
|
|
|
$
|
2,209
|
|
|
$
|
2,139
|
|
|
$
|
2,162
|
|
|
$
|
1,549
|
|
(Loss) income from continuing operations
|
|
(157
|
)
|
|
136
|
|
|
(85
|
)
|
|
(362
|
)
|
|
(171
|
)
|
|||||
(Loss) income per share from continuing operations attributable to Venator ordinary shareholders
|
|
$
|
(1.53
|
)
|
|
$
|
1.19
|
|
|
$
|
(0.89
|
)
|
|
$
|
(3.47
|
)
|
|
$
|
(1.63
|
)
|
Balance Sheet Data (at year end):
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Total assets
|
|
$
|
2,485
|
|
|
$
|
2,847
|
|
|
$
|
2,661
|
|
|
$
|
3,413
|
|
|
$
|
3,933
|
|
Total long-term liabilities
|
|
1,087
|
|
|
1,083
|
|
|
1,309
|
|
|
1,477
|
|
|
1,579
|
|
|||||
Total assets from continuing operations
(1)
|
|
2,485
|
|
|
2,847
|
|
|
2,535
|
|
|
3,205
|
|
|
3,722
|
|
|||||
Total long-term liabilities from continuing operations
(2)
|
|
1,087
|
|
|
1,083
|
|
|
1,231
|
|
|
1,359
|
|
|
1,447
|
|
|
|
(1)
|
Defined as total assets less current assets of discontinued operations and noncurrent assets of discontinued operations.
|
(2)
|
Defined as total long-term liabilities less noncurrent liabilities of discontinued operations.
|
|
Year Ended December 31,
|
|
Percent Change
Year Ended December 31,
|
||||||||||||||
(Dollars in millions)
|
2018
|
|
2017
|
|
2016
|
|
2018 vs. 2017
|
|
2017 vs. 2016
|
||||||||
Revenues
|
$
|
2,265
|
|
|
$
|
2,209
|
|
|
$
|
2,139
|
|
|
3
|
%
|
|
3
|
%
|
Cost of goods sold
|
1,550
|
|
|
1,744
|
|
|
1,989
|
|
|
(11
|
)%
|
|
(12
|
)%
|
|||
Operating expenses
(4)
|
218
|
|
|
226
|
|
|
176
|
|
|
(4
|
)%
|
|
28
|
%
|
|||
Restructuring, impairment and plant closing and transition costs
|
628
|
|
|
52
|
|
|
35
|
|
|
1,108
|
%
|
|
49
|
%
|
|||
Operating (loss) income
|
(131
|
)
|
|
187
|
|
|
(61
|
)
|
|
NM
|
|
|
NM
|
|
|||
Interest expense, net
|
(40
|
)
|
|
(40
|
)
|
|
(44
|
)
|
|
—
|
%
|
|
(9
|
)%
|
|||
Other income (expense)
|
6
|
|
|
39
|
|
|
(3
|
)
|
|
(85
|
)%
|
|
NM
|
|
|||
(Loss) income from continuing operations before income taxes
|
(165
|
)
|
|
186
|
|
|
(108
|
)
|
|
NM
|
|
|
NM
|
|
|||
Income tax benefit (expense) from continuing operations
|
8
|
|
|
(50
|
)
|
|
23
|
|
|
NM
|
|
|
NM
|
|
|||
(Loss) income from continuing operations
|
(157
|
)
|
|
136
|
|
|
(85
|
)
|
|
NM
|
|
|
NM
|
|
|||
Income from discontinued operations, net of tax
|
—
|
|
|
8
|
|
|
8
|
|
|
(100
|
)%
|
|
—
|
%
|
|||
Net (loss) income
|
(157
|
)
|
|
144
|
|
|
(77
|
)
|
|
NM
|
|
|
NM
|
|
|||
Reconciliation of net (loss) income to adjusted EBITDA:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Interest expense, net
|
40
|
|
|
40
|
|
|
44
|
|
|
—
|
%
|
|
(9
|
)%
|
|||
Income tax (benefit) expense from continuing operations
|
(8
|
)
|
|
50
|
|
|
(23
|
)
|
|
NM
|
|
|
NM
|
|
|||
Depreciation and amortization
|
132
|
|
|
127
|
|
|
114
|
|
|
4
|
%
|
|
11
|
%
|
|||
Net income attributable to noncontrolling interests
|
(6
|
)
|
|
(10
|
)
|
|
(10
|
)
|
|
(40
|
)%
|
|
—
|
%
|
|||
Other adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Business acquisition and integration expenses
|
20
|
|
|
5
|
|
|
11
|
|
|
|
|
|
|
|
|||
Separation expense, net
|
2
|
|
|
7
|
|
|
—
|
|
|
|
|
|
|
|
|||
U.S. income tax reform
|
—
|
|
|
(34
|
)
|
|
—
|
|
|
|
|
|
|
|
|||
Net income of discontinued operations, net of tax
|
—
|
|
|
(8
|
)
|
|
(8
|
)
|
|
|
|
|
|
|
|||
Loss (gain) on disposition of businesses/assets
|
2
|
|
|
—
|
|
|
(22
|
)
|
|
|
|
|
|
|
|||
Certain legal settlements and related expenses
|
—
|
|
|
1
|
|
|
2
|
|
|
|
|
|
|
|
|||
Amortization of pension and postretirement actuarial losses
|
15
|
|
|
17
|
|
|
10
|
|
|
|
|
|
|
|
|||
Net plant incident (credits) costs
|
(232
|
)
|
|
4
|
|
|
1
|
|
|
|
|
|
|
|
|||
Restructuring, impairment and plant closing and transition costs
|
628
|
|
|
52
|
|
|
35
|
|
|
|
|
|
|
|
|||
Adjusted EBITDA
(1)
|
$
|
436
|
|
|
$
|
395
|
|
|
$
|
77
|
|
|
10
|
%
|
|
413
|
%
|
|
|
|
|
|
|
|
|
|
|
||||||||
Net cash provided by operating activities from continuing operations
|
282
|
|
|
337
|
|
|
80
|
|
|
(16
|
)%
|
|
321
|
%
|
|||
Net cash used in investing activities from continuing operations
|
(321
|
)
|
|
(11
|
)
|
|
(96
|
)
|
|
2,818
|
%
|
|
(89
|
)%
|
|||
Net cash (used in) provided by financing activities from continuing operations
|
(18
|
)
|
|
(123
|
)
|
|
32
|
|
|
(85
|
)%
|
|
NM
|
|
|||
Capital expenditures
|
(326
|
)
|
|
(197
|
)
|
|
(103
|
)
|
|
65
|
%
|
|
91
|
%
|
|
Year Ended
December 31, 2018 |
|
Year Ended
December 31, 2017 |
|
Year Ended
December 31, 2016 |
||||||||||||||||||||||||
(Dollars in millions)
|
Gross
|
|
Tax
(3)
|
|
Net
|
|
Gross
|
|
Tax
(3)
|
|
Net
|
|
Gross
|
|
Tax
(3)
|
|
Net
|
||||||||||||
Reconciliation of net (loss) income to adjusted net income (loss) attributable to Venator Materials PLC ordinary shareholders:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Net (loss) income
|
|
|
|
|
$
|
(157
|
)
|
|
|
|
|
|
$
|
144
|
|
|
|
|
|
|
$
|
(77
|
)
|
||||||
Net income attributable to noncontrolling interests
|
|
|
|
|
(6
|
)
|
|
|
|
|
|
(10
|
)
|
|
|
|
|
|
(10
|
)
|
|||||||||
Other adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Business acquisition and integration expenses
|
20
|
|
|
(3
|
)
|
|
17
|
|
|
5
|
|
|
(2
|
)
|
|
3
|
|
|
11
|
|
|
(5
|
)
|
|
6
|
|
|||
Separation expense, net
|
2
|
|
|
—
|
|
|
2
|
|
|
7
|
|
|
—
|
|
|
7
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||
U.S. income tax reform
|
—
|
|
|
—
|
|
|
—
|
|
|
(34
|
)
|
|
16
|
|
|
(18
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|||
Significant changes to income tax valuation allowances
(3)
|
—
|
|
|
(5
|
)
|
|
(5
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||
Net income of discontinued operations
|
—
|
|
|
—
|
|
|
—
|
|
|
(11
|
)
|
|
3
|
|
|
(8
|
)
|
|
(9
|
)
|
|
1
|
|
|
(8
|
)
|
|||
Loss (gain) on disposition of businesses/assets
|
2
|
|
|
—
|
|
|
2
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(22
|
)
|
|
5
|
|
|
(17
|
)
|
|||
Certain legal settlements and related expenses
|
—
|
|
|
—
|
|
|
—
|
|
|
1
|
|
|
—
|
|
|
1
|
|
|
2
|
|
|
(1
|
)
|
|
1
|
|
|||
Amortization of pension and postretirement actuarial losses
|
15
|
|
|
—
|
|
|
15
|
|
|
17
|
|
|
—
|
|
|
17
|
|
|
10
|
|
|
—
|
|
|
10
|
|
|||
Net plant incident (credits) costs
|
(232
|
)
|
|
47
|
|
|
(185
|
)
|
|
4
|
|
|
(1
|
)
|
|
3
|
|
|
1
|
|
|
(1
|
)
|
|
—
|
|
|||
Restructuring, impairment and plant closing and transition costs
|
628
|
|
|
(76
|
)
|
|
552
|
|
|
52
|
|
|
(5
|
)
|
|
47
|
|
|
35
|
|
|
(7
|
)
|
|
28
|
|
|||
Adjusted net income (loss) attributable to Venator Materials PLC ordinary shareholders
(2)
|
|
|
|
|
|
|
$
|
235
|
|
|
|
|
|
|
$
|
186
|
|
|
|
|
|
|
$
|
(67
|
)
|
||||
Weighted-average shares-basic
|
|
|
|
|
106.4
|
|
|
|
|
|
|
106.3
|
|
|
|
|
|
|
106.3
|
|
|||||||||
Weighted-average shares-diluted
|
|
|
|
|
106.7
|
|
|
|
|
|
|
106.7
|
|
|
|
|
|
|
106.3
|
|
|||||||||
Net (loss) income attributable to Venator Materials PLC ordinary shareholders per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Basic
|
|
|
|
|
$
|
(1.53
|
)
|
|
|
|
|
|
$
|
1.26
|
|
|
|
|
|
|
$
|
(0.82
|
)
|
||||||
Diluted
|
|
|
|
|
$
|
(1.53
|
)
|
|
|
|
|
|
$
|
1.26
|
|
|
|
|
|
|
$
|
(0.82
|
)
|
||||||
Other non-GAAP measures:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Adjusted net income (loss) attributable to Venator Materials PLC ordinary shareholders per share:
(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Basic
|
|
|
|
|
$
|
2.21
|
|
|
|
|
|
|
$
|
1.75
|
|
|
|
|
|
|
$
|
(0.63
|
)
|
||||||
Diluted
|
|
|
|
|
$
|
2.20
|
|
|
|
|
|
|
$
|
1.74
|
|
|
|
|
|
|
$
|
(0.63
|
)
|
|
|
(1)
|
Our management uses adjusted EBITDA to assess financial performance. Adjusted EBITDA is defined as net (loss) income before interest expense, net, income tax benefit (expense) from continuing operations, depreciation and amortization, and net income attributable to noncontrolling interests, as well as eliminating the following adjustments: (a) business acquisition and integration expenses; (b) separation expense, net; (c) U.S. income tax reform; (d) net income of discontinued operations, net of tax; (e) loss (gain) on disposition of businesses/assets; (f) certain legal settlements and related expenses; (g) amortization of pension and postretirement actuarial losses; (h) net plant incident (credits) costs; and (i) restructuring, impairment and plant closing and transition costs. We believe that net income is the performance measure calculated and presented in accordance with U.S. GAAP that is most directly comparable to adjusted EBITDA.
|
(2)
|
Adjusted net income (loss) attributable to Venator Materials PLC ordinary shareholders is computed by eliminating the after-tax amounts related to the following from net income attributable to Venator Materials PLC ordinary shareholders: (a) business acquisition and integration expenses; (b) separation expense, net; (c) U.S. income tax reform; (d) significant changes to income tax valuation allowances; (e) net income of discontinued operations; (f) loss (gain) on disposition of businesses/assets; (g) certain legal settlements and related expenses; (h) amortization of pension and postretirement actuarial losses; (i) net plant incident (credits) costs; (j) restructuring, impairment and plant closing and transition costs. Basic adjusted net income (loss) per share excludes dilution and is computed by dividing adjusted net income (loss) by the weighted average number of shares outstanding during the period. Adjusted diluted net income (loss) per share reflects all potential dilutive ordinary shares outstanding during the period increased by the number of additional shares that would have been outstanding as dilutive securities. For the periods prior to our IPO, the average number of ordinary shares outstanding used to calculate basic and diluted adjusted net income (loss) per share was based on the ordinary shares that were outstanding at the time of our IPO.
|
(3)
|
The income tax impacts, if any, of each adjusting item represent a ratable allocation of the total difference between the unadjusted tax expense and the total adjusted tax expense, computed without consideration of any adjusting items using a with and without approach. We eliminated the effect of significant changes to income tax valuation allowances from our presentation of adjusted net income to allow investors to better compare our ongoing financial performance from period to period. We do not adjust for insignificant changes in tax valuation allowances because we do not believe it provides more meaningful information than is provided under U.S. GAAP.
|
(4)
|
As presented within Item 7, operating expense includes selling. general and administrative expenses and other operating expense (income), net.
|
•
|
Revenues for the year ended
December 31, 2018
increased by
$56 million
, or
3%
, as compared with the same period in
2017
. The increase was due to a
$62 million
, or
4%
, increase in revenue in our Titanium Dioxide segment primarily due to an increase in average selling price, partially offset by a
$6 million
, or
1%
, decrease in revenue in our Performance Additives segment due primarily to decreases in volumes. See “—Segment Analysis” below.
|
•
|
Our operating expenses for the year ended
December 31, 2018
decreased by
$8 million
, or
4%
, as compared to the same period in
2017
, primarily resulting from reduced overhead costs.
|
•
|
Restructuring, impairment and plant closing and transition costs for the year ended
December 31, 2018
increased to
$628 million
from
$52 million
for the same period in
2017
. For more information concerning restructuring activities, see “Part II. Item 8. Financial Statements and Supplementary Data—
Note 12. Restructuring, Impairment and Plant Closing and Transition Costs
” of this report.
|
•
|
Other income for the year ended
December 31, 2018
decreased by
$33 million
primarily as a result of the recognition of income in 2017 related to the change in the future payment to Huntsman pursuant to the tax matters agreement entered into as part of our separation. The change in future expected payment was due to the 2017 Tax Act’s reduction of the U.S. federal corporate income tax rate from 35% to 21%.
|
•
|
Our income tax benefit for the year ended
December 31, 2018
was
$8 million
compared to
$50 million
of income tax expense for the same period in
2017
. Our income tax expense is significantly affected by the mix of income and losses in the tax jurisdictions in which we operate, as impacted by the presence of valuation allowances in certain tax jurisdictions. For further information concerning taxes, see “Part II. Item 8. Financial Statements and Supplementary Data—
Note 19. Income Taxes
” of this report.
|
|
|
Year Ended
December 31, |
|
Percent
Change Favorable (Unfavorable) |
|||||||
(in millions)
|
|
2018
|
|
2017
|
|
||||||
Revenues
|
|
|
|
|
|
|
|
|
|
||
Titanium Dioxide
|
|
$
|
1,666
|
|
|
$
|
1,604
|
|
|
4
|
%
|
Performance Additives
|
|
599
|
|
|
605
|
|
|
(1
|
)%
|
||
Total
|
|
$
|
2,265
|
|
|
$
|
2,209
|
|
|
3
|
%
|
Segment adjusted EBITDA
|
|
|
|
|
|
|
|||||
Titanium Dioxide
|
|
$
|
417
|
|
|
$
|
387
|
|
|
8
|
%
|
Performance Additives
|
|
62
|
|
|
72
|
|
|
(14
|
)%
|
||
Corporate and other
|
|
(43
|
)
|
|
(64
|
)
|
|
33
|
%
|
||
Total
|
|
$
|
436
|
|
|
$
|
395
|
|
|
10
|
%
|
|
Year Ended December 31, 2018 vs. 2017
|
||||||||||
|
Average Selling
Price
(1)
|
|
|
|
|
||||||
|
Local
Currency
|
|
Foreign
Currency
Translation
Impact
|
|
Mix &
Other
|
|
Sales
Volumes
(2)
|
||||
Period-Over-Period Increase (Decrease)
|
|
|
|
|
|
|
|
|
|
|
|
Titanium Dioxide
|
13
|
%
|
|
3
|
%
|
|
1
|
%
|
|
(13
|
)%
|
Performance Additives
|
3
|
%
|
|
2
|
%
|
|
(2
|
)%
|
|
(4
|
)%
|
|
|
(1)
|
Excludes revenues from tolling arrangements, by-products and raw materials.
|
(2)
|
Excludes sales volumes of by-products and raw materials.
|
•
|
Revenues for the year ended December 31, 2017 increased by $70 million, or 3%, as compared with the same period in 2016. The increase was due to a $50 million, or 3%, increase in revenue in our Titanium Dioxide segment primarily due to increases in selling price, and a $20 million, or 3%, increase in revenue in our Performance Additives segment due to increases in selling price and volumes. See “—Segment Analysis” below.
|
•
|
Our operating expenses for the year ended December 31, 2017 increased by $50 million, or 28%, as compared to the same period in 2016, primarily as a result of a $23 million gain on disposals of businesses and a $6 million gain from an insurance recovery in 2016, both of which were non-recurring. In addition, $14 million of incremental costs related to our separation from Huntsman were incurred during 2017, along with $6 million of unfavorable foreign currency exchange losses. These increases were partially offset by $6 million in savings from our restructuring programs.
|
•
|
Restructuring, impairment and plant closing and transition costs for the year ended December 31, 2017 increased to $52 million from $35 million for the same period in 2016. For more information concerning restructuring activities, see “Part II. Item 8. Financial Statements and Supplementary Data—Note 12. Restructuring, Impairment and Plant Closing and Transition Costs” of this report.
|
•
|
Other income for the year ended December 31, 2017 increased by $42 million primarily as a result of the change in the future expected payment to Huntsman pursuant to the tax matters agreement entered into as part of our separation. The change in future expected payment is due to the 2017 Tax Act’s reduction of the U.S. federal corporate income tax rate from 35% to 21%.
|
•
|
Our income tax expense for the year ended December 31, 2017 increased to $50 million from a $23 million income tax benefit for the same period in 2016. Our income tax expense is significantly affected by the mix of income and losses in the tax jurisdictions in which we operate, as impacted by the presence of valuation allowances in certain tax jurisdictions. For further information concerning taxes, see “Part II. Item 8. Financial Statements and Supplementary Data—Note 19. Income Taxes” of this report.
|
|
|
Year
Ended
December 31,
|
|
Percent
Change
Favorable
(Unfavorable)
|
|||||||
(in millions)
|
|
2017
|
|
2016
|
|
||||||
Revenues
|
|
|
|
|
|
|
|
|
|
||
Titanium Dioxide
|
|
$
|
1,604
|
|
|
$
|
1,554
|
|
|
3
|
%
|
Performance Additives
|
|
605
|
|
|
585
|
|
|
3
|
%
|
||
Total
|
|
$
|
2,209
|
|
|
$
|
2,139
|
|
|
3
|
%
|
Segment adjusted EBITDA
|
|
|
|
|
|
|
|||||
Titanium Dioxide
|
|
$
|
387
|
|
|
$
|
61
|
|
|
534
|
%
|
Performance Additives
|
|
72
|
|
|
69
|
|
|
4
|
%
|
||
Corporate and other
|
|
(64
|
)
|
|
(53
|
)
|
|
(21
|
)%
|
||
Total
|
|
$
|
395
|
|
|
$
|
77
|
|
|
413
|
%
|
|
Year Ended December 31, 2017 vs. 2016
|
||||||||||
|
Average Selling
Price
(1)
|
|
|
|
|
||||||
|
Local
Currency
|
|
Foreign
Currency
Translation
Impact
|
|
Mix &
Other
|
|
Sales
Volumes
(2)
|
||||
Period-Over-Period Increase (Decrease)
|
|
|
|
|
|
|
|
|
|
|
|
Titanium Dioxide
|
18
|
%
|
|
1
|
%
|
|
(2
|
)%
|
|
(14
|
)%
|
Performance Additives
|
1
|
%
|
|
—
|
%
|
|
—
|
%
|
|
2
|
%
|
|
|
(1)
|
Excludes revenues from tolling arrangements, by-products and raw materials.
|
(2)
|
Excludes sales volumes of by-products and raw materials.
|
•
|
Revenues for the year ended December 31, 2016 decreased by $23 million, or 1%, as compared with 2015. The decrease was due to lower average selling prices in all of our segments, partially offset by higher sales volumes in all of our segments. See “—Segment Analysis” below.
|
•
|
Our operating expenses for the year ended December 31, 2016 decreased by $87 million, or 33%, as compared to 2015, primarily related to a $33 million decrease in acquisition expenses, $30 million decrease in other selling, general and administrative expenses as a result of cost savings from restructuring programs and a favorable $5 million foreign currency exchange impact of the strengthening U.S. dollar against other major international currencies.
|
•
|
Restructuring, impairment and plant closing and transition costs for the year ended December 31, 2016 decreased to $35 million from $220 million in 2015. For more information concerning restructuring activities, see “Part II. Item 8. Financial Statements and Supplementary Data—Note 12. Restructuring, Impairment and Plant Closing and Transition Costs” of this report.
|
•
|
Our interest expense, net for the year ended December 31, 2016 increased to $44 million from $30 million in 2015, partially due to an increase in interest expense of $7 million from 2015 to 2016 as a result of higher average levels of notes payable to related parties during 2016 partially offset by a $7 million decrease in interest income for the year ended December 31, 2016 as compared with 2015 resulting from a significant decrease in notes receivable from affiliates during 2016 as compared to 2015.
|
•
|
Our income tax benefit for the year ended December 31, 2016 decreased to $23 million from $34 million in 2015. Our tax benefit is significantly affected by the mix of income and losses in the tax jurisdictions in which we operate, as impacted by the presence of valuation allowances in certain tax jurisdictions. For further information concerning taxes, see “Part II. Item 8. Financial Statements and Supplementary Data—
Note 19. Income Taxes
” of this report.
|
|
|
Year
Ended
December 31,
|
|
Percent
Change
Favorable
(Unfavorable)
|
|||||||
(in millions)
|
|
2016
|
|
2015
|
|
||||||
Revenues
|
|
|
|
|
|
|
|
|
|
||
Titanium Dioxide
|
|
$
|
1,554
|
|
|
$
|
1,584
|
|
|
(2
|
)%
|
Performance Additives
|
|
585
|
|
|
578
|
|
|
1
|
%
|
||
Total
|
|
$
|
2,139
|
|
|
$
|
2,162
|
|
|
(1
|
)%
|
Segment adjusted EBITDA
|
|
|
|
|
|
|
|
||||
Titanium Dioxide
|
|
$
|
61
|
|
|
$
|
(8
|
)
|
|
NM
|
|
Performance Additives
|
|
69
|
|
|
69
|
|
|
—
|
%
|
||
Corporate and other
|
|
(53
|
)
|
|
(53
|
)
|
|
—
|
%
|
||
Total
|
|
$
|
77
|
|
|
$
|
8
|
|
|
863
|
%
|
|
Year Ended December 31, 2016 vs. 2015
|
||||||||||
|
Average Selling
Price
(1)
|
|
|
|
|
||||||
|
Local
Currency
|
|
Foreign
Currency
Translation
Impact
|
|
Mix &
Other
|
|
Sales
Volumes
(2)
|
||||
Period-Over-Period Increase (Decrease)
|
|
|
|
|
|
|
|
|
|
|
|
Titanium Dioxide
|
(6
|
)%
|
|
(1
|
)%
|
|
1
|
%
|
|
4
|
%
|
Performance Additives
|
—
|
%
|
|
(1
|
)%
|
|
(2
|
)%
|
|
4
|
%
|
|
|
(1)
|
Excludes revenues from tolling arrangements, by-products and raw materials.
|
(2)
|
Excludes sales volumes of by-products and raw materials.
|
•
|
Cash inflows from our accounts receivable and inventory, net of accounts payable, decreased by
$140 million
for the year ended
December 31, 2018
as reflected in our consolidated and combined statements of cash flows. For
2019
, we expect to spend approximately $130 million on capital expenditures. Our future expenditures include certain EHS maintenance and upgrades; periodic maintenance and repairs applicable to major units of manufacturing facilities; expansions of our existing facilities or construction of new facilities; certain cost reduction projects; and the cost to transfer our specialty and differentiated manufacturing from Pori, Finland to other sites within our manufacturing network. We expect to fund this spending with cash on hand as well as cash provided by operations and borrowings.
|
•
|
During the year ended
December 31, 2018
, we made contributions to our pension and postretirement benefit plans of
$47 million
. During the first quarter of
2019
, we expect to contribute an additional amount of approximately $6 million to these plans.
|
•
|
We are involved in a number of cost reduction programs for which we have established restructuring accruals. As of
December 31, 2018
, we had
$32 million
of accrued restructuring costs of which
$18 million
is classified as current. We expect to incur and pay additional restructuring and plant closing costs of approximately $26 million during
2019
. For further discussion of these plans and the costs involved, see “Part II. Item 8. Financial Statements and Supplementary Data—
Note 12. Restructuring, Impairment and Plant Closing and Transition Costs
” of this report.
|
•
|
In the first quarter of 2019 we announced additional cost reduction initiatives which are expected to provide approximately $40 million of annual adjusted EBITDA benefit compared to 2018. Actions will be complete in 2020 ending 2020 at the full run rate level.
|
•
|
On January 30, 2017, our TiO
2
manufacturing facility in Pori, Finland, experienced fire damage. The loss was covered by insurance for property damage as well as business interruption losses subject to retained deductibles of $15 million and 60 days, respectively. During the twelve months ended December 31, 2018, we recorded
$371 million
of income related to insurance recoveries in cost of goods sold while
$187 million
was recognized in 2017.The Pori facility had a nameplate capacity of 130,000 metric tons per year, which represented approximately 17% of our total TiO
2
nameplate capacity and approximately 2% of total global TiO
2
demand. Prior to the fire, 60% of the site capacity produced specialty products which, on average, contributed greater than 75% of the site EBITDA from January 1, 2015 through January 30, 2017. We have restored 20% of the total prior capacity, which is dedicated to production of specialty products.
|
•
|
We have $735 million in aggregate principal outstanding under $370 million, 5.75% of Senior Notes due 2025, and a $365 million Term Loan Facility. See further discussion under "Financing Arrangements."
|
(Dollars in millions)
|
December 31, 2018
|
|
December 31, 2017
|
|
Increase (Decrease)
|
|
Percent Change
|
|||||||
Cash and cash equivalents
|
$
|
165
|
|
|
$
|
238
|
|
|
$
|
(73
|
)
|
|
(31
|
)%
|
Accounts and notes receivable, net
|
351
|
|
|
380
|
|
|
(29
|
)
|
|
(8
|
)%
|
|||
Accounts receivable from affiliates
|
—
|
|
|
12
|
|
|
(12
|
)
|
|
(100
|
)%
|
|||
Inventories
|
538
|
|
|
454
|
|
|
84
|
|
|
19
|
%
|
|||
Prepaid expenses
|
20
|
|
|
19
|
|
|
1
|
|
|
5
|
%
|
|||
Other current assets
|
51
|
|
|
66
|
|
|
(15
|
)
|
|
(23
|
)%
|
|||
Total current assets from continuing operations
|
1,125
|
|
|
1,169
|
|
|
(44
|
)
|
|
(4
|
)%
|
|||
Accounts payable
|
382
|
|
|
385
|
|
|
(3
|
)
|
|
(1
|
)%
|
|||
Accounts payable to affiliates
|
18
|
|
|
16
|
|
|
2
|
|
|
13
|
%
|
|||
Accrued liabilities
|
135
|
|
|
244
|
|
|
(109
|
)
|
|
(45
|
)%
|
|||
Current portion of debt
|
8
|
|
|
14
|
|
|
(6
|
)
|
|
(43
|
)%
|
|||
Total current liabilities from continuing operations
|
543
|
|
|
659
|
|
|
(116
|
)
|
|
(18
|
)%
|
|||
Working capital
|
$
|
582
|
|
|
$
|
510
|
|
|
$
|
72
|
|
|
14
|
%
|
|
|
•
|
Cash and cash equivalents decreased by
$73 million
primarily due to inflows of
$282 million
from operating activities from continuing operations partially offset by
$321 million
of cash outflows from investing activities from continuing operations and outflows of
$18 million
from financing activities of continuing operations.
|
•
|
Accounts receivable decreased by
$29 million
primarily due to lower sales year over year.
|
•
|
Inventories increased by
$84 million
primarily due to customer destocking during the year ended
December 31, 2018
.
|
•
|
Accrued liabilities decreased by
$109 million
primarily due to capital accruals for the Pori, Finland rebuild at December 31, 2017 which are no longer in place.
|
•
|
Accounts receivable from and accounts payable to affiliates represent financing arrangements with affiliates of Huntsman. For further information, see “Part II. Item 8. Financial Statements and Supplementary Data—
Note 15. Debt
” of this report as well as accrued costs for our restructuring programs.
|
(Dollars in millions)
|
December 31, 2017
|
|
December 31, 2016
|
|
Increase (Decrease)
|
|
Percent Change
|
|||||||
Cash and cash equivalents
|
$
|
238
|
|
|
$
|
29
|
|
|
$
|
209
|
|
|
721
|
%
|
Accounts and notes receivable, net
|
380
|
|
|
247
|
|
|
133
|
|
|
54
|
%
|
|||
Accounts receivable from affiliates
|
12
|
|
|
243
|
|
|
(231
|
)
|
|
(95
|
)%
|
|||
Inventories
|
454
|
|
|
426
|
|
|
28
|
|
|
7
|
%
|
|||
Prepaid expenses
|
19
|
|
|
11
|
|
|
8
|
|
|
73
|
%
|
|||
Other current assets
|
66
|
|
|
59
|
|
|
7
|
|
|
12
|
%
|
|||
Total current assets from continuing operations
|
1,169
|
|
|
1,015
|
|
|
154
|
|
|
15
|
%
|
|||
Accounts payable
|
385
|
|
|
297
|
|
|
88
|
|
|
30
|
%
|
|||
Accounts payable to affiliates
|
16
|
|
|
695
|
|
|
(679
|
)
|
|
(98
|
)%
|
|||
Accrued liabilities
|
244
|
|
|
146
|
|
|
98
|
|
|
67
|
%
|
|||
Current portion of debt
|
14
|
|
|
10
|
|
|
4
|
|
|
40
|
%
|
|||
Total current liabilities from continuing operations
|
659
|
|
|
1,148
|
|
|
(489
|
)
|
|
(43
|
)%
|
|||
Working capital (deficit)
|
$
|
510
|
|
|
$
|
(133
|
)
|
|
$
|
643
|
|
|
NM
|
|
•
|
Cash and cash equivalents increased by
$209 million
primarily due to inflows of
$337 million
from operating activities from continuing operations partially offset by
$11 million
of cash outflows from investing activities from continuing operations and outflows of
$123 million
from financing activities of continuing operations.
|
•
|
Accounts receivable increased by
$133 million
primarily due to higher revenues in the year ended
December 31, 2017
compared to the year ended
December 31, 2016
as well as from the impacts of discontinuing our participation in Huntsman’s accounts receivable securitization program.
|
•
|
Accrued liabilities increased by
$98 million
primarily due to deferred income recorded in connection with the partial progress payment received from our insurer related to the fire at our Pori, Finland manufacturing facility.
|
•
|
Accounts receivable from and accounts payable to affiliates represent financing arrangements with affiliates of Huntsman. For further information, see “Part II. Item 8. Financial Statements and Supplementary Data—Note 15. Debt” of this report as well as accrued costs for our restructuring programs.
|
Year ending December 31:
|
|
Amount
|
||
2019
|
|
$
|
1
|
|
2020
|
|
2
|
|
|
2021
|
|
1
|
|
|
2022
|
|
1
|
|
|
Thereafter
|
|
8
|
|
|
Total minimum payments
|
|
13
|
|
|
Less: Amounts representing interest
|
|
(3
|
)
|
|
Present value of minimum lease payments
|
|
10
|
|
|
Less: Current portion of capital leases
|
|
(1
|
)
|
|
Long-term portion of capital leases
|
|
$
|
9
|
|
(Dollars in millions)
|
2019
|
|
2020-2021
|
|
2022-2023
|
|
After 2023
|
|
Total
|
||||||||||
Long-term debt, including current portion
(1)
|
$
|
7
|
|
|
$
|
9
|
|
|
$
|
9
|
|
|
$
|
723
|
|
|
$
|
748
|
|
Interest
(2)
|
43
|
|
|
86
|
|
|
89
|
|
|
57
|
|
|
275
|
|
|||||
Operating leases
|
13
|
|
|
20
|
|
|
10
|
|
|
40
|
|
|
83
|
|
|||||
Purchase commitments
(3)
|
110
|
|
|
167
|
|
|
67
|
|
|
25
|
|
|
369
|
|
|||||
Total
(4)(5)
|
$
|
173
|
|
|
$
|
282
|
|
|
$
|
175
|
|
|
$
|
845
|
|
|
$
|
1,475
|
|
|
|
(1)
|
In connection with our IPO, we entered into the Senior Credit Facilities and two of our subsidiaries issued the Senior Notes, which includes (i) $375 million of Senior Notes and (ii) borrowings of $375 million under our term loan facility. In addition, we entered into a $300 million ABL facility at closing of our IPO, which, together with the term loan facility, we refer to as the Senior Credit Facilities. We used the net proceeds of the Senior Notes offering and the term loan facility to repay $732 million of net intercompany debt owed to Huntsman and to pay related fees and expenses of $18 million. For more information, See “—Financing Arrangements.”
|
(2)
|
Interest calculated using actual and forecasted interest rates as of
December 31, 2018
and contractual maturity dates.
|
(3)
|
We have various purchase commitments extending through
2029
for materials, supplies and services entered into in the ordinary course of business. Included in the purchase commitments table above are contracts which require minimum volume purchases that extend beyond one year or are renewable annually and have been renewed for
2018
. Certain contracts allow for changes in minimum required purchase volumes in the event of a temporary or permanent shutdown of a facility. To the extent the contract requires a minimum notice period, such notice period has been included in the above table. The contractual purchase price for substantially all of these contracts is variable based upon market prices, subject to annual negotiations. We have estimated our contractual obligations by using the terms of our current pricing for each contract. We also have a limited number of contracts which require a minimum payment even if no volume is purchased. We believe that all of our purchase obligations will be utilized in our normal operations. For each of the years ended
December 31, 2018
,
2017
and
2016
, we made minimum payments of
nil
,
$2 million
and
$1 million
, respectively, under such take or pay contracts without taking the product.
|
(4)
|
Totals do not include commitments pertaining to our pension and other postretirement obligations. Our estimated future contributions to our pension and postretirement plans are as follows:
|
(Dollars in millions)
|
2019
|
|
2020-2021
|
|
2022-2023
|
|
5-Year
Average Annual |
||||||||
Pension plans
|
$
|
24
|
|
|
$
|
54
|
|
|
$
|
58
|
|
|
$
|
32
|
|
Other postretirement obligations
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
(5)
|
The above table does not reflect expected tax payments and unrecognized tax benefits due to the inability to make reasonably reliable estimates of the timing and amount of payments. For additional discussion on unrecognized tax benefits, see “Part II. Item 8. Financial Statements and Supplementary Data—
Note 19. Income Taxes
” of this report.
|
|
2018
|
|
2017
|
|
2016
|
|||
Defined benefit plans
|
|
|
|
|
|
|||
Projected benefit obligation
|
2.38
|
%
|
|
2.21
|
%
|
|
2.28
|
%
|
Net periodic pension cost
|
2.21
|
%
|
|
1.86
|
%
|
|
3.27
|
%
|
Other postretirement benefit plans
|
|
|
|
|
|
|||
Projected benefit obligation
|
3.50
|
%
|
|
3.38
|
%
|
|
3.72
|
%
|
Net periodic pension cost
|
3.30
|
%
|
|
3.72
|
%
|
|
6.94
|
%
|
Assumptions
|
|
Statement of
Operations
(1)
|
|
Balance Sheet
Impact
(2)
|
||||
Discount rate
|
|
|
|
|
|
|||
1% increase
|
|
$
|
(12
|
)
|
|
$
|
(154
|
)
|
1% decrease
|
|
12
|
|
|
175
|
|
||
Expected long-term rates of return on plan assets
|
|
|
|
|
||||
1% increase
|
|
(9
|
)
|
|
—
|
|
||
1% decrease
|
|
9
|
|
|
—
|
|
||
Rate of compensation increase
|
|
|
|
|
||||
1% increase
|
|
2
|
|
|
12
|
|
||
1% decrease
|
|
(2
|
)
|
|
(11
|
)
|
|
|
(1)
|
Estimated (decrease) increase on
2018
net periodic benefit cost
|
(2)
|
Estimated (decrease) increase on
December 31, 2018
pension and postretirement liabilities and accumulated other comprehensive loss
|
|
Page
|
Audited Consolidated and Combined Financial Statements
|
|
(In millions, except par value)
|
December 31,
2018 |
|
December 31,
2017 |
||||
ASSETS
|
|||||||
Current assets:
|
|
|
|
|
|
||
Cash and cash equivalents
(a)
|
$
|
165
|
|
|
$
|
238
|
|
Accounts receivable (net of allowance for doubtful accounts of $5, each)
(a)
|
351
|
|
|
380
|
|
||
Accounts receivable from affiliates
|
—
|
|
|
12
|
|
||
Inventories
(a)
|
538
|
|
|
454
|
|
||
Prepaid expenses
|
20
|
|
|
19
|
|
||
Other current assets
|
51
|
|
|
66
|
|
||
Total current assets
|
1,125
|
|
|
1,169
|
|
||
Property, plant and equipment, net
(a)
|
994
|
|
|
1,367
|
|
||
Intangible assets, net
(a)
|
16
|
|
|
20
|
|
||
Investment in unconsolidated affiliates
|
83
|
|
|
86
|
|
||
Deferred income taxes
|
178
|
|
|
167
|
|
||
Other noncurrent assets
|
89
|
|
|
38
|
|
||
Total assets
|
$
|
2,485
|
|
|
$
|
2,847
|
|
LIABILITIES AND EQUITY
|
|||||||
Current liabilities:
|
|
|
|
|
|
||
Accounts payable
(a)
|
$
|
382
|
|
|
$
|
385
|
|
Accounts payable to affiliates
|
18
|
|
|
16
|
|
||
Accrued liabilities
(a)
|
135
|
|
|
244
|
|
||
Current portion of debt
(a)
|
8
|
|
|
14
|
|
||
Total current liabilities
|
543
|
|
|
659
|
|
||
Long-term debt
|
740
|
|
|
743
|
|
||
Other noncurrent liabilities
|
313
|
|
|
306
|
|
||
Noncurrent payable to affiliates
|
34
|
|
|
34
|
|
||
Total liabilities
|
1,630
|
|
|
1,742
|
|
||
Commitments and contingencies (Notes 22 and 23)
|
|
|
|
|
|
||
Equity
|
|
|
|
|
|
||
Ordinary shares $0.001 par value, 200 shares authorized, 106 each issued and 106 each outstanding, respectively
|
—
|
|
|
—
|
|
||
Additional paid-in capital
|
1,316
|
|
|
1,311
|
|
||
Retained (deficit) earnings
|
(96
|
)
|
|
67
|
|
||
Accumulated other comprehensive loss
|
(373
|
)
|
|
(283
|
)
|
||
Total Venator
|
847
|
|
|
1,095
|
|
||
Noncontrolling interest in subsidiaries
|
8
|
|
|
10
|
|
||
Total equity
|
855
|
|
|
1,105
|
|
||
Total liabilities and equity
|
$
|
2,485
|
|
|
$
|
2,847
|
|
|
|
(a)
|
At
December 31, 2018
and
2017
respectively, $5 each of cash and cash equivalents, $5 and $7 of accounts receivable (net), $1 and $2 of inventories, $5 each of property, plant and equipment (net), $14 and $17 of intangible assets (net), $1 each of accounts payable, $4 each of accrued liabilities, and $2 each of current portion of debt from consolidated variable interest entities are included in the respective balance sheet captions above. See “
Note 8. Variable Interest Entities
.”
|
|
Year ended December 31,
|
||||||||||
(Dollars in millions, except per share amounts)
|
2018
|
|
2017
|
|
2016
|
||||||
Trade sales, services and fees, net
|
$
|
2,265
|
|
|
$
|
2,209
|
|
|
$
|
2,139
|
|
Cost of goods sold
|
1,550
|
|
|
1,744
|
|
|
1,989
|
|
|||
Operating expenses:
|
|
|
|
|
|
||||||
Selling, general and administrative (includes corporate allocations from Huntsman of nil, $62 and $104, respectively)
|
212
|
|
|
216
|
|
|
221
|
|
|||
Restructuring, impairment and plant closing and transition costs
|
628
|
|
|
52
|
|
|
35
|
|
|||
Other operating expense (income), net
|
6
|
|
|
10
|
|
|
(45
|
)
|
|||
Total operating expenses
|
846
|
|
|
278
|
|
|
211
|
|
|||
Operating (loss) income
|
(131
|
)
|
|
187
|
|
|
(61
|
)
|
|||
Interest expense
|
(53
|
)
|
|
(100
|
)
|
|
(59
|
)
|
|||
Interest income
|
13
|
|
|
60
|
|
|
15
|
|
|||
Other income (expense), net
|
6
|
|
|
39
|
|
|
(3
|
)
|
|||
(Loss) income from continuing operations before income taxes
|
(165
|
)
|
|
186
|
|
|
(108
|
)
|
|||
Income tax benefit (expense)
|
8
|
|
|
(50
|
)
|
|
23
|
|
|||
(Loss) income from continuing operations
|
(157
|
)
|
|
136
|
|
|
(85
|
)
|
|||
Income from discontinued operations, net of tax
|
—
|
|
|
8
|
|
|
8
|
|
|||
Net (loss) income
|
(157
|
)
|
|
144
|
|
|
(77
|
)
|
|||
Net income attributable to noncontrolling interests
|
(6
|
)
|
|
(10
|
)
|
|
(10
|
)
|
|||
Net (loss) income attributable to Venator
|
$
|
(163
|
)
|
|
$
|
134
|
|
|
$
|
(87
|
)
|
|
|
|
|
|
|
||||||
Basic (losses) earnings per share:
|
|
|
|
|
|
||||||
(Loss) income from continuing operations attributable to Venator Materials PLC ordinary shareholders
|
$
|
(1.53
|
)
|
|
$
|
1.19
|
|
|
$
|
(0.89
|
)
|
Income from discontinued operations attributable to Venator Materials PLC ordinary shareholders
|
—
|
|
|
0.07
|
|
|
0.07
|
|
|||
Net (loss) income attributable to Venator Materials PLC ordinary shareholders
|
$
|
(1.53
|
)
|
|
$
|
1.26
|
|
|
$
|
(0.82
|
)
|
|
|
|
|
|
|
||||||
Diluted (losses) earnings per share:
|
|
|
|
|
|
||||||
(Loss) income from continuing operations attributable to Venator Materials PLC ordinary shareholders
|
$
|
(1.53
|
)
|
|
$
|
1.18
|
|
|
$
|
(0.89
|
)
|
Income from discontinued operations attributable to Venator Materials PLC ordinary shareholders
|
—
|
|
|
0.08
|
|
|
0.07
|
|
|||
Net (loss) income attributable to Venator Materials PLC ordinary shareholders
|
$
|
(1.53
|
)
|
|
$
|
1.26
|
|
|
$
|
(0.82
|
)
|
|
Year ended December 31,
|
||||||||||
(Dollars in millions)
|
2018
|
|
2017
|
|
2016
|
||||||
Net (loss) income
|
$
|
(157
|
)
|
|
$
|
144
|
|
|
$
|
(77
|
)
|
Other comprehensive (loss) income, net of tax:
|
|
|
|
|
|
||||||
Foreign currency translation adjustment
|
(90
|
)
|
|
106
|
|
|
32
|
|
|||
Pension and other postretirement benefits adjustments
|
(11
|
)
|
|
39
|
|
|
(54
|
)
|
|||
Hedging instruments
|
11
|
|
|
(5
|
)
|
|
—
|
|
|||
Other comprehensive (loss) income, net of tax
|
(90
|
)
|
|
140
|
|
|
(22
|
)
|
|||
Comprehensive (loss) income
|
(247
|
)
|
|
284
|
|
|
(99
|
)
|
|||
Comprehensive income attributable to noncontrolling interest
|
(6
|
)
|
|
(10
|
)
|
|
(10
|
)
|
|||
Comprehensive (loss) income attributable to Venator
|
$
|
(253
|
)
|
|
$
|
274
|
|
|
$
|
(109
|
)
|
|
Total Venator Materials PLC Equity
|
|
|
|
|
||||||||||||||||||||||
(Dollars in millions)
|
Parent's Net
Investment
and
Advances
|
|
Ordinary
Shares
|
|
Additional
Paid-In
Capital
|
|
Retained (Deficit)
Earnings
|
|
Accumulated
Other
Comprehensive
Loss
|
|
Noncontrolling
Interest in
Subsidiaries
|
|
Total
|
||||||||||||||
Balance, January 1, 2016
|
$
|
1,112
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
(401
|
)
|
|
$
|
17
|
|
|
$
|
728
|
|
Net (loss) income
|
(87
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
10
|
|
|
(77
|
)
|
|||||||
Net changes in other comprehensive loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(22
|
)
|
|
—
|
|
|
(22
|
)
|
|||||||
Dividends paid to noncontrolling interests
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(14
|
)
|
|
(14
|
)
|
|||||||
Net changes in parent’s net investment and advances
|
(437
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1
|
)
|
|
(438
|
)
|
|||||||
Balance, December 31, 2016
|
$
|
588
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
(423
|
)
|
|
$
|
12
|
|
|
$
|
177
|
|
Net income
|
67
|
|
|
—
|
|
|
—
|
|
|
67
|
|
|
—
|
|
|
10
|
|
|
144
|
|
|||||||
Net changes in other comprehensive loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
140
|
|
|
—
|
|
|
140
|
|
|||||||
Dividends paid to noncontrolling interests
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(12
|
)
|
|
(12
|
)
|
|||||||
Net changes in parent’s net investment and advances
|
653
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
653
|
|
|||||||
Conversion of parent's net investment and advances to paid-in capital
|
$
|
(1,308
|
)
|
|
$
|
—
|
|
|
$
|
1,308
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Activity related to stock plans
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
3
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
3
|
|
Balance, December 31, 2017
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,311
|
|
|
$
|
67
|
|
|
$
|
(283
|
)
|
|
$
|
10
|
|
|
$
|
1,105
|
|
Net (loss) income
|
—
|
|
|
—
|
|
|
—
|
|
|
(163
|
)
|
|
—
|
|
|
6
|
|
|
(157
|
)
|
|||||||
Net changes in other comprehensive loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(90
|
)
|
|
—
|
|
|
(90
|
)
|
|||||||
Dividends paid to noncontrolling interests
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(8
|
)
|
|
(8
|
)
|
|||||||
Activity related to stock plans
|
—
|
|
|
—
|
|
|
5
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
5
|
|
|||||||
Balance, December 31, 2018
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,316
|
|
|
$
|
(96
|
)
|
|
$
|
(373
|
)
|
|
$
|
8
|
|
|
$
|
855
|
|
|
Year ended December 31,
|
||||||||||
(Dollars in millions)
|
2018
|
|
2017
|
|
2016
|
||||||
Operating Activities:
|
|
|
|
|
|
|
|
|
|||
Net (loss) income
|
$
|
(157
|
)
|
|
$
|
144
|
|
|
$
|
(77
|
)
|
Income from discontinued operations, net of tax
|
—
|
|
|
(8
|
)
|
|
(8
|
)
|
|||
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
|
|
|
|
|
|
||||||
Depreciation and amortization
|
132
|
|
|
127
|
|
|
114
|
|
|||
Deferred income taxes
|
(19
|
)
|
|
19
|
|
|
(14
|
)
|
|||
Loss (gain) on disposal of assets
|
—
|
|
|
1
|
|
|
(22
|
)
|
|||
Noncash restructuring and impairment charges
|
591
|
|
|
7
|
|
|
10
|
|
|||
Insurance proceeds for business interruption, net of gain on recovery
|
—
|
|
|
21
|
|
|
—
|
|
|||
Noncash interest
|
1
|
|
|
18
|
|
|
44
|
|
|||
Noncash (gain) loss on foreign currency transactions
|
(6
|
)
|
|
1
|
|
|
(9
|
)
|
|||
Other, net
|
9
|
|
|
13
|
|
|
1
|
|
|||
Changes in assets and liabilities:
|
|
|
|
|
|
||||||
Accounts receivable
|
25
|
|
|
(24
|
)
|
|
(12
|
)
|
|||
Inventories
|
(103
|
)
|
|
8
|
|
|
106
|
|
|||
Prepaid expenses
|
(1
|
)
|
|
(2
|
)
|
|
1
|
|
|||
Other current assets
|
(13
|
)
|
|
(1
|
)
|
|
(4
|
)
|
|||
Other noncurrent assets
|
(49
|
)
|
|
9
|
|
|
(9
|
)
|
|||
Accounts payable
|
(27
|
)
|
|
51
|
|
|
17
|
|
|||
Accrued liabilities
|
(96
|
)
|
|
13
|
|
|
(40
|
)
|
|||
Other noncurrent liabilities
|
(5
|
)
|
|
(60
|
)
|
|
(18
|
)
|
|||
Net cash provided by operating activities from continuing operations
|
282
|
|
|
337
|
|
|
80
|
|
|||
Net cash provided by operating activities from discontinued operations
|
—
|
|
|
1
|
|
|
17
|
|
|||
Net cash provided by operating activities
|
282
|
|
|
338
|
|
|
97
|
|
|||
Investing Activities:
|
|
|
|
|
|
||||||
Capital expenditures
|
(326
|
)
|
|
(197
|
)
|
|
(103
|
)
|
|||
Insurance proceeds for recovery of property damage
|
—
|
|
|
76
|
|
|
—
|
|
|||
Cash received from unconsolidated affiliates
|
34
|
|
|
44
|
|
|
32
|
|
|||
Investment in unconsolidated affiliates
|
(30
|
)
|
|
(50
|
)
|
|
(29
|
)
|
|||
Repayment of government grant
|
—
|
|
|
(5
|
)
|
|
—
|
|
|||
Net payments from (advances to) affiliates
|
—
|
|
|
121
|
|
|
(5
|
)
|
|||
Proceeds from sale of businesses/assets
|
1
|
|
|
—
|
|
|
9
|
|
|||
Net cash used in investing activities from continuing operations
|
(321
|
)
|
|
(11
|
)
|
|
(96
|
)
|
|||
Net cash used in investing activities from discontinued operations
|
—
|
|
|
(1
|
)
|
|
(22
|
)
|
|||
Net cash used in investing activities
|
(321
|
)
|
|
(12
|
)
|
|
(118
|
)
|
|||
Financing Activities:
|
|
|
|
|
|
||||||
Proceeds from short-term debt
|
—
|
|
|
1
|
|
|
1
|
|
|||
Net (repayments) borrowings from affiliate accounts payable
|
—
|
|
|
(100
|
)
|
|
47
|
|
|||
Payments on notes payable
|
(6
|
)
|
|
—
|
|
|
—
|
|
|||
Final settlement of affiliate balances at separation
|
—
|
|
|
(732
|
)
|
|
—
|
|
|||
Principal payments on long-term debt
|
(4
|
)
|
|
(12
|
)
|
|
(2
|
)
|
|||
Dividends paid to noncontrolling interests
|
(8
|
)
|
|
(12
|
)
|
|
(14
|
)
|
|||
Proceeds from issuance of long-term debt
|
—
|
|
|
750
|
|
|
—
|
|
|||
Debt issuance costs paid
|
—
|
|
|
(18
|
)
|
|
—
|
|
|||
Net cash (used in) provided by financing activities from continuing operations
|
(18
|
)
|
|
(123
|
)
|
|
32
|
|
|||
Net cash used in financing activities from discontinued operations
|
—
|
|
|
—
|
|
|
(2
|
)
|
|||
Net cash (used in) provided by financing activities
|
(18
|
)
|
|
(123
|
)
|
|
30
|
|
|||
Effect of exchange rate changes on cash
|
(16
|
)
|
|
5
|
|
|
(1
|
)
|
|||
(Decrease) increase in cash and cash equivalents, including discontinued operations
|
(73
|
)
|
|
208
|
|
|
8
|
|
|||
Cash and cash equivalents at beginning of period, including discontinued operations
|
238
|
|
|
30
|
|
|
22
|
|
|||
Cash and cash equivalents at end of period, including discontinued operations
|
$
|
165
|
|
|
$
|
238
|
|
|
$
|
30
|
|
Supplemental cash flow information:
|
|
|
|
|
|
||||||
Cash paid for interest
|
$
|
46
|
|
|
$
|
28
|
|
|
$
|
5
|
|
Cash paid for income taxes
|
34
|
|
|
21
|
|
|
7
|
|
|||
Noncash investing and financing activities:
|
|
|
|
|
|
||||||
The amount of capital expenditures in accounts payable
|
$
|
70
|
|
|
$
|
39
|
|
|
$
|
21
|
|
Received noncash settlements of notes receivable from affiliates
|
—
|
|
|
57
|
|
|
270
|
|
|||
Settled noncash long-term debt to affiliates
|
—
|
|
|
792
|
|
|
145
|
|
Patents, trademarks and technology
|
|
5 - 30 years
|
Other intangibles
|
|
5 - 15 years
|
Buildings and leasehold improvements
|
|
5 - 50 years
|
Plant and equipment
|
|
3 - 30 years
|
|
2018
|
|
2017
|
|
2016
|
||||||||||||||||||||||||||||||
|
Titanium Dioxide
|
|
Performance Additives
|
|
Total
|
|
Titanium Dioxide
|
|
Performance Additives
|
|
Total
|
|
Titanium Dioxide
|
|
Performance Additives
|
|
Total
|
||||||||||||||||||
North America
|
$
|
296
|
|
|
$
|
277
|
|
|
$
|
573
|
|
|
$
|
281
|
|
|
$
|
301
|
|
|
$
|
582
|
|
|
$
|
260
|
|
|
$
|
291
|
|
|
$
|
551
|
|
Europe
|
828
|
|
|
206
|
|
|
1,034
|
|
|
794
|
|
|
194
|
|
|
988
|
|
|
733
|
|
|
187
|
|
|
920
|
|
|||||||||
Asia
|
368
|
|
|
98
|
|
|
466
|
|
|
349
|
|
|
97
|
|
|
446
|
|
|
336
|
|
|
90
|
|
|
426
|
|
|||||||||
Other
|
174
|
|
|
18
|
|
|
192
|
|
|
180
|
|
|
13
|
|
|
193
|
|
|
225
|
|
|
17
|
|
|
242
|
|
|||||||||
Total Revenues
|
$
|
1,666
|
|
|
$
|
599
|
|
|
$
|
2,265
|
|
|
$
|
1,604
|
|
|
$
|
605
|
|
|
$
|
2,209
|
|
|
$
|
1,554
|
|
|
$
|
585
|
|
|
$
|
2,139
|
|
|
2018
|
|
2017
|
|
2016
|
||||||||||||||||||||||||||||||
|
Titanium Dioxide
|
|
Performance Additives
|
|
Total
|
|
Titanium Dioxide
|
|
Performance Additives
|
|
Total
|
|
Titanium Dioxide
|
|
Performance Additives
|
|
Total
|
||||||||||||||||||
TiO
2
|
$
|
1,666
|
|
|
$
|
—
|
|
|
$
|
1,666
|
|
|
$
|
1,604
|
|
|
$
|
—
|
|
|
$
|
1,604
|
|
|
$
|
1,554
|
|
|
$
|
—
|
|
|
$
|
1,554
|
|
Color Pigments
|
—
|
|
|
294
|
|
|
294
|
|
|
—
|
|
|
302
|
|
|
302
|
|
|
—
|
|
|
296
|
|
|
296
|
|
|||||||||
Functional Additives
|
—
|
|
|
140
|
|
|
140
|
|
|
—
|
|
|
130
|
|
|
130
|
|
|
—
|
|
|
126
|
|
|
126
|
|
|||||||||
Timber Treatment
|
—
|
|
|
142
|
|
|
142
|
|
|
—
|
|
|
151
|
|
|
151
|
|
|
—
|
|
|
140
|
|
|
140
|
|
|||||||||
Water Treatment
|
—
|
|
|
23
|
|
|
23
|
|
|
—
|
|
|
22
|
|
|
22
|
|
|
—
|
|
|
23
|
|
|
23
|
|
|||||||||
Total Revenues
|
$
|
1,666
|
|
|
$
|
599
|
|
|
$
|
2,265
|
|
|
$
|
1,604
|
|
|
$
|
605
|
|
|
$
|
2,209
|
|
|
$
|
1,554
|
|
|
$
|
585
|
|
|
$
|
2,139
|
|
|
For the years ended December 31,
|
||||||||||
|
2018
|
|
2017
|
|
2016
|
||||||
Numerator:
|
|
|
|
|
|
|
|
|
|||
Basic and diluted (loss) income from continuing operations:
|
|
|
|
|
|
|
|
|
|||
(Loss) income from continuing operations attributable to Venator Materials PLC ordinary shareholders
|
$
|
(163
|
)
|
|
$
|
126
|
|
|
$
|
(95
|
)
|
Basic and diluted income from discontinued operations:
|
|
|
|
|
|
||||||
Income from discontinued operations attributable to Venator Materials PLC ordinary shareholders
|
$
|
—
|
|
|
$
|
8
|
|
|
$
|
8
|
|
Basic and diluted net (loss) income:
|
|
|
|
|
|
||||||
Net (loss) income attributable to Venator Materials PLC ordinary shareholders
|
$
|
(163
|
)
|
|
$
|
134
|
|
|
$
|
(87
|
)
|
Denominator:
|
|
|
|
|
|
||||||
Weighted average shares outstanding
|
106.4
|
|
|
106.3
|
|
|
106.3
|
|
|||
Dilutive share-based awards
|
0.3
|
|
|
0.4
|
|
|
—
|
|
|||
Total weighted average shares outstanding, including dilutive shares
|
106.7
|
|
|
106.7
|
|
|
106.3
|
|
|
December 31,
|
||||||
|
2018
|
|
2017
|
||||
Raw materials and supplies
|
$
|
165
|
|
|
$
|
149
|
|
Work in process
|
56
|
|
|
46
|
|
||
Finished goods
|
317
|
|
|
259
|
|
||
Total
|
$
|
538
|
|
|
$
|
454
|
|
|
December 31,
|
||||||
|
2018
|
|
2017
|
||||
Land and land improvements
|
$
|
98
|
|
|
$
|
101
|
|
Buildings
|
236
|
|
|
236
|
|
||
Plant and equipment
|
1,926
|
|
|
2,048
|
|
||
Construction in progress
|
144
|
|
|
255
|
|
||
Total
|
2,404
|
|
|
2,640
|
|
||
Less accumulated depreciation
|
(1,410
|
)
|
|
(1,273
|
)
|
||
Property, plant, and equipment—net
|
$
|
994
|
|
|
$
|
1,367
|
|
•
|
Pacific Iron Products Sdn Bhd is our
50%
-owned joint venture with Coogee Chemicals that manufactures products for Venator. It was determined that the activities that most significantly impact its economic performance are raw material supply, manufacturing and sales. In this joint venture we supply all the raw materials through a fixed cost supply contract, operate the manufacturing facility and market the products of the joint venture to customers. Through a fixed price raw materials supply contract with the joint venture we are exposed to the risk related to the fluctuation of raw material pricing. As a result, we concluded that we are the primary beneficiary.
|
•
|
Viance, LLC (“Viance”) is our
50%
-owned joint venture with DowDuPont. Viance markets timber treatment products for Venator. Our joint venture interest in Viance was acquired as part of the Rockwood acquisition. It was determined that the activity that most significantly impacts its economic performance is manufacturing. The joint venture sources all of its products through a contract manufacturing arrangement at our Harrisburg, North Carolina facility and we bear a disproportionate amount of working capital risk of loss due to the supply arrangement whereby we control manufacturing on Viance’s behalf. As a result, we concluded that we are the primary beneficiary and began consolidating Viance upon the Rockwood acquisition on October 1, 2014.
|
|
Year ended December 31,
|
||||||||||
|
2018
|
|
2017
|
|
2016
|
||||||
Revenues
|
$
|
117
|
|
|
$
|
127
|
|
|
$
|
116
|
|
Income from continuing operations before income taxes
|
13
|
|
|
21
|
|
|
21
|
|
|||
Net cash provided by operating activities
|
16
|
|
|
25
|
|
|
26
|
|
|
December 31, 2018
|
|
December 31, 2017
|
||||||||||||||||||||
|
Carrying
Amount
|
|
Accumulated
Amortization
|
|
Net
|
|
Carrying
Amount
|
|
Accumulated
Amortization
|
|
Net
|
||||||||||||
Patents, trademarks and technology
|
$
|
18
|
|
|
$
|
9
|
|
|
$
|
9
|
|
|
$
|
17
|
|
|
$
|
6
|
|
|
$
|
11
|
|
Other intangibles
|
14
|
|
|
7
|
|
|
7
|
|
|
15
|
|
|
6
|
|
|
9
|
|
||||||
Total
|
$
|
32
|
|
|
$
|
16
|
|
|
$
|
16
|
|
|
$
|
32
|
|
|
$
|
12
|
|
|
$
|
20
|
|
Year ending December 31,
|
|
Amount
|
||
2019
|
|
$
|
3
|
|
2020
|
|
3
|
|
|
2021
|
|
3
|
|
|
2022
|
|
3
|
|
|
2023
|
|
3
|
|
|
December 31,
|
||||||
|
2018
|
|
2017
|
||||
Spare parts inventory
|
$
|
25
|
|
|
$
|
13
|
|
Notes receivable
|
10
|
|
|
9
|
|
||
Pension assets
|
46
|
|
|
1
|
|
||
Debt issuance costs
|
4
|
|
|
4
|
|
||
Other
|
4
|
|
|
11
|
|
||
Total
|
$
|
89
|
|
|
$
|
38
|
|
|
December 31,
|
||||||
|
2018
|
|
2017
|
||||
Payroll and benefits
|
$
|
49
|
|
|
$
|
50
|
|
Restructuring and plant closing costs
|
18
|
|
|
11
|
|
||
Rebate accrual
|
19
|
|
|
22
|
|
||
Current taxes payable
|
—
|
|
|
14
|
|
||
Asset retirement obligation
|
10
|
|
|
19
|
|
||
Taxes other than income taxes
|
2
|
|
|
2
|
|
||
Pension liabilities
|
1
|
|
|
1
|
|
||
Deferred income
|
—
|
|
|
69
|
|
||
Other miscellaneous accruals
|
36
|
|
|
56
|
|
||
Total
|
$
|
135
|
|
|
$
|
244
|
|
|
Workforce
reductions
(1)
|
|
Other
restructuring
costs
|
|
Total
(2)
|
||||||
Accrued liabilities as of January 1, 2016
|
$
|
90
|
|
|
$
|
—
|
|
|
$
|
90
|
|
2016 charges for 2015 and prior initiatives
|
3
|
|
|
16
|
|
|
19
|
|
|||
2016 charges for 2016 initiatives
|
6
|
|
|
—
|
|
|
6
|
|
|||
Distribution of prefunded restructuring costs
|
(36
|
)
|
|
—
|
|
|
(36
|
)
|
|||
2016 payments for 2015 and prior initiatives
|
(36
|
)
|
|
(16
|
)
|
|
(52
|
)
|
|||
2016 payments for 2016 initiatives
|
(6
|
)
|
|
—
|
|
|
(6
|
)
|
|||
Accrued liabilities as of December 31, 2016
|
$
|
21
|
|
|
$
|
—
|
|
|
$
|
21
|
|
2017 charges for 2016 and prior initiatives
|
—
|
|
|
8
|
|
|
8
|
|
|||
2017 charges for 2017 initiatives
|
33
|
|
|
4
|
|
|
37
|
|
|||
Reversal of reserves no longer required
|
(1
|
)
|
|
—
|
|
|
(1
|
)
|
|||
2017 payments for 2016 and prior initiatives
|
(12
|
)
|
|
(8
|
)
|
|
(20
|
)
|
|||
2017 payments for 2017 initiatives
|
(8
|
)
|
|
(4
|
)
|
|
(12
|
)
|
|||
Foreign currency effect on liability balance
|
1
|
|
|
—
|
|
|
1
|
|
|||
Accrued liabilities as of December 31, 2017
|
$
|
34
|
|
|
$
|
—
|
|
|
$
|
34
|
|
2018 charges for 2017 and prior initiatives
|
2
|
|
|
16
|
|
|
18
|
|
|||
2018 charges for 2018 initiatives
|
17
|
|
|
2
|
|
|
19
|
|
|||
2018 payments for 2017 and prior initiatives
|
(17
|
)
|
|
(16
|
)
|
|
(33
|
)
|
|||
2018 payments for 2018 initiatives
|
(2
|
)
|
|
(2
|
)
|
|
(4
|
)
|
|||
Foreign currency effect on liability balance
|
(2
|
)
|
|
—
|
|
|
(2
|
)
|
|||
Accrued liabilities as of December 31, 2018
|
$
|
32
|
|
|
$
|
—
|
|
|
$
|
32
|
|
|
|
(1)
|
The total workforce reduction reserves of
$32 million
relate to the termination of
591
positions, of which
three
positions had been terminated but not yet paid as of
December 31, 2018
.
|
(2)
|
Accrued liabilities remaining at
December 31, 2018
,
2017
and
2016
by year of initiatives were as follows:
|
|
December 31,
|
||||||||||
|
2018
|
|
2017
|
|
2016
|
||||||
2016 initiatives and prior
|
$
|
4
|
|
|
$
|
9
|
|
|
$
|
21
|
|
2017 initiatives
|
14
|
|
|
25
|
|
|
—
|
|
|||
2018 initiatives
|
14
|
|
|
—
|
|
|
—
|
|
|||
Total
|
$
|
32
|
|
|
$
|
34
|
|
|
$
|
21
|
|
|
Titanium
Dioxide
|
|
Performance
Additives
|
|
Total
|
||||||
Accrued liabilities as of January 1, 2016
|
$
|
57
|
|
|
$
|
33
|
|
|
$
|
90
|
|
2016 charges for 2015 and prior initiatives
|
3
|
|
|
16
|
|
|
19
|
|
|||
2016 charges for 2016 initiatives
|
6
|
|
|
—
|
|
|
6
|
|
|||
Distribution of prefunded restructuring costs
|
(23
|
)
|
|
(13
|
)
|
|
(36
|
)
|
|||
2016 payments for 2015 and prior initiatives
|
(23
|
)
|
|
(29
|
)
|
|
(52
|
)
|
|||
2016 payments for 2016 initiatives
|
(6
|
)
|
|
—
|
|
|
(6
|
)
|
|||
Foreign currency effect on liability balance
|
(2
|
)
|
|
2
|
|
|
—
|
|
|||
Accrued liabilities as of December 31, 2016
|
$
|
12
|
|
|
$
|
9
|
|
|
$
|
21
|
|
2017 charges for 2016 and prior initiatives
|
4
|
|
|
4
|
|
|
8
|
|
|||
2017 charges for 2017 initiatives
|
34
|
|
|
3
|
|
|
37
|
|
|||
Reversal of reserves no longer required
|
(1
|
)
|
|
—
|
|
|
(1
|
)
|
|||
2017 payments for 2016 and prior initiatives
|
(9
|
)
|
|
(11
|
)
|
|
(20
|
)
|
|||
2017 payments for 2017 initiatives
|
(10
|
)
|
|
(2
|
)
|
|
(12
|
)
|
|||
Foreign currency effect on liability balance
|
—
|
|
|
1
|
|
|
1
|
|
|||
Accrued liabilities as of December 31, 2017
|
$
|
30
|
|
|
$
|
4
|
|
|
$
|
34
|
|
2018 charges for 2017 and prior initiatives
|
18
|
|
|
—
|
|
|
18
|
|
|||
2018 charges for 2018 initiative
|
15
|
|
|
4
|
|
|
19
|
|
|||
2018 payments for 2017 and prior initiatives
|
(28
|
)
|
|
(5
|
)
|
|
(33
|
)
|
|||
2018 payments for 2018 initiatives
|
(1
|
)
|
|
(3
|
)
|
|
(4
|
)
|
|||
Foreign currency effect on liability balance
|
(2
|
)
|
|
—
|
|
|
(2
|
)
|
|||
Accrued liabilities as of December 31, 2018
|
$
|
32
|
|
|
$
|
—
|
|
|
$
|
32
|
|
Current portion of restructuring reserves
|
$
|
18
|
|
|
$
|
—
|
|
|
$
|
18
|
|
Long-term portion of restructuring reserve
|
14
|
|
|
—
|
|
|
14
|
|
Cash charges
|
$
|
37
|
|
Pension-related charges
|
25
|
|
|
Accelerated depreciation
|
556
|
|
|
Other non-cash charges
|
10
|
|
|
Total 2018 Restructuring, Impairment of Plant Closing and Transition Costs
|
$
|
628
|
|
|
|
||
Cash charges
|
$
|
45
|
|
Accelerated depreciation
|
3
|
|
|
Impairment of assets
|
3
|
|
|
Other non-cash charges
|
1
|
|
|
Total 2017 Restructuring, Impairment of Plant Closing and Transition Costs
|
$
|
52
|
|
|
|
||
Cash charges
|
$
|
25
|
|
Accelerated depreciation
|
8
|
|
|
Impairment of assets
|
1
|
|
|
Other non-cash charges
|
1
|
|
|
Total 2016 Restructuring, Impairment and Plant Closing and Transition Costs
|
$
|
35
|
|
|
December 31,
|
||||||
|
2018
|
|
2017
|
||||
Asset retirement obligations at beginning of year
|
$
|
45
|
|
|
$
|
39
|
|
Accretion expense
|
2
|
|
|
2
|
|
||
Liabilities incurred
|
—
|
|
|
5
|
|
||
Liabilities settled
|
(8
|
)
|
|
(5
|
)
|
||
Foreign currency effect on reserve balance
|
(2
|
)
|
|
4
|
|
||
Asset retirement obligations at end of year
|
$
|
37
|
|
|
$
|
45
|
|
|
December 31,
|
||||||
|
2018
|
|
2017
|
||||
Pension liabilities
|
$
|
253
|
|
|
$
|
230
|
|
Employee benefit accrual
|
4
|
|
|
4
|
|
||
Asset retirement obligations
|
27
|
|
|
26
|
|
||
Other postretirement benefits
|
3
|
|
|
3
|
|
||
Environmental reserves
|
11
|
|
|
11
|
|
||
Restructuring and plant closing costs
|
14
|
|
|
23
|
|
||
Other
|
1
|
|
|
9
|
|
||
Total
|
$
|
313
|
|
|
$
|
306
|
|
|
December 31,
2018 |
|
December 31,
2017 |
||||
Senior notes
|
$
|
370
|
|
|
$
|
370
|
|
Term loan facility
|
365
|
|
|
367
|
|
||
Other
|
13
|
|
|
20
|
|
||
Total debt—excluding debt to affiliates
|
$
|
748
|
|
|
$
|
757
|
|
Less: short-term debt and current portion of long-term debt
|
8
|
|
|
14
|
|
||
Total long-term debt—excluding debt to affiliates
|
$
|
740
|
|
|
$
|
743
|
|
Long-term debt to affiliates
|
—
|
|
|
—
|
|
||
Total long-term debt
|
$
|
740
|
|
|
$
|
743
|
|
•
|
the Term Loan Facility in an aggregate principal amount of
$375 million
, with a maturity of
seven years
; and
|
•
|
the ABL Facility in an aggregate principal amount of up to
$300 million
, with a maturity of
five years
.
|
Year ending December 31,
|
|
Amount
|
||
2019
|
|
$
|
1
|
|
2020
|
|
2
|
|
|
2021
|
|
1
|
|
|
2022
|
|
1
|
|
|
Thereafter
|
|
8
|
|
|
Total minimum payments
|
|
13
|
|
|
Less: Amounts representing interest
|
|
(3
|
)
|
|
Present value of minimum lease payments
|
|
10
|
|
|
Less: Current portion of capital leases
|
|
(1
|
)
|
|
Long-term portion of capital leases
|
|
$
|
9
|
|
Year ended December 31,
|
|
Amount
|
||
2019
|
|
$
|
7
|
|
2020
|
|
4
|
|
|
2021
|
|
5
|
|
|
2022
|
|
4
|
|
|
2023
|
|
5
|
|
|
Thereafter
|
|
723
|
|
|
Total
|
|
$
|
748
|
|
|
Year ended December 31,
|
||||||||||
|
2018
|
|
2017
|
|
2016
|
||||||
Revenues:
|
|
|
|
|
|
|
|||||
Trade sales, services and fees, net
|
$
|
—
|
|
|
$
|
15
|
|
|
$
|
110
|
|
Related party sales
|
—
|
|
|
17
|
|
|
60
|
|
|||
Total revenues
|
—
|
|
|
32
|
|
|
170
|
|
|||
Cost of goods sold
|
—
|
|
|
26
|
|
|
147
|
|
|||
Operating expenses:
|
|
|
|
|
|
||||||
Selling, general, and administrative (includes corporate allocations from Huntsman of nil, $1 and $7, respectively)
|
—
|
|
|
(7
|
)
|
|
15
|
|
|||
Restructuring, impairment and plant closing costs
|
—
|
|
|
1
|
|
|
—
|
|
|||
Other income, net
|
—
|
|
|
1
|
|
|
(1
|
)
|
|||
Total operating expenses
|
—
|
|
|
(5
|
)
|
|
14
|
|
|||
Income from discontinued operations before tax
|
—
|
|
|
11
|
|
|
9
|
|
|||
Income tax expense
|
—
|
|
|
(3
|
)
|
|
(1
|
)
|
|||
Net income from discontinued operations
|
$
|
—
|
|
|
$
|
8
|
|
|
$
|
8
|
|
•
|
All vested Huntsman awards remained as Huntsman awards.
|
•
|
After the separation, unvested Huntsman awards were converted to Venator awards. Huntsman stock options were converted to Venator stock options and Huntsman restricted stock, performance awards and phantom shares were converted to Venator restricted stock units.
|
•
|
39
employees were affected by the conversion.
|
•
|
Each Huntsman award was converted to approximately
1.33
Venator awards.
|
•
|
The converted awards are generally subject to the same vesting, expiration and other terms and conditions as applied to the underlying Huntsman awards immediately prior to the separation.
|
|
Year ended December 31,
|
||||
|
2018
|
|
2017
|
||
Dividend yield
|
—
|
|
|
—
|
|
Expected volatility
|
38.8
|
%
|
|
41.0
|
%
|
Risk-free interest rate
|
2.8
|
%
|
|
2.0
|
%
|
Expected life of stock options granted during the period (in years)
|
6.0
|
|
|
6.0
|
|
|
Shares
|
|
Weighted
Average
Exercise
Price
|
|
Weighted
Average
Remaining
Contractual
Term
|
|
Aggregate
Intrinsic
Value
|
|||||
|
(in thousands)
|
|
|
|
(in years)
|
|
(in millions)
|
|||||
Outstanding at December 31, 2017
|
628
|
|
|
$
|
12.24
|
|
|
|
|
|
||
Granted
|
412
|
|
|
21.82
|
|
|
|
|
|
|||
Exercised
|
—
|
|
|
—
|
|
|
|
|
|
|||
Forfeited
|
(37
|
)
|
|
14.10
|
|
|
|
|
|
|||
Expired
|
—
|
|
|
—
|
|
|
|
|
|
|||
Outstanding at December 31, 2018
|
1,003
|
|
|
16.10
|
|
|
8.5
|
|
$
|
—
|
|
|
Exercisable at December 31, 2018
|
290
|
|
|
11.74
|
|
|
7.3
|
|
—
|
|
|
Shares
|
|
Weighted
Average
Grant-Date
Fair Value
|
|||
|
(in thousands)
|
|
|
|||
Nonvested at December 31, 2017
|
504
|
|
|
$
|
13.96
|
|
Granted
|
219
|
|
|
21.83
|
|
|
Vested
(1)
|
(251
|
)
|
|
12.34
|
|
|
Forfeited
|
(24
|
)
|
|
14.17
|
|
|
Nonvested at December 31, 2018
|
448
|
|
|
18.71
|
|
|
|
(1)
|
As of
December 31, 2018
, a total of
53,779
restricted stock units were vested but not yet issued. These shares have not been reflected as vested shares in the table because, in accordance with the restricted stock unit agreements, these shares are not issued for vested restricted stock until termination of employment.
|
|
Year ended December 31,
|
||||||||||
|
2018
|
|
2017
|
|
2016
|
||||||
Income tax (benefit) expense:
|
|
|
|
|
|
|
|
||||
U.K.
|
|
|
|
|
|
|
|
||||
Current
|
$
|
2
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Deferred
|
—
|
|
|
—
|
|
|
—
|
|
|||
Non-U.K.
|
|
|
|
|
|
||||||
Current
|
9
|
|
|
30
|
|
|
(9
|
)
|
|||
Deferred
|
(19
|
)
|
|
20
|
|
|
(14
|
)
|
|||
Total
|
$
|
(8
|
)
|
|
$
|
50
|
|
|
$
|
(23
|
)
|
|
Year ended December 31,
|
||||||||||
|
2018
|
|
2017
|
|
2016
|
||||||
(Loss) income from continuing operations before income taxes
|
$
|
(165
|
)
|
|
$
|
186
|
|
|
$
|
(108
|
)
|
Expected tax expense (benefit) at U.K. statutory rate of 19%, 19% and 20%, respectively
|
$
|
(31
|
)
|
|
$
|
35
|
|
|
$
|
(22
|
)
|
Change resulting from:
|
|
|
|
|
|
||||||
Non-U.K. tax rate differentials
|
(7
|
)
|
|
(1
|
)
|
|
(19
|
)
|
|||
Other non-U.K. tax effects, including nondeductible expenses, tax effect of rate changes and transfer pricing adjustments
|
(5
|
)
|
|
—
|
|
|
(7
|
)
|
|||
Non-taxable portion of gain on sale of businesses
|
—
|
|
|
—
|
|
|
(3
|
)
|
|||
Unrealized currency exchange gains and losses
|
—
|
|
|
7
|
|
|
1
|
|
|||
Tax authority audits and dispute resolutions
|
—
|
|
|
1
|
|
|
(1
|
)
|
|||
Tax benefit of losses with valuation allowances as a result of other comprehensive income
|
—
|
|
|
—
|
|
|
(1
|
)
|
|||
Change in valuation allowance
|
39
|
|
|
3
|
|
|
27
|
|
|||
Effects of U.S. tax reform
|
—
|
|
|
3
|
|
|
—
|
|
|||
Other, net
|
(4
|
)
|
|
2
|
|
|
2
|
|
|||
Total income tax expense (benefit)
|
$
|
(8
|
)
|
|
$
|
50
|
|
|
$
|
(23
|
)
|
|
December 31,
|
||||||
|
2018
|
|
2017
|
||||
Deferred income tax assets:
|
|
|
|
|
|||
Net operating loss carryforwards
|
$
|
313
|
|
|
$
|
325
|
|
Pension and other employee compensation
|
48
|
|
|
50
|
|
||
Property, plant and equipment
|
28
|
|
|
47
|
|
||
Intangible assets
|
6
|
|
|
13
|
|
||
Other, net
|
43
|
|
|
41
|
|
||
Total
|
$
|
438
|
|
|
$
|
476
|
|
Total deferred income tax liabilities:
|
|
|
|
||||
Property, plant and equipment
|
$
|
(32
|
)
|
|
$
|
(55
|
)
|
Pension and other employee compensation
|
(4
|
)
|
|
—
|
|
||
Other, net
|
(4
|
)
|
|
(1
|
)
|
||
Total
|
$
|
(40
|
)
|
|
$
|
(56
|
)
|
Net deferred tax assets before valuation allowance
|
$
|
398
|
|
|
$
|
420
|
|
Valuation allowance
|
(220
|
)
|
|
(253
|
)
|
||
Net deferred tax assets
|
$
|
178
|
|
|
$
|
167
|
|
Non-current deferred tax assets
|
178
|
|
|
167
|
|
||
Non-current deferred tax liabilities
|
—
|
|
|
—
|
|
||
Net deferred tax assets
|
$
|
178
|
|
|
$
|
167
|
|
|
2018
|
|
2017
|
|
2016
|
||||||
Unrecognized tax benefits as of January 1
|
$
|
23
|
|
|
$
|
20
|
|
|
$
|
22
|
|
Gross increases and decreases—tax positions taken during a prior period
|
2
|
|
|
—
|
|
|
—
|
|
|||
Gross increases and decreases—tax positions taken during the current period
|
—
|
|
|
1
|
|
|
(1
|
)
|
|||
Decreases related to settlements of amounts due to tax authorities
|
—
|
|
|
—
|
|
|
—
|
|
|||
Reductions resulting from the lapse of statutes of limitation
|
(7
|
)
|
|
—
|
|
|
—
|
|
|||
Foreign currency movements
|
(1
|
)
|
|
2
|
|
|
(1
|
)
|
|||
Unrecognized tax benefits as of December 31,
|
$
|
17
|
|
|
$
|
23
|
|
|
$
|
20
|
|
Tax Jurisdiction
|
|
Open Tax Years
|
Finland
|
|
2012 and later
|
France
|
|
2015 and later
|
Germany
|
|
2007 and later
|
Italy
|
|
2013 and later
|
Malaysia
|
|
2013 and later
|
Spain
|
|
2008 and later
|
United Kingdom
|
|
2017 and later
|
United States federal
|
|
2015 and later
|
|
Defined Benefit
Plans
|
|
Other
Postretirement
Benefit Plans
|
||||||||||||
|
2018
|
|
2017
|
|
2018
|
|
2017
|
||||||||
Change in benefit obligation
|
|
|
|
|
|
|
|
||||||||
Benefit obligation at beginning of year
|
$
|
1,136
|
|
|
$
|
1,053
|
|
|
$
|
3
|
|
|
$
|
3
|
|
Service cost
|
5
|
|
|
5
|
|
|
—
|
|
|
—
|
|
||||
Interest cost
|
25
|
|
|
25
|
|
|
—
|
|
|
—
|
|
||||
Actuarial gain
|
(60
|
)
|
|
(1
|
)
|
|
—
|
|
|
—
|
|
||||
Gross benefits paid
|
(58
|
)
|
|
(55
|
)
|
|
—
|
|
|
—
|
|
||||
Plan amendments
|
6
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||
Exchange rates
|
(56
|
)
|
|
116
|
|
|
—
|
|
|
—
|
|
||||
Curtailments
|
23
|
|
|
(4
|
)
|
|
—
|
|
|
—
|
|
||||
Transfers
|
—
|
|
|
(3
|
)
|
|
—
|
|
|
—
|
|
||||
Benefit obligation at end of year
|
$
|
1,021
|
|
|
$
|
1,136
|
|
|
$
|
3
|
|
|
$
|
3
|
|
Accumulated benefit obligation at end of year
|
983
|
|
|
1,091
|
|
|
|
|
|
||||||
Change in plan assets
|
|
|
|
|
|
|
|
||||||||
Fair value of plan assets at beginning of year
|
$
|
906
|
|
|
$
|
790
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Actual return on plan assets
|
(34
|
)
|
|
63
|
|
|
—
|
|
|
—
|
|
||||
Employer contribution
|
47
|
|
|
29
|
|
|
—
|
|
|
—
|
|
||||
Gross benefits paid
|
(58
|
)
|
|
(55
|
)
|
|
—
|
|
|
—
|
|
||||
Transfers
|
—
|
|
|
(5
|
)
|
|
—
|
|
|
—
|
|
||||
Exchange rates
|
(48
|
)
|
|
84
|
|
|
—
|
|
|
—
|
|
||||
Fair value of plan assets at end of year
|
$
|
813
|
|
|
$
|
906
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Funded status
|
|
|
|
|
|
|
|
||||||||
Fair value of plan assets
|
$
|
813
|
|
|
$
|
906
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Benefit obligation
|
(1,021
|
)
|
|
(1,136
|
)
|
|
(3
|
)
|
|
(3
|
)
|
||||
Accrued benefit cost
|
$
|
(208
|
)
|
|
$
|
(230
|
)
|
|
$
|
(3
|
)
|
|
$
|
(3
|
)
|
Amounts recognized in balance sheet:
|
|
|
|
|
|
|
|
||||||||
Noncurrent asset
|
$
|
46
|
|
|
$
|
1
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Current liability
|
(1
|
)
|
|
(1
|
)
|
|
—
|
|
|
—
|
|
||||
Noncurrent liability
|
(253
|
)
|
|
(230
|
)
|
|
(3
|
)
|
|
(3
|
)
|
||||
Total
|
$
|
(208
|
)
|
|
$
|
(230
|
)
|
|
$
|
(3
|
)
|
|
$
|
(3
|
)
|
Amounts recognized in accumulated other comprehensive loss:
|
|
|
|
|
|
|
|
||||||||
Net actuarial loss (gain)
|
$
|
302
|
|
|
$
|
296
|
|
|
$
|
(4
|
)
|
|
$
|
(4
|
)
|
Prior service cost (credit)
|
11
|
|
|
7
|
|
|
(1
|
)
|
|
(1
|
)
|
||||
Total
|
$
|
313
|
|
|
$
|
303
|
|
|
$
|
(5
|
)
|
|
$
|
(5
|
)
|
|
Defined
Benefit Plans
|
|
Other
Postretirement
Benefit Plans
|
||||
Actuarial loss
|
$
|
15
|
|
|
$
|
—
|
|
Prior service cost
|
1
|
|
|
—
|
|
||
Total
|
$
|
16
|
|
|
$
|
—
|
|
|
Defined Benefit Plans
|
||||||||||
|
2018
|
|
2017
|
|
2016
|
||||||
Service cost
|
$
|
5
|
|
|
$
|
5
|
|
|
$
|
4
|
|
Interest cost
|
25
|
|
|
25
|
|
|
31
|
|
|||
Expected return on plan assets
|
(47
|
)
|
|
(43
|
)
|
|
(39
|
)
|
|||
Amortization of actuarial loss
|
15
|
|
|
16
|
|
|
10
|
|
|||
Amortization of prior service cost
|
3
|
|
|
1
|
|
|
1
|
|
|||
Curtailment loss (gain)
|
23
|
|
|
(4
|
)
|
|
—
|
|
|||
Net periodic benefit cost
|
$
|
24
|
|
|
$
|
—
|
|
|
$
|
7
|
|
|
Other Postretirement Benefit Plans
|
||||||||||
|
2018
|
|
2017
|
|
2016
|
||||||
Amortization of actuarial loss
|
—
|
|
|
1
|
|
|
—
|
|
|||
Amortization of prior service credit
|
—
|
|
|
(3
|
)
|
|
—
|
|
|||
Net periodic benefit credit
|
$
|
—
|
|
|
$
|
(2
|
)
|
|
$
|
—
|
|
|
Defined Benefit Plans
|
||||||||||
|
2018
|
|
2017
|
|
2016
|
||||||
Current year actuarial gain (loss)
|
$
|
45
|
|
|
$
|
(24
|
)
|
|
$
|
86
|
|
Amortization of actuarial loss
|
(15
|
)
|
|
(16
|
)
|
|
(11
|
)
|
|||
Current year prior service cost
|
5
|
|
|
—
|
|
|
—
|
|
|||
Amortization of prior service cost
|
(3
|
)
|
|
(1
|
)
|
|
(1
|
)
|
|||
Curtailment effects
|
(23
|
)
|
|
4
|
|
|
—
|
|
|||
Other
|
—
|
|
|
(3
|
)
|
|
—
|
|
|||
Total recognized in other comprehensive income (loss)
|
9
|
|
|
(40
|
)
|
|
74
|
|
|||
Amount related to discontinued operations
|
—
|
|
|
—
|
|
|
(8
|
)
|
|||
Total recognized in other comprehensive income (loss) from continuing operations
|
9
|
|
|
(40
|
)
|
|
66
|
|
|||
Net periodic benefit cost
|
24
|
|
|
—
|
|
|
7
|
|
|||
Total recognized in net periodic benefit cost and other comprehensive income (loss)
|
$
|
33
|
|
|
$
|
(40
|
)
|
|
$
|
81
|
|
|
Other Postretirement Benefit Plans
|
||||||||||
|
2018
|
|
2017
|
|
2016
|
||||||
Current year actuarial loss
|
$
|
—
|
|
|
$
|
(1
|
)
|
|
$
|
—
|
|
Amortization of actuarial loss
|
—
|
|
|
(1
|
)
|
|
—
|
|
|||
Current year prior service credits
|
—
|
|
|
—
|
|
|
(2
|
)
|
|||
Amortization of prior service credit
|
—
|
|
|
3
|
|
|
—
|
|
|||
Total recognized in other comprehensive (loss) income
|
—
|
|
|
1
|
|
|
(2
|
)
|
|||
Net periodic benefit cost
|
—
|
|
|
(2
|
)
|
|
—
|
|
|||
Total recognized in net periodic benefit cost and other comprehensive loss
|
$
|
—
|
|
|
$
|
(1
|
)
|
|
$
|
(2
|
)
|
|
Defined Benefit Plans
|
|||||||
|
2018
|
|
2017
|
|
2016
|
|||
Projected benefit obligation:
|
|
|
|
|
|
|
|
|
Discount rate
|
2.38
|
%
|
|
2.21
|
%
|
|
2.28
|
%
|
Rate of compensation increase
|
3.69
|
%
|
|
3.74
|
%
|
|
3.79
|
%
|
Net periodic pension cost:
|
|
|
|
|
|
|||
Discount rate
|
2.21
|
%
|
|
1.86
|
%
|
|
3.27
|
%
|
Rate of compensation increase
|
3.74
|
%
|
|
3.53
|
%
|
|
3.24
|
%
|
Expected return on plan assets
|
5.23
|
%
|
|
5.71
|
%
|
|
5.22
|
%
|
|
Other Postretirement Benefit Plans
|
|||||||
|
2018
|
|
2017
|
|
2016
|
|||
Projected benefit obligation:
|
|
|
|
|
|
|
|
|
Discount rate
|
3.50
|
%
|
|
3.38
|
%
|
|
3.72
|
%
|
Net periodic pension cost:
|
|
|
|
|
|
|||
Discount rate
|
3.30
|
%
|
|
3.72
|
%
|
|
6.94
|
%
|
|
December 31,
|
||||||
|
2018
|
|
2017
|
||||
Projected benefit obligation
|
$
|
385
|
|
|
$
|
364
|
|
Fair value of plan assets
|
131
|
|
|
133
|
|
|
December 31,
|
||||||
|
2018
|
|
2017
|
||||
Projected benefit obligation
|
$
|
385
|
|
|
$
|
364
|
|
Accumulated benefit obligation
|
375
|
|
|
355
|
|
||
Fair value of plan assets
|
131
|
|
|
133
|
|
|
Defined
Benefit Plans
|
|
Other
Postretirement
Benefit Plans
|
||||
2019 expected employer contributions:
|
|
|
|
||||
To plan trusts
|
$
|
25
|
|
|
$
|
—
|
|
Expected benefit payments:
|
|
|
|
||||
2019
|
38
|
|
|
—
|
|
||
2020
|
41
|
|
|
—
|
|
||
2021
|
43
|
|
|
—
|
|
||
2022
|
44
|
|
|
—
|
|
||
2023
|
46
|
|
|
—
|
|
||
2024 - 2028
|
236
|
|
|
1
|
|
Asset Category
|
|
December 31,
2018 |
|
Fair Value
Amounts Using
Quoted Prices in
Active Markets for
Identical Assets
(Level 1)
|
|
Significant
Other
Observable
Inputs
(Level 2)
|
|
Significant
Unobservable
Inputs
(Level 3)
|
||||||||
Pension plans:
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Equities
|
|
$
|
213
|
|
|
$
|
202
|
|
|
$
|
11
|
|
|
$
|
—
|
|
Fixed income
|
|
547
|
|
|
39
|
|
|
501
|
|
|
7
|
|
||||
Real estate/other
|
|
34
|
|
|
—
|
|
|
6
|
|
|
28
|
|
||||
Cash and cash equivalents
|
|
19
|
|
|
19
|
|
|
—
|
|
|
—
|
|
||||
Total pension plan assets
|
|
$
|
813
|
|
|
$
|
260
|
|
|
$
|
518
|
|
|
$
|
35
|
|
Asset Category
|
December 31,
2017 |
|
Fair Value
Amounts Using
Quoted Prices in
Active Markets for
Identical Assets
(Level 1)
|
|
Significant
Other
Observable
Inputs
(Level 2)
|
|
Significant
Unobservable
Inputs
(Level 3)
|
||||||||
Pension plans:
|
|
|
|
|
|
|
|
|
|
|
|||||
Equities
|
$
|
265
|
|
|
$
|
252
|
|
|
$
|
13
|
|
|
$
|
—
|
|
Fixed income
|
598
|
|
|
41
|
|
|
550
|
|
|
7
|
|
||||
Real estate/other
|
33
|
|
|
—
|
|
|
3
|
|
|
30
|
|
||||
Cash and cash equivalents
|
10
|
|
|
5
|
|
|
5
|
|
|
—
|
|
||||
Total pension plan assets
|
$
|
906
|
|
|
$
|
298
|
|
|
$
|
571
|
|
|
$
|
37
|
|
|
Real Estate/Other
Year ended December 31,
|
||||||
|
2018
|
|
2017
|
||||
Fair Value Measurements of Plan Assets Using Significant Unobservable Inputs (Level 3)
|
|
|
|
|
|
||
Balance at the beginning of the period
|
$
|
30
|
|
|
$
|
27
|
|
Return on pension plan assets
|
(1
|
)
|
|
5
|
|
||
Purchases, sales and settlements
|
(1
|
)
|
|
(2
|
)
|
||
Transfers (out of) into Level 3
|
—
|
|
|
—
|
|
||
Disposals
|
—
|
|
|
—
|
|
||
Balance at the end of the period
|
$
|
28
|
|
|
$
|
30
|
|
|
Fixed Income
Year ended December 31,
|
||||||
|
2018
|
|
2017
|
||||
Fair Value Measurements of Plan Assets Using Significant Unobservable Inputs (Level 3)
|
|
|
|
|
|
||
Balance at the beginning of the period
|
$
|
7
|
|
|
$
|
6
|
|
Return on pension plan assets
|
—
|
|
|
1
|
|
||
Purchases, sales and settlements
|
—
|
|
|
—
|
|
||
Transfers (out of) into Level 3
|
—
|
|
|
—
|
|
||
Balance at the end of the period
|
$
|
7
|
|
|
$
|
7
|
|
Asset category
|
Target
allocation
2019
|
|
Allocated at
December 31, 2018 |
|
Allocated at
December 31, 2017 |
|||
Pension plans:
|
|
|
|
|
|
|
|
|
Equities
|
29
|
%
|
|
26
|
%
|
|
29
|
%
|
Fixed income
|
61
|
%
|
|
64
|
%
|
|
66
|
%
|
Real estate/other
|
1
|
%
|
|
1
|
%
|
|
4
|
%
|
Cash
|
9
|
%
|
|
9
|
%
|
|
1
|
%
|
Total pension plans
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
Year ended December 31,
|
|
Amounts
|
||
2019
|
|
$
|
13
|
|
2020
|
|
11
|
|
|
2021
|
|
9
|
|
|
2022
|
|
6
|
|
|
2023
|
|
4
|
|
|
Thereafter
|
|
40
|
|
|
Total
|
|
$
|
83
|
|
|
Foreign
currency
translation
adjustment
(1)
|
|
Pension and
other
postretirement
benefits
adjustments,
net of tax
(2)
|
|
Other
comprehensive
income of
unconsolidated
affiliates
|
|
Hedging
instruments
|
|
Total
|
|
Amounts
attributable to
noncontrolling
interests
|
|
Amounts
attributable
to
Venator
|
||||||||||||||
Beginning balance, January 1, 2017
|
(112
|
)
|
|
(306
|
)
|
|
(5
|
)
|
|
—
|
|
|
(423
|
)
|
|
—
|
|
|
(423
|
)
|
|||||||
Adjustment due to discontinued operations
|
5
|
|
|
24
|
|
|
—
|
|
|
—
|
|
|
29
|
|
|
—
|
|
|
29
|
|
|||||||
Tax expense
|
—
|
|
|
(3
|
)
|
|
—
|
|
|
—
|
|
|
(3
|
)
|
|
—
|
|
|
(3
|
)
|
|||||||
Other comprehensive (loss) income before reclassifications
|
101
|
|
|
4
|
|
|
—
|
|
|
(5
|
)
|
|
100
|
|
|
—
|
|
|
100
|
|
|||||||
Tax expense
|
—
|
|
|
(1
|
)
|
|
—
|
|
|
—
|
|
|
(1
|
)
|
|
—
|
|
|
(1
|
)
|
|||||||
Amounts reclassified from accumulated other comprehensive loss, gross
(3)
|
—
|
|
|
15
|
|
|
—
|
|
|
—
|
|
|
15
|
|
|
—
|
|
|
15
|
|
|||||||
Tax expense
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Net current-period other comprehensive (loss) income
|
106
|
|
|
39
|
|
|
—
|
|
|
(5
|
)
|
|
140
|
|
|
—
|
|
|
140
|
|
|||||||
Ending balance, December 31, 2017
|
(6
|
)
|
|
(267
|
)
|
|
(5
|
)
|
|
(5
|
)
|
|
(283
|
)
|
|
—
|
|
|
(283
|
)
|
|||||||
Adjustment due to discontinued operations
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Tax expense
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Other comprehensive (loss) income before reclassifications
|
(90
|
)
|
|
(27
|
)
|
|
—
|
|
|
11
|
|
|
(106
|
)
|
|
—
|
|
|
(106
|
)
|
|||||||
Tax expense
|
—
|
|
|
(2
|
)
|
|
—
|
|
|
—
|
|
|
(2
|
)
|
|
—
|
|
|
(2
|
)
|
|||||||
Amounts reclassified from accumulated other comprehensive loss, gross
(3)
|
—
|
|
|
18
|
|
|
—
|
|
|
—
|
|
|
18
|
|
|
—
|
|
|
18
|
|
|||||||
Tax expense
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Net current-period other comprehensive (loss) income
|
(90
|
)
|
|
(11
|
)
|
|
—
|
|
|
11
|
|
|
(90
|
)
|
|
—
|
|
|
(90
|
)
|
|||||||
Ending balance, December 31, 2018
|
$
|
(96
|
)
|
|
$
|
(278
|
)
|
|
$
|
(5
|
)
|
|
$
|
6
|
|
|
$
|
(373
|
)
|
|
$
|
—
|
|
|
$
|
(373
|
)
|
|
|
(1)
|
Amounts are net of tax of
nil
each as of January 1,
2017
,
December 31, 2017
and
December 31, 2018
.
|
(2)
|
Amounts are net of tax of
$56 million
,
$52 million
and
$50 million
as of January 1,
2017
,
December 31, 2017
and
December 31, 2018
, respectively.
|
(3)
|
See table below for details about the amounts reclassified from accumulated other comprehensive loss.
|
|
Year ended
December 31, |
|
Affected line item in the statement
where net income is presented
|
||||||
|
2018
|
|
2017
|
|
|||||
Details about Accumulated Other Comprehensive Loss Components:
|
|
|
|
|
|
|
|
||
Amortization of pension and other postretirement benefits:
|
|
|
|
|
|
|
|
||
Actuarial loss
|
$
|
15
|
|
|
$
|
17
|
|
|
(a)
|
Prior service cost
|
3
|
|
|
(2
|
)
|
|
(a)
|
||
|
18
|
|
|
15
|
|
|
Total before tax
|
||
Income tax benefit
|
—
|
|
|
—
|
|
|
Income tax (expense) benefit
|
||
Total reclassifications for the period
|
$
|
18
|
|
|
$
|
15
|
|
|
Net of tax
|
|
|
(a)
|
These accumulated other comprehensive loss components are included in the computation of net periodic pension costs. See “
Note 20. Employee Benefit Plans
.”
|
Segment
|
|
Product Group
|
Titanium Dioxide
|
|
titanium dioxide
|
Performance Additives
|
|
functional additives, color pigments, timber treatment and water treatment chemicals
|
|
Year ended December 31,
|
||||||||||
|
2018
|
|
2017
|
|
2016
|
||||||
Revenues:
|
|
|
|
|
|
|
|
|
|||
Titanium Dioxide
|
$
|
1,666
|
|
|
$
|
1,604
|
|
|
$
|
1,554
|
|
Performance Additives
|
599
|
|
|
605
|
|
|
585
|
|
|||
Total
|
$
|
2,265
|
|
|
$
|
2,209
|
|
|
$
|
2,139
|
|
Segment adjusted EBITDA
(1)
:
|
|
|
|
|
|
||||||
Titanium Dioxide
|
$
|
417
|
|
|
$
|
387
|
|
|
$
|
61
|
|
Performance Additives
|
62
|
|
|
72
|
|
|
69
|
|
|||
Corporate and other
|
(43
|
)
|
|
(64
|
)
|
|
(53
|
)
|
|||
Total
|
$
|
436
|
|
|
$
|
395
|
|
|
$
|
77
|
|
Reconciliation of adjusted EBITDA to net (loss) income:
|
|
|
|
|
|
||||||
Interest expense
|
(53
|
)
|
|
(100
|
)
|
|
(59
|
)
|
|||
Interest income
|
13
|
|
|
60
|
|
|
15
|
|
|||
Income tax benefit (expense)—continuing operations
|
8
|
|
|
(50
|
)
|
|
23
|
|
|||
Depreciation and amortization
|
(132
|
)
|
|
(127
|
)
|
|
(114
|
)
|
|||
Net income attributable to noncontrolling interests
|
6
|
|
|
10
|
|
|
10
|
|
|||
Other adjustments:
|
|
|
|
|
|
||||||
Business acquisition and integration expenses
|
(20
|
)
|
|
(5
|
)
|
|
(11
|
)
|
|||
Separation expense, net
|
(2
|
)
|
|
(7
|
)
|
|
—
|
|
|||
U.S. income tax reform
|
—
|
|
|
34
|
|
|
—
|
|
|||
Net income of discontinued operations, net of tax
|
—
|
|
|
8
|
|
|
8
|
|
|||
(Loss) gain on disposition of business/assets
|
(2
|
)
|
|
—
|
|
|
22
|
|
|||
Certain legal settlements and related expenses
|
—
|
|
|
(1
|
)
|
|
(2
|
)
|
|||
Amortization of pension and postretirement actuarial losses
|
(15
|
)
|
|
(17
|
)
|
|
(10
|
)
|
|||
Net plant incident credits (costs)
|
232
|
|
|
(4
|
)
|
|
(1
|
)
|
|||
Restructuring, impairment and plant closing and transition costs
|
(628
|
)
|
|
(52
|
)
|
|
(35
|
)
|
|||
Net (loss) income
|
$
|
(157
|
)
|
|
$
|
144
|
|
|
$
|
(77
|
)
|
Depreciation and Amortization:
|
|
|
|
|
|
||||||
Titanium Dioxide
|
$
|
93
|
|
|
$
|
85
|
|
|
$
|
87
|
|
Performance Additives
|
27
|
|
|
36
|
|
|
19
|
|
|||
Corporate and other
|
12
|
|
|
6
|
|
|
8
|
|
|||
Total
|
$
|
132
|
|
|
$
|
127
|
|
|
$
|
114
|
|
|
Year ended December 31,
|
||||||||||
|
2018
|
|
2017
|
|
2016
|
||||||
Capital Expenditures:
|
|
|
|
|
|
|
|
|
|||
Titanium Dioxide
|
$
|
301
|
|
|
$
|
178
|
|
|
$
|
73
|
|
Performance Additives
|
24
|
|
|
17
|
|
|
30
|
|
|||
Corporate and other
|
1
|
|
|
2
|
|
|
—
|
|
|||
Total
|
$
|
326
|
|
|
$
|
197
|
|
|
$
|
103
|
|
Total Assets
(2)
:
|
|
|
|
|
|
||||||
Titanium Dioxide
|
$
|
1,631
|
|
|
$
|
1,794
|
|
|
$
|
1,561
|
|
Performance Additives
|
592
|
|
|
703
|
|
|
764
|
|
|||
Corporate and other
|
262
|
|
|
350
|
|
|
210
|
|
|||
Total
|
$
|
2,485
|
|
|
$
|
2,847
|
|
|
$
|
2,535
|
|
|
|
(1)
|
Adjusted EBITDA is defined as net (loss) income before interest expense, interest income, income tax benefit (expense), depreciation and amortization and net income attributable to noncontrolling interests, as well as eliminating the following adjustments: (a) business acquisition and integration expenses; (b) separation expense, net; (c) U.S. income tax reform; (d) (loss) gain on disposition of businesses/assets; (e) net income of discontinued operations, net of tax; (f) certain legal
|
(2)
|
Defined as total assets less current assets of discontinued operations and noncurrent assets of discontinued operations.
|
|
|
Year ended December 31,
|
||||||||||
By Geographic Area
|
|
2018
|
|
2017
|
|
2016
|
||||||
Revenues
(1)
:
|
|
|
|
|
|
|
|
|
|
|||
United States
|
|
$
|
518
|
|
|
$
|
526
|
|
|
$
|
491
|
|
Germany
|
|
257
|
|
|
230
|
|
|
210
|
|
|||
China
|
|
131
|
|
|
112
|
|
|
113
|
|
|||
Italy
|
|
126
|
|
|
126
|
|
|
130
|
|
|||
United Kingdom
|
|
116
|
|
|
114
|
|
|
102
|
|
|||
Spain
|
|
96
|
|
|
86
|
|
|
79
|
|
|||
France
|
|
89
|
|
|
94
|
|
|
98
|
|
|||
India
|
|
65
|
|
|
63
|
|
|
54
|
|
|||
Canada
|
|
55
|
|
|
56
|
|
|
59
|
|
|||
Other nations
|
|
812
|
|
|
802
|
|
|
803
|
|
|||
Total
|
|
$
|
2,265
|
|
|
$
|
2,209
|
|
|
$
|
2,139
|
|
Long Lived Assets:
|
|
|
|
|
|
|
||||||
Germany
|
|
$
|
263
|
|
|
$
|
256
|
|
|
$
|
215
|
|
United Kingdom
|
|
180
|
|
|
208
|
|
|
198
|
|
|||
Italy
|
|
164
|
|
|
170
|
|
|
155
|
|
|||
United States
|
|
111
|
|
|
253
|
|
|
263
|
|
|||
Finland
(2)
|
|
69
|
|
|
257
|
|
|
146
|
|
|||
Other nations
|
|
207
|
|
|
223
|
|
|
201
|
|
|||
Total
|
|
$
|
994
|
|
|
$
|
1,367
|
|
|
$
|
1,178
|
|
|
|
(1)
|
Geographic information for revenues is based upon countries into which product is sold.
|
(2)
|
The Pori, Finland plant closure was announced in the third quarter of 2018 and is anticipated to be completed in 2022.
|
2018
|
First Quarter
|
|
Second Quarter
|
|
Third Quarter
|
|
Fourth Quarter
|
||||||||
Revenue
|
$
|
622
|
|
|
$
|
626
|
|
|
$
|
533
|
|
|
$
|
484
|
|
Cost of goods sold
|
454
|
|
|
193
|
|
|
463
|
|
|
440
|
|
||||
Restructuring, impairment and plant closing and transition costs
|
9
|
|
|
136
|
|
|
428
|
|
|
55
|
|
||||
Income (loss) from continuing operations
|
80
|
|
|
198
|
|
|
(366
|
)
|
|
(69
|
)
|
||||
Net income (loss)
|
80
|
|
|
198
|
|
|
(366
|
)
|
|
(69
|
)
|
||||
Net income (loss) attributable to Venator
|
78
|
|
|
196
|
|
|
(368
|
)
|
|
(69
|
)
|
||||
Basic income (loss) per share:
|
|
|
|
|
|
|
|
||||||||
Income (loss) from continuing operations attributable to Venator Materials PLC ordinary shareholders
|
0.73
|
|
|
1.84
|
|
|
(3.46
|
)
|
|
(0.65
|
)
|
||||
Net income (loss) attributable to Venator Materials PLC ordinary shareholders
|
0.73
|
|
|
1.84
|
|
|
(3.46
|
)
|
|
(0.65
|
)
|
||||
Diluted income (loss) per share:
|
|
|
|
|
|
|
|
||||||||
Income (loss) per share from continuing operations attributable to Venator Materials PLC ordinary shareholders
|
0.73
|
|
|
1.84
|
|
|
(3.46
|
)
|
|
(0.65
|
)
|
||||
Net income (loss) per share attributable to Venator Materials PLC ordinary shareholders
|
0.73
|
|
|
1.84
|
|
|
(3.46
|
)
|
|
(0.65
|
)
|
||||
2017
|
|
|
|
|
|
|
|
||||||||
Revenue
|
537
|
|
|
562
|
|
|
582
|
|
|
528
|
|
||||
Cost of goods sold
|
465
|
|
|
480
|
|
|
448
|
|
|
388
|
|
||||
Restructuring, impairment and plant closing and transition costs
|
26
|
|
|
7
|
|
|
16
|
|
|
3
|
|
||||
(Loss) income from continuing operations
|
(21
|
)
|
|
34
|
|
|
53
|
|
|
70
|
|
||||
Net (loss) income
|
(13
|
)
|
|
34
|
|
|
53
|
|
|
70
|
|
||||
Net (loss) income attributable to Venator
|
(16
|
)
|
|
31
|
|
|
51
|
|
|
68
|
|
||||
Basic (loss) income per share:
|
|
|
|
|
|
|
|
||||||||
(Loss) income per share from continuing operations attributable to Venator Materials PLC ordinary shareholders
|
(0.23
|
)
|
|
0.29
|
|
|
0.48
|
|
|
0.64
|
|
||||
Net (loss) income per share attributable to Venator Materials PLC ordinary shareholders
|
(0.15
|
)
|
|
0.29
|
|
|
0.48
|
|
|
0.64
|
|
||||
Diluted (loss) income per share:
|
|
|
|
|
|
|
|
||||||||
(Loss) income per share from continuing operations attributable to Venator Materials PLC ordinary shareholders
|
(0.23
|
)
|
|
0.29
|
|
|
0.48
|
|
|
0.64
|
|
||||
Net (loss) income per share attributable to Venator Materials PLC ordinary shareholders
|
(0.15
|
)
|
|
0.29
|
|
|
0.48
|
|
|
0.64
|
|
•
|
pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of our Company;
|
•
|
provide reasonable assurance that transactions are recorded properly to allow for the preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of our Company are being made only in accordance with authorizations of management and our Board of Directors;
|
•
|
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our consolidated financial statements; and
|
•
|
provide reasonable assurance as to the detection of fraud.
|
(a)
|
Documents filed with this report.
|
(1)
|
Consolidated and Combined Financial Statements
|
i.
|
All financial statements of the Company as set forth under Item 8 of this annual report on Form 10-K
|
(2)
|
Financial Statement Schedules
|
i.
|
Schedule II – Valuation and Qualifying Accounts
|
(3)
|
Exhibits – The exhibits to this report are listed on the Exhibit Index below.
|
Exhibit
No.
|
|
Description
|
|
3.1
|
|
|
|
4.1
|
|
|
|
4.2
|
|
|
|
4.3
|
|
|
|
4.4
|
|
|
|
4.5
|
|
|
|
10.1
|
|
|
|
10.2
|
|
|
|
10.3+
|
|
|
|
10.4
|
|
|
|
10.5
|
|
|
|
10.6+
|
|
|
10.7+
|
|
|
10.8+
|
|
|
10.9+
|
|
|
10.10+
|
|
|
10.11+
|
|
|
10.12+
|
|
|
10.13+
|
|
|
10.14+
|
|
|
10.15+
|
|
|
10.16+
|
|
|
10.17+
|
|
|
10.18+
|
|
|
10.19+
|
|
|
10.20*
|
|
|
10.21+*
|
|
|
10.22+*
|
|
|
10.23+*
|
|
|
10.24+*
|
|
|
10.25+*
|
|
|
10.26+*
|
|
|
21.1*
|
|
|
23.1*
|
|
|
23.2*
|
|
31.1*
|
|
|
31.2*
|
|
|
32.1*
|
|
|
32.2*
|
|
|
101.INS*
|
|
XBRL Instance Document
|
101.SCH*
|
|
XBRL Taxonomy Extension Schema Document
|
101.CAL*
|
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
101.DEF*
|
|
XBRL Taxonomy Definition Linkbase Document
|
101.LAB*
|
|
XBRL Taxonomy Extension Labels Linkbase Document
|
101.PRE*
|
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
|
|
|
Additions
|
|
|
|
|
||||||||||||
Description
|
|
Balance at
beginning
of period
|
|
Charges
to cost
and expenses
|
|
Charged
to other
accounts
|
|
Deductions
|
|
Balance at
end of period
|
||||||||||
Allowance for doubtful accounts:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Year ended December 31, 2018
|
|
$
|
5
|
|
|
$
|
1
|
|
|
$
|
—
|
|
|
$
|
(1
|
)
|
|
$
|
5
|
|
Year ended December 31, 2017
|
|
4
|
|
|
1
|
|
|
—
|
|
|
—
|
|
|
5
|
|
|||||
Year ended December 31, 2016
|
|
4
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
4
|
|
Dated: February 20, 2019
|
|
|
|
|
|
|
VENATOR MATERIALS PLC
|
|
|
|
|
|
By:
|
/s/ KURT D. OGDEN
|
|
|
Kurt D. Ogden
|
|
|
Executive Vice President and Chief Financial Officer
|
/s/ Simon Turner
|
|
President and Chief Executive Officer, and Director (Principal Executive Officer)
|
|
February 20, 2019
|
Simon Turner
|
|
|
|
|
|
|
|
|
|
/s/ Kurt D. Ogden
|
|
Executive Vice President and Chief Financial Officer (Principal Financial Officer), and Venator’s Authorized Representative in the United States
|
|
February 20, 2019
|
Kurt D. Ogden
|
|
|
|
|
|
|
|
|
|
/s/ Stephen Ibbotson
|
|
Vice President and Corporate Controller (Principal Accounting Officer)
|
|
February 20, 2019
|
Stephen Ibbotson
|
|
|
|
|
|
|
|
|
|
/s/ Peter R. Huntsman
|
|
Director
|
|
February 20, 2019
|
Peter R. Huntsman
|
|
|
|
|
|
|
|
|
|
/s/ Sir Robert J. Margetts
|
|
Director
|
|
February 20, 2019
|
Sir Robert J. Margetts
|
|
|
|
|
|
|
|
|
|
/s/ Douglas D. Anderson
|
|
Director
|
|
February 20, 2019
|
Douglas D. Anderson
|
|
|
|
|
|
|
|
|
|
/s/ Daniele Ferrari
|
|
Director
|
|
February 20, 2019
|
Daniele Ferrari
|
|
|
|
|
|
|
|
|
|
/s/ Kathy D. Patrick
|
|
Director
|
|
February 20, 2019
|
Kathy D. Patrick
|
|
|
|
|
1.
|
Definitions
. As used in this Deed:
|
(a)
|
“
Application for Relief
” means an application made by Indemnitee to the court under sections 661(3) or 661 (4) or section 1157 of the Companies Act.
|
(b)
|
“
Associated Company
” has the meaning given in section 256 of the Companies Act.
|
(c)
|
“
Company
” means Venator Materials PLC (company number 10747130) and any Associated Company.
|
(d)
|
“
Companies Act
” means the Companies Act 2006 as amended from time to time.
|
(e)
|
“
Expenses
” include, all attorneys’ fees and disbursements, accountants’ fees, private investigation fees and disbursements, retainers, court costs, transcript costs, fees of experts, fees and expenses of witnesses, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other disbursements, or expenses, reasonably incurred by or for Indemnitee in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in a Proceeding or establishing Indemnitee’s right of entitlement to indemnification for any of the foregoing.
|
(f)
|
“
final
” in relation to any conviction, judgment or refusal of relief, has the meaning given in section 204(3) of the Companies Act.
|
(g)
|
“
Party
” or “
Parties
” means the Company or the Indemnitee or both as appropriate;
|
(h)
|
“
Proceeding
” includes any threatened, pending or completed action, suit, inquiry or proceeding, whether brought by or in the right of the Company or otherwise and whether of a civil, criminal, administrative, arbitrative or investigative nature, in which Indemnitee is or will be involved as a party, as a witness or otherwise, by reason of the fact that Indemnitee is or was a director or officer of the Company, by reason of any action taken by him or of any inaction on his part while acting as a director or officer or by reason of the fact that he is or was serving at the request of the Company as a director, officer, trustee, employee or agent of another company, partnership, joint venture, trust, limited liability company or other enterprise including any predecessor, subsidiary of affiliated entity of the Company; in each case whether or not he is acting or serving in any such capacity at the time any liability or expense is incurred for which indemnification or reimbursement can be provided under this Deed; provided, however, that any such action, suit or proceeding which is brought by Indemnitee or any person or entity on behalf of or in the right of Indemnitee against the Company or directors or officers of the Company, shall not be deemed a Proceeding without prior approval by a majority of the Board of Directors of the Company.
|
(i)
|
“
Liabilities
” include, without limitation any judgments, fines and penalties against Indemnitee in connection with a Proceeding and amounts paid by Indemnitee in settlement of a Proceeding.
|
(j)
|
“
Restricted Proceeding
” means any (1) criminal Proceedings, (1) Proceedings brought by the Company and (1) Application for Relief.
|
(k)
|
“
Stock Exchange
” means any stock exchange upon which securities issued by the Company (or depositary receipts representing such securities) are listed;
|
(l)
|
“
substantiating documentation
” shall mean copies of bills or invoices for costs incurred by or for Indemnitee, or copies of court or agency orders or decrees or settlement agreements, as the case may be, accompanied by a sworn statement from Indemnitee that such bills, invoices, court or agency orders or decrees or settlement agreements, represent costs or liabilities meeting the definition of Liabilities or Expenses.
|
(m)
|
References to Indemnitee’s being or acting as “a director or officer of the Company” or “serving at the request of the Company as a director, officer, trustee, employee or agent of
|
(n)
|
“he” and “his” have been used for convenience and mean “she” and “her” if Indemnitee is a female.
|
2.
|
Agreement to Serve
. Indemnitee agrees to serve as a director and/or officer of the Company, at the will of the Company or under separate contract, if such exists, for so long as Indemnitee is duly elected or appointed and qualified in accordance with the provisions of the Articles and, in the case of officers, the Board of Directors’ appointment, or until such time as Indemnitee tenders his resignation in writing or is removed.
|
3.
|
Indemnity of Director or Officer; D&O Insurance
.
|
(a)
|
To Fullest Extent Permitted
. The Company shall indemnify and hold harmless Indemnitee against Liabilities and Expenses to the fullest extent authorized or permitted by law (including the applicable provisions of the Companies Act) and without prejudice to any other indemnity to which the Indemnitee may otherwise be entitled. The phrase “to the fullest extent permitted by law” shall include (1) to the fullest extent permitted by any provision of the Companies Act that authorizes or permits additional indemnification by agreement, or the corresponding provision of any amendment to or replacement of the Companies Act and (1) to the fullest extent authorized or permitted by any amendments to or replacements of the Companies Act adopted after the date of this Deed that increase the extent to which a company may indemnify its directors and officers. Any amendment, alteration or repeal of the Companies Act that adversely affects any right of Indemnitee shall be prospective only and shall not limit or eliminate any such right with respect to any Proceeding involving any occurrence or alleged occurrence that took place prior to such amendment or repeal.
|
(b)
|
In Third Party Proceedings
. The Company further agrees to indemnify and hold harmless Indemnitee in accordance with this Section 3(b) against Liabilities and Expenses incurred in connection with any Proceeding, other than a Proceeding by or in the right of the Company, but only if Indemnitee acted in good faith and, in the case of conduct in his official capacity, in a manner he reasonably believed to be in the best interests of the Company and, in all other cases, not opposed to the best interests of the Company and with respect to any criminal proceeding, Indemnitee had no reasonable cause to believe that his conduct was unlawful. The termination of any Proceeding by judgment, order of the court, settlement, conviction or upon a plea of nolo contendere, or its equivalent, shall not, of itself, create a presumption that Indemnitee did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interest of the Company, and with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his conduct was unlawful.
|
(c)
|
In Proceedings By The Company
. The Company hereby further agrees to indemnify and hold harmless Indemnitee in accordance with the provisions of this Section 3(c) against Expenses incurred in connection with any Proceeding by or in the right of the Company except that no indemnification shall be made under this Section 3(c) in respect of any such Proceeding if final judgement is given against the Indemnitee unless, and then only to the extent that, the court shall determine upon an Application for Relief that, despite the
|
(d)
|
D&O Insurance
. The Company shall at its cost purchase and maintain Directors’ and Officers’ Liability Insurance (“
D&O Insurance
”) to insure Indemnitee (commonly referred to as “Side A” coverage) for any Liabilities and Expenses arising out of facts or events that occurred while Indemnitee was a director and/or officer of the Company to the extent that such insurance can be obtained at such cost and on such terms as are reasonable and do not exceed 200% of the annual cost of the D&O Insurance in place for the year in which this Deed is entered into. The Company shall for a period of six years after Indemnitee ceases to be a director or officer of the Company purchase and maintain D&O Insurance to insure Indemnitee and Indemnitee’s personal representatives/estate in respect of Indemnitee’s appointment as a director or officer of the Company to the extent that such insurance can be obtained at such cost and on such terms as are reasonable and do not exceed 200% of the annual cost of the D&O Insurance in place for the year in which this Deed is entered into. In the event that the aggregate premium for the insurance required by this Section 3(d) exceeds the maximum amount provided, the Company shall purchase as much coverage as is reasonably obtainable for such maximum amount. The Company shall not be in breach of its obligations under this Section 3(b) where its inability to purchase and maintain D&O Insurance to insure Indemnitee is attributable to a failure by Indemnitee to comply with Indemnitee’s obligations to the insurers. The Company shall ensure that Indemnitee is provided at all times with a copy of the Company’ current D&O Insurance policy, to the extent it relates to Indemnitee, or with a summary of the terms of the Company’s current D&O Insurance policy, to the said extent.
|
4.
|
Contribution
. If the indemnification provided under Section 3 is unavailable by reason of a court decision, based on grounds other than any of those set forth in Section 15, then, in respect of any Proceeding in which the Company is jointly liable with Indemnitee, the Company shall contribute to the amount of Liabilities and Expenses actually and reasonably incurred and paid or payable by Indemnitee in such proportion as the Company reasonably and in good faith determines is appropriate to reflect the relative benefits received by the Company on one hand and Indemnitee on the other from the transaction from which such Proceeding arose and the relative fault of the Company on the one hand and of Indemnitee on the other in connection with the events that resulted in such Liabilities and Expenses as well as any other relevant equitable considerations. The relative fault of the Company on the one hand and of Indemnitee on the other shall be determined by reference to, among other things, the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent the circumstances resulting in such Liabilities and Expenses. The Company agrees that it would not be just and equitable if contribution pursuant to this Section 4 were determined by pro rata allocation or any other method of allocation that does not take into account of the foregoing equitable considerations.
|
5.
|
Choice of Counsel
. If Indemnitee is not an officer of the Company, he, together with the other directors who are not officers of the Company (the “
Outside Directors
”), shall be entitled to employ, and be reimbursed for the fees and disbursements of, counsel separate from that chosen by Indemnitees who are officers of the Company. The principal counsel for Outside Directors (“
Principal Counsel
”) shall be determined by majority vote of the Outside Directors, and the Principal Counsel for the Indemnitees who are not Outside Directors (“
Separate Counsel
”) shall be determined by majority vote of such Indemnitees, in each case subject to the consent of the Company (not to be unreasonably withheld or delayed). The obligation of the Company to reimburse Indemnitee for the
|
6.
|
Advances of Expenses
. Expenses incurred by Indemnitee shall be paid by the Company in advance of the final disposition of the Proceeding, and within 20 calendar days after receipt of Indemnitee’s written request accompanied by substantiating documentation and Indemnitee’s (x) written affirmation that he has met the standard of conduct for indemnification and (y) written undertaking to repay such amount to the extent it is ultimately determined that Indemnitee is not entitled to indemnification. No interest shall accrue on the advances. No objections based on or involving the question whether such charges meet the definition of “Expenses,” including any question regarding the reasonableness of such Expenses, shall be grounds for failure to advance to such Indemnitee, or to reimburse such Indemnitee for, the amount claimed within the 20-day period referenced in the first sentence of this Section 6, and the undertaking of Indemnitee set forth in Section 8 hereof to repay any such amount to the extent it is ultimately determined that Indemnitee is not entitled to indemnification shall be deemed to include an undertaking to repay any such amounts determined not to have met such definition.
|
7.
|
Right to Indemnification or Advancement of Expenses Upon Application; Procedure Upon Application
.
|
(a)
|
Any indemnification under this Deed shall be made no later than 60 days after receipt by the Company of the written request of Indemnitee, accompanied by substantiating documentation, unless a determination is made within said 60-day period by (1) the Board of Directors by a majority vote of a quorum consisting of directors who are not or were not parties to the relevant Proceeding, (1) a committee of the Board of Directors designated by majority vote of the Board of Directors, even though less than a quorum or (1) if there are no such directors, or if such directors so direct, independent legal counsel in a written opinion that Indemnitee has not met the applicable standards for indemnification set forth in this Deed.
|
(b)
|
The right to indemnification or advances as provided by this Deed shall be enforceable by Indemnitee in any court of competent jurisdiction. The burden of proving that indemnification or advancement of Expenses is not appropriate shall be on the Company. Neither the failure of the Company (including its Board of Directors, any committee thereof, or independent legal counsel) to have made a determination prior to the commencement of such action that indemnification is proper in the circumstances because Indemnitee has met the applicable standards of conduct, nor an actual determination by the Company (including its Board of Directors, any committee thereof or independent legal counsel) that Indemnitee
|
(c)
|
The Company shall to the fullest extent permitted by applicable law be precluded from asserting in any Proceeding that the provisions of this Deed are not valid, binding and enforceable or that there is insufficient consideration for this Deed.
|
(d)
|
Promptly after receipt of a notice of a Proceeding pursuant to Section 8(b) of this Deed, the Company shall give notice of the commencement of any such Proceeding to the insurers under any D&O Insurance in accordance with the procedures set forth in the policies. Thereafter, the Company shall take all reasonable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies.
|
8.
|
Undertaking by Indemnitee
.
|
(a)
|
Indemnitee undertakes and promises to repay to the Company for all advances of Expenses pursuant to Section 6 hereof, (1) in respect of particular Restricted Proceedings if, in respect of those Proceedings (as applicable): (x) Indemnitee is convicted, (y) judgement is given against Indemnitee’ or (z) the court refuses to grant Indemnitee relief on an Application for Relief, and (1) in respect of all other Proceedings, to the extent that it is finally determined that Indemnitee is not entitled to indemnification under this Deed. Any repayment required by clause (i) of this subsection shall be made no later than the date when the conviction, judgement or the refusal of relief (as applicable) becomes final and any repayment otherwise required shall be made no later than 30 days after notice to Indemnitee of the final determination described in clause (ii).
|
(b)
|
Indemnitee shall give the Company notice in writing as soon as practicable (and in no event later than 5 business days following Indemnitee’s becoming aware) of any Proceeding in respect of which Indemnitee intends to seek indemnification or advancement of Expenses hereunder. Notice to the Company shall be directed to the General Counsel of the Company (or if there is no such position, the chief executive officer) and given in accordance with Section 18(e) of this Deed. Subject to Section 12 of this Deed, the delay or omission by Indemnitee to so notify the Company shall not relieve the Company from any liability that it may have to Indemnitee hereunder or otherwise
|
9.
|
Rights Hereunder Not Exclusive
. The rights to indemnification and to advancement of Expenses provided by this Deed shall not be deemed exclusive of limit or be limited by any other rights to which Indemnitee may be entitled under the Articles, applicable law, any D&O Insurance, any agreement, any shareholder vote or otherwise, both as to action in his official capacity and as to action in another capacity while holding such office; provided, that this Deed supersedes all prior written indemnification agreements between the Company and Indemnitee with respect to the subject matter hereof; provided, that Indemnitee shall reimburse the Company for amounts paid to him pursuant to such other rights to the extent such payments duplicate any payments received pursuant to this Deed.
|
10.
|
Continuation of Indemnity
. All agreements and obligations of the Company contained herein shall continue during the period Indemnitee is a director or officer of the Company (or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, limited liability company or other enterprise) and shall continue
|
11.
|
Partial Indemnification
. If Indemnitee is entitled under any provision of this Deed to indemnification by the Company or to receive advancement by the Company in each case for, some portion of, Expenses, but not, however, for the total amount thereof, the Company shall nevertheless indemnify Indemnitee, and to the extent applicable advancement of Expenses, for the portion of such Expenses to which Indemnitee is entitled.
|
12.
|
Settlements
. The Company shall not be liable to indemnify Indemnitee under this Deed for any amounts paid in settlement of any Proceedings effected without the Company’s written consent. The Company shall not settle any Proceedings in any manner which would impose any penalty or limitation on Indemnitee without Indemnitee’s written consent. Neither the Company nor Indemnitee shall unreasonably withhold or delay their consent to any proposed settlement. The Company shall not be liable to indemnify Indemnitee under this Deed with regard to any judicial award if the Company was not given a reasonable and timely opportunity, at its expense, to participate in the defense of such action.
|
13.
|
Acknowledgements
.
|
(a)
|
Company Acknowledgment
. The Company expressly confirms and agrees that it has entered into this Deed and assumed the obligations imposed on the Company hereby in order to induce Indemnitee to serve or to continue to serve as a director or officer of the Company, and acknowledges that Indemnitee is relying upon this Deed in agreeing to serve or in continuing to serve as a director or officer of the Company.
|
(b)
|
Mutual Acknowledgment.
Both the Company and Indemnitee acknowledge that in certain instances, applicable law or public policy may prohibit the Company from indemnifying its directors and officers under this Deed or otherwise. For example, the Company and Indemnitee acknowledge that the United States Securities and Exchange Commission (the “
SEC
”) has taken the position that indemnification is not permissible for liabilities arising under certain United States federal securities laws, and federal legislation prohibits indemnification for certain ERISA violations. Indemnitee understands and acknowledges that the Company has undertaken or may be required in the future to undertake with the SEC to submit the question of indemnification to a court in certain circumstances for a determination of the Company’s right under public policy to indemnify Indemnitee.
|
14.
|
Enforcement
. In the event Indemnitee is required to bring any action or other proceeding to enforce rights or to collect moneys due under this Deed and is successful in such action, the Company shall reimburse Indemnitee for all of Indemnitee’s Expenses in bringing and pursuing such action.
|
15.
|
Exceptions
. Any other provision herein to the contrary notwithstanding, the Company shall not be obligated pursuant to the terms of this Deed:
|
(a)
|
No Entitlement to Indemnification
. To indemnify Indemnitee for any Expenses incurred by Indemnitee with respect to any action instituted by Indemnitee to enforce or interpret this Deed, if a court of competent jurisdiction determines that Indemnitee was not entitled to indemnification hereunder;
|
(b)
|
Insured Claims
. To indemnify Indemnitee for Expenses or Liabilities of any type whatsoever (including, but not limited to, judgments, fines, ERISA excise taxes or penalties, and amounts paid in settlement) to the extent such Expenses or Liabilities have been paid directly to Indemnitee by an insurance carrier under any insurance policy maintained by the Company;
|
(c)
|
Remuneration in Violation of Law
. To indemnify Indemnitee in respect of remuneration paid to Indemnitee if it shall be determined by a final judgment or other final adjudication that such remuneration was in violation of law;
|
(d)
|
Indemnification Unlawful
. To indemnify Indemnitee if prohibited by the Companies Act or otherwise by law or a final decision by a court having jurisdiction in the matter shall determine that such indemnification is not lawful;
|
(e)
|
Fines
. To indemnify Indemnitee for any fines imposed on Indemnitee in any criminal proceeding or amounts payable by Indemnitee to a regulatory authority or Stock Exchange as a penalty in respect of non-compliance with any requirement of a regulatory nature, provided, however, that this clause (e) shall not limit the Company’s obligation to pay to Indemnitee such amounts as are required to meet Expenses of Indemnitee in defending himself in an investigation or against any action proposed to be taken by a regulatory authority or Stock Exchange;
|
(f)
|
Misconduct, Etc
. To indemnify Indemnitee on account of Indemnitee’s conduct which is finally adjudged to have been knowingly fraudulent or deliberately dishonest or to constitute intentional misconduct, a knowing violation of law, or a transaction from which Indemnitee derived an improper personal benefit;
|
(g)
|
Claims under Sarbanes-Oxley Act of 2002
. To indemnify Indemnitee for any reimbursement of the Company by Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by Indemnitee from the sale of securities of the Company, as required in each case under the Securities Exchange Act of 1934, as amended (including any such reimbursements that arise from an accounting restatement of the Company pursuant to Section 304 of the Sarbanes-Oxley Act of 2002, or the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 306 of the Sarbanes-Oxley Act of 2002.
|
(h)
|
Breach of Duty
. To indemnify Indemnitee on account of Indemnitee’s conduct which is the subject of any Proceeding brought by the Company and approved by a majority of the Board of Directors which alleges willful misappropriation of corporate assets by Indemnitee, disclosure of confidential information in violation of Indemnitee’s fiduciary or contractual obligations to the Company, or any other willful and deliberate breach in bad faith of Indemnitee’s duty to the Company or its shareholders;
|
(i)
|
Claims Under Section 16(b)
. To indemnify Indemnitee for Expenses or the payment of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 16(b) of the Securities Exchange Act of 1934, as amended, or any similar successor statute;
|
(j)
|
Taxation
. To indemnify Indemnitee for any Liabilities or Expenses relating to any taxation or national insurance payable by Indemnitee in connection with his remuneration or other benefits from the Company; or
|
(k)
|
Restricted Proceedings
. To indemnify Indemnitee for any Liabilities or Expenses related to any Restricted Proceedings in which (1) Indemnitee is convicted; (1) judgement is given against Indemnitee; or (1) the court refuses to grant Indemnitee relief on the application.
|
18.
|
Miscellaneous
.
|
(a)
|
Governing Law
. This Deed and all acts and transactions pursuant hereto and the rights and obligations of the Parties shall be construed and interpreted in accordance with and governed by the laws of England and Wales and the Parties hereto submit irrevocably to the nonexclusive jurisdiction of the Courts of England for resolution of any dispute arising hereunder.
|
(b)
|
Entire Agreement; Modifications; Enforcement of Rights
. This Deed represents the entire understanding, and constitutes the whole agreement, in relation to its subject matter and supersedes any previous agreement between the Parties with respect thereto and, without prejudice to the generality of the foregoing, excludes any warranty, condition or other undertaking implied at law or by custom, usage or course of dealing. No modification of or amendment to this Deed, nor any waiver of any rights under this Deed, shall be effective unless in writing signed by the Parties to this Deed except that the Company may amend the terms of this Deed without consent of the Indemnitee after giving Indemnitee 60 days’ notice of such proposed amendment. No amendment effected without the Indemnitees’ consent shall affect the rights of the Indemnitee hereunder in respect of any Proceeding arising out of act, omission or event occurring before any such amendment is made or alter the obligation of the Company set forth in the second sentence of Section 3(d). The failure by either Party to enforce any right, power or remedy under this Deed shall not be construed as a waiver of any right, power or remedy of such Party. A single or partial exercise of any
|
(c)
|
Assignment; Third Party Rights
. This Deed shall not be assignable by either Party without the consent of the other. This Deed is made for the benefit of Indemnitee and shall inure for the benefit of the successors, personal representatives, heirs and estate of Indemnitee. Subject to the preceding sentence, no term of this Deed is enforceable under the Contracts (Rights of Third Parties) Act 1999 by a person who is not Party.
|
(d)
|
Inspection
. The Indemnitee acknowledges and accepts that a copy of this Deed as varied from time to time will be available for inspection at the registered office of the Company by any shareholder of the Company in accordance with the provisions of the Companies Act, and may further be disclosed in whole in part to such persons as the Company determines in its absolute discretion including, without limitation, in the accounts of the Company.
|
(e)
|
Notices
. All notices, demands or other communications to be given or delivered under or by reason of the provisions of this Deed shall be in writing and shall be deemed to have been given (1) when delivered personally to the recipient, (1) when sent to the recipient by telecopy (receipt electronically confirmed by sender’s telecopy machine) if during normal business hours of the recipient, otherwise on the next business day, (1) one business day after the date when sent to the recipient by reputable overnight courier service (charges prepaid), or (1) five business days after the date when mailed to the recipient by certified or registered mail, return receipt requested and postage prepaid. Such notices, demands and other communications shall be sent to the Parties at the addresses indicated on the signature page hereto, or to such other address as any Party may, from time to time, designate in writing delivered pursuant to the terms of this Section 18(e).
|
(f)
|
Counterparts
. This Deed may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument.
|
(g)
|
Successors and Assigns
. This Deed shall be binding upon the Company and its successors and permitted assigns and shall inure to the benefit of Indemnitee and Indemnitee’s heirs, legal representatives and assigns. The Company shall require and cause any successor (whether direct or indirect, and whether by purchase, merger, consolidation or otherwise) to all, substantially all, or a substantial part, of the business or assets of the Company, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume
|
(h)
|
Subrogation
. In the event of payment under this Deed, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all documents required and shall do all acts that may be necessary to secure such rights and to enable the Company to effectively bring suit to enforce such rights.
|
1.1
|
The terms set out in this Agreement, together with any documents incorporated into this Agreement by reference as set out in clause 1.2 (each referred to as an “
Incorporated Document
”), govern your employment relationship with the Company and bind the parties to this Agreement. If there is any conflict between the terms of this Agreement and the terms of an Incorporated Document, the terms of this Agreement will prevail.
|
1.2
|
Except as stated otherwise in this Agreement, the terms of each of the following documents are incorporated by reference into this Agreement and are made a part hereof:
|
(a)
|
the Venator Materials PLC Amended and Restated Executive Severance Plan adopted on November 14, 2017 (the “
Severance Plan
”);
|
(b)
|
the Venator Materials PLC 2017 Stock Incentive Plan adopted August 1, 2017, and all Award Agreements thereunder (together, the “
Stock Incentive Plan
”);
|
(c)
|
the Venator Materials PLC 2018 Short Term Incentive Plan adopted April 23, 2018;
|
(d)
|
the Venator Materials PLC Incentive Repayment Policy (or “
Clawback
”) adopted February 13, 2018, as may be amended from time to time;
|
(e)
|
the Venator UK Management Car Scheme, as may be amended from time to time; and
|
(f)
|
the letter-agreement titled Company Pension Benefits (and attachment), dated September 14, 2012 and signed by the Senior Vice President of Huntsman Corporation (the “
Supplemental Pension Benefits Agreement
”), regarding the Company’s removal of limits imposed on your accrued pension benefits and related matters.
|
2.1
|
You are employed as President and CEO of Venator Materials PLC. You began your employment in this role on June 21, 2017, and you are credited with continuous employment with the Company (including its predecessors) since December 1, 1989.
|
2.2
|
Your duties in your role are the global substantive and administrative oversight of the businesses and corporate functions of Venator Materials PLC.
|
2.3
|
Whilst employed by the Company you must:
|
(a)
|
during your hours of work devote the whole of your time, attention and abilities to the business of the Company and carry out your duties with due care and attention;
|
(b)
|
not, without the Company’s prior written consent, be in any way directly or indirectly engaged or concerned with any other business (other than managing your personal investments) or employment whether during or outside your hours of work for the Company;
|
(c)
|
use your best efforts to promote and protect the interests of the Company and observe the utmost good faith towards the Company; and
|
(d)
|
comply with the Company’s rules, regulations and policies from time to time in force.
|
3.1
|
Your gross base salary is the GBP equivalent of US $850,000.00 (or such higher sum as may be determined by the Compensation Committee from time to time). The salary will be paid after deduction of required or estimated withholding for income taxes, for national insurance and for any benefit plan contributions you elect, and is payable no less frequently than in equal monthly instalments on or around the last day of each month into your nominated bank account.
|
3.2
|
Your salary will be reviewed for increase at regular annual intervals.
|
3.3
|
For the purposes of the Employment Rights Act 1996, sections 13-27, you agree that the Company may deduct from your remuneration any sums due from you to the Company including, without limitation, your pension contributions (if any) and any overpayments, loans or advances made to you by the Company.
|
4.1
|
Your target bonus for each calendar year is a sum equal to 100% (or such higher percentage as may be determined by the Compensation Committee from time to time) of your annual base salary in effect at the end of that calendar year. The actual amount of bonus to be paid to you for a particular year will be determined by the Company by reference to your performance against individual performance targets and the performance of Venator Materials PLC for that year against objective performance targets set for the executive leadership team of Venator Materials PLC each year, with an opportunity each year to earn up to two (2) times your bonus target upon achievement of the maximum performance targets set for that year. For 2018, the objective performance targets are as described in the Venator Materials PLC 2018 Short Term Incentive Plan adopted April 23, 2018, as adjusted by the Compensation Committee on November 14, 2018.
|
4.2
|
The bonus will be paid to you in cash no later than the end of the month following the month in which the Company’s auditors have completed their audit of the financial statements of the Company. To be eligible to receive a bonus, except as provided in the Severance Plan, you must be in employment with the Company at the time of payment of the bonus.
|
5.1
|
You continue to participate in the Stock Incentive Plan and your Awards under the Stock Incentive Plan are governed by the terms thereof, except that, as an additional term, upon a “Termination for Good Reason” under the Severance Plan following a Change of Control all Replacement Awards shall become fully vested in accordance with Section 6(j)(ix)(B) of the Stock Incentive Plan.
|
5.2
|
For each of the next three calendar years (and thereafter if renewed by the Compensation Committee) you will receive an Award under the Stock Incentive Plan, comprising stock options, restricted share units and/or performance share units (or such other type of Award as may be allowed under the Stock Incentive Plan as determined by the Compensation Committee of Venator Materials PLC), having a value on the date of grant of at least the amount of your grant on February 14, 2018. Each Award
|
5.3
|
In the event that Venator Materials PLC terminates the Stock Incentive Plan during the next three calendar years (or thereafter during any period renewed by the Compensation Committee as described in clause 5.2), you will be entitled thereafter during each year of your employment during by the Company or an affiliate during such three calendar years or renewal thereof to receive in lieu of an Award under the Stock Incentive Plan an annual grant of performance units or similar long term incentive compensation, in each case having a grant value of at least the amount of your grant on February 14, 2018, and which will vest in such increments over the next three years after the date of each such annual grant as are determined by the Compensation Committee.
|
7.1
|
Your normal hours of work will be Monday to Friday 9am – 5pm. You acknowledge that your duties may require you to work additional hours as required from time to time and that you are not entitled to any additional remuneration for any such additional hours worked. For the purposes of the Working Time Regulations 1998 you agree to opt out of the 48 hour maximum working hours per week.
|
8.1
|
Your normal place of work will be Titanium House, Hanzard Drive, Wynyard Park, Stockton- on-Tees, TS22 5FD, UK. The Company may not change your normal place of work to a location other than a location within England without your prior written consent.
|
9.1
|
The length of prior written notice that you must give the Company in order to terminate your employment is 3 months. The length of prior written notice that the Company must give you in order to terminate your employment is 0 months.
|
9.2
|
You continue to participate in the Severance Plan, the terms of which shall continue to apply to your employment, except that, as an additional term, a breach of this Agreement by the Company or its affiliate shall be deemed to be a sufficient cause for a “Termination for Good Reason” under the Severance Plan. For the avoidance of doubt the 30-day remedy provision set out Clause 2.13 of the Severance Plan shall also apply to any breach of this Agreement.
|
9.3
|
The Company may, at its absolute discretion, require you not to attend at work and/or not to undertake all or any of your duties hereunder during any period of notice (whether given by the Company or you), provided always that the Company shall continue to pay your salary and contractual benefits. For the avoidance of doubt, there is no obligation on the Company to provide you with any work during any period of notice and you will not be entitled to work on your own account or on account of any other person, firm or company during that period without the Company’s prior written consent.
|
10.1
|
Each holiday year, you are entitled to 32 working days paid holiday and all customary public holidays recognised by the Company in that particular holiday year.
|
10.2
|
The Company’s holiday year runs from 1st January to 31st December and holiday entitlement (other than customary public holidays) will accrue pro rata on a monthly basis through the holiday year.
|
10.3
|
If your employment ends part way through the holiday year your holiday entitlement for that year will be assessed on a pro rata basis.
|
10.4
|
On termination of your employment you will be entitled to pay in lieu of any holidays which have accrued to you in the holiday year in which the termination takes place but which you have not taken at that time. The Company may require you to take unused holidays during your notice period.
|
12.1
|
You are a member of the following pension plans and subject to the rules thereof: (1) the Tioxide Pension Fund (in which you have deferred member status); (2) the U.K. Defined Contribution Scheme (in which you have deferred member status); (3) the AECI Pension Fund in South Africa (in which you have deferred member status); and (4) the Huntsman Global Pension Scheme (the “HGPS”) (in which you have active deferred status). Because you have met the applicable lifetime contribution limit and are therefore not receiving any additional contributions from the Company into your U.K. Defined Contribution Scheme account in which you have deferred member status, the Company will provide you with a monthly cash payment approximately equivalent to the amount you would have been eligible to receive as a contribution to your plan account had you not met the lifetime limit, which is 15% of your base salary.
|
12.2
|
Pursuant to Company policy, the Company will provide you with a “top up” payment to the HGPS should you wish to withdraw your funds from this pension scheme, in an amount sufficient to enable the HGPS Trustee to transfer a fully funded (unreduced) account value attributable to your years of service in accordance with the terms of the HGPS.
|
12.3
|
Additionally, the Company will provide you with the retirement and pension benefits further set out in the Supplemental Pension Benefits Agreement and which will be governed by the rules governing payments under the UK Tioxide Pension Fund.
|
12.4
|
Pursuant and subject to the terms of the Venator UK Life Assurance Scheme, the Company will provide you with a Death in Service Benefit of eight times (8x) your annual salary at the time of your death, and an additional seven times (7x) your annual salary at the time of your death if your death is the result of a work-related accident, up to a maximum benefit of £5 million unless a higher amount is approved by the Company’s underwriter.
|
(a)
|
divulge or communicate to any person;
|
(b)
|
use for your own purposes or for any purposes other than those of the Company or, as appropriate, any of its customers; or
|
(c)
|
through any failure to exercise due care and diligence, cause any unauthorised disclosure of;
|
14.1
|
In the course of your employment you will be exposed to Confidential Information and will acquire other proprietary knowledge relating to the Company’ and its affiliates’ current and planned operations. Therefore, you will not during the period of your employment with the Company and for a period of twelve months after the termination of your employment, either directly, or indirectly through any other person, firm or other organisation (any a “Person”):
|
(a)
|
solicit, entice or induce any Person which at any time during the last year of your employment with the Company (that period referred to as the “Relevant Period”) was a supplier of the Company or any of its affiliates (and with whom you or one of your direct reports was actively involved during that time or in respect of which you are in possession of material Confidential Information) to reduce the level of business between the supplier and the Company or its affiliates and you will not approach any supplier for that purpose or authorise or approve the taking of such actions by any other person;
|
(b)
|
solicit business which is of the same or similar nature as the business with which you were materially concerned at any time during the Relevant Period or in respect of which you are in possession of Confidential Information as a result of your employment during the Relevant Period (such business referred to as the “Business”) from any Person which at any time during the Relevant Period was a customer of the Company or any of its affiliates (and with whom you or one of your direct reports was actively involved during that time or in respect of which you are in possession of material Confidential Information) and you will not approach any customer for that purpose or authorise or approve the taking of such actions by any other Person. For the purposes of this restriction, the expression “customer” shall include all Persons from whom the Company or any of its affiliates has received inquiries for the provision of goods or services where such inquiries have not been concluded;
|
(c)
|
employ or engage or otherwise solicit, entice or induce any person who, during the Relevant Period, was an employee, consultant or contractor of the Company or any of its affiliates who was employed during that period in a senior sales, marketing, financial, managerial, professional or equivalent capacity to become employed or engaged by you or any other Person and you will not approach any such person for such purpose or authorise or approve the taking of such actions by any other Person; and
|
(d)
|
within the Restricted Area, be employed or engaged in that part of a business which is involved in the business of researching, developing, manufacturing, distributing, selling, supplying or otherwise dealing with Restricted Products, if the business or person is or seeks to be in competition with the Company. For the purposes of this sub- clause, acts done by you outside the Restricted Area shall nonetheless be deemed to be done within the Restricted Area where their primary purpose is to distribute, sell, supply or otherwise deal with Restricted Products in the Restricted Area. For the purposes of this sub-clause, “Restricted Area” shall mean any country in the world where, on the date you cease to be employed by the Company, the Company researches, develops, manufactures, supplies, markets, distributes or sells Restricted Products, and “Restricted Products” shall mean (i) Titanium Dioxide pigments and commercial co- products and (ii) Iron Oxide pigments.
|
14.2
|
If the Company suspends any of your duties under Clause 9.3 during any period after notice of termination has been given by the Company or you, the aggregate of the period of the suspension and the period after the end of your employment with the Company during which the restrictions in this Clause 14 shall apply shall not exceed 12 months and, if the aggregate of the two periods would exceed 12 months, the period after the end of your employment during which the restrictions shall apply shall be reduced accordingly.
|
14.3
|
The restrictions in this Clause 14 are separate and severable restrictions and are considered by the parties to be reasonable in all the circumstances. It is agreed that if any such restrictions by themselves, or taken together, shall be adjudged to go beyond what is reasonable in all the circumstances for the protection of the legitimate interests of the Company but would be adjudged reasonable if part or parts of the wording were deleted, the relevant restriction or restrictions shall apply with such deletion(s) as may be necessary to make it or them valid and effective.
|
14.4
|
You agree that money damages would not be a sufficient remedy for any breach of the restrictions in this Clause 14 and that the Company shall be entitled to seek equitable relief, including an injunction and specific performance, as a remedy for any such breach. Such remedies shall not be deemed to be the exclusive remedies for any such breach, but shall be in addition to all other remedies available at law or in equity.
|
15.1
|
The Company will hold, collect and otherwise process certain personal data as set out in the Company’s privacy notice, which is on the intranet. All personal data will be treated in accordance with applicable data protection laws and regulations.
|
16.1
|
This Agreement and the Incorporated Documents constitute the entire agreement and understanding of the parties and supersede and extinguish all previous agreements, promises, assurances, warranties, representations and understandings between the parties, whether written or oral, relating to the subject matter of this Agreement; provided, however, for the avoidance of doubt, that this Agreement shall not supersede, extinguish or otherwise affect the Indemnification Deed For Officers And Directors between you and Venator Materials PLC.
|
16.2
|
Each party acknowledges that in entering into this Agreement it does not rely on, and shall have no remedies in respect of, any statement, representation, assurance or warranty (whether made innocently or negligently) that is not set out in this Agreement.
|
17.1
|
Notwithstanding anything in the Incorporated Documents to the contrary, this Agreement and all acts and transactions pursuant hereto and the rights and obligations of the Parties shall be construed and interpreted in accordance with and governed by the laws of England, without giving effect to the conflict of law principles thereof, and the Parties hereto submit irrevocably to the exclusive jurisdiction of the English courts for resolution of any dispute arising hereunder.
|
1.
|
TERMS OF EMPLOYMENT
|
1.1
|
The terms set out in this Agreement, together with any documents incorporated into this Agreement by reference as set out in clause
1.2
(each referred to as an
“Incorporated Document”
), govern your employment relationship with the Company and bind the parties to this Agreement. If there is any conflict between the terms of this Agreement and the terms of an Incorporated Document, the terms of this Agreement will prevail.
|
1.2
|
Except as stated otherwise in this Agreement, the terms of each of the following documents are incorporated by reference into this Agreement and are made a part hereof:
|
(a)
|
the Venator Materials PLC Amended and Restated Executive Severance Plan adopted on November 14, 2017 (the “
Severance Plan
”);
|
(b)
|
the Venator Materials PLC 2017 Stock Incentive Plan adopted August 1, 2017, and all Award Agreements thereunder (together, the “
Stock Incentive Plan
”);
|
(c)
|
the Venator Materials PLC 2018 Short Term Incentive Plan adopted April 23, 2018;
|
(d)
|
the Venator Materials PLC Incentive Repayment Policy (or “
Clawback
”), as may be amended from time to time;
|
(e)
|
the Venator 401(k) Plan, as may be amended from time to time;
|
(f)
|
the Venator Executive Elective Deferral Plan adopted February 13, 2018, as may be amended from time to time; and
|
(g)
|
the letter-agreement sent to you from the VP Human Resources of Venator Materials PLC detailing the terms of your temporary assignment to the UK dated July 11, 2017 (the
“Assignment Letter”
).
|
2.
|
JOB TITLE AND DUTIES
|
2.1
|
You are employed as Senior Vice President and Chief Financial Officer of Venator Materials PLC and its subsidiaries, with effect from June 21, 2017. You are credited with continuous employment with the Company (including its predecessors) since October 18, 2004.
|
2.2
|
Your duties in your role are the global substantive and administrative responsibilities for the Finance, Accounting, Tax, Treasury, Credit, Internal Audit & Controls, Investor Relations, Risk Management, and IT functions of Venator Materials PLC and its subsidiaries.
|
2.3
|
Whilst employed by the Company you must:
|
(a)
|
during your hours of work devote the whole of your time, attention and abilities to the business of the Company and carry out your duties with due care and attention;
|
(b)
|
not, without the Company’s prior written consent, be in any way directly or indirectly engaged or concerned with any other business (other than managing your personal investments) or employment whether during or outside your hours of work for the Company;
|
(c)
|
use your best efforts to promote and protect the interests of the Company and observe the utmost good faith towards the Company; and
|
(d)
|
comply with the Company’s rules, regulations and policies from time to time in force.
|
3.
|
REMUNERATION
|
3.1
|
Your gross base salary is US $530,000.00 (or such higher sum as may be determined by the Compensation Committee from time to time). The salary will be paid after deduction of required or estimated withholding for income taxes and for any benefit plan contributions you elect, and is payable no less frequently than in equal monthly instalments on or around the last day of each month into your nominated bank account.
|
3.2
|
Your salary will be reviewed for increase at regular annual intervals.
|
3.3
|
For the purposes of the Employment Rights Act 1996, sections 13-27, you agree that the Host Company may deduct from your remuneration any sums due from you to the Company including, without limitation, any overpayments, loans or advances made to you by the Company.
|
4.
|
ANNUAL BONUS
|
4.1
|
Your target bonus for each calendar year is a sum equal to 70% (or such higher percentage as may be determined by the Compensation Committee from time to time) of your annual base salary in effect at the end of that calendar year. The actual amount of bonus to be paid to you for a particular year will be determined by the Company by reference to your performance against individual performance targets and the performance of Venator Materials PLC for that year against objective performance targets set for the executive leadership team of Venator Materials PLC each year, with an opportunity each year to earn up to two (2) times your bonus target upon achievement of the maximum performance targets set for that year. For 2018, the objective performance targets are as described in the Venator Materials PLC 2018 Short Term Incentive Plan adopted April 23, 2018, as adjusted by the Compensation Committee on November 14, 2018.
|
4.2
|
The bonus will be paid to you in cash no later than the end of the month following the month in which the Company’s auditors have completed their audit of the financial statements of the Company. To be eligible to receive a bonus, except as provided in the Severance Plan, you must be in employment with the Company at the time of payment of the bonus.
|
5.
|
LONG TERM INCENTIVE
|
5.1
|
You continue to participate in the Stock Incentive Plan and your Awards under the Stock Incentive Plan are governed by the terms thereof, except that, as an additional term, upon a “Termination for Good Reason” under the Severance Plan following a Change of Control all Replacement Awards shall become fully vested in accordance with Section 6(j)(ix)(B) of the Stock Incentive Plan.
|
5.2
|
For each of the next three calendar years (and thereafter if renewed by the Compensation Committee) you will receive an Award under the Stock Incentive Plan, comprising stock options, restricted share units and/or performance share units (or such other type of Award as may be allowed under the Stock Incentive Plan as determined by the Compensation Committee of Venator Materials PLC), having a value on the date of grant of at least the amount of your grant on February 13, 2018. Each Award will vest in such increments over the next three years after the date of each Award as are determined by the Compensation Committee and, except as provided herein, will be subject to the terms of the Stock Incentive Plan and the Award Agreement pursuant to which the Award is made. Capitalised terms used in this clause but not defined in this clause have the meaning given to them in the Stock Incentive Plan.
|
5.3
|
In the event that Venator Materials PLC terminates the Stock Incentive Plan during the next three calendar years (or thereafter during any period renewed by the Compensation Committee as described in clause 5.2), you will be entitled thereafter during each year of your employment by the Company or an affiliate during such three calendar years or renewal thereof to receive in lieu of an Award under the Stock Incentive Plan an annual grant of performance units or similar long term incentive compensation, in each case having a grant value of at least the amount of your grant on February 13, 2018, and which will vest in such increments over the next three years after the date of each such annual grant as are determined by the Compensation Committee.
|
6.
|
EXPENSES
|
7.
|
NORMAL HOURS OF WORK
|
7.1
|
Your normal hours of work will be Monday to Friday 9am – 5pm. You acknowledge that your duties may require you to work additional hours as required from time to time and that you are not entitled to any additional remuneration for any such additional hours worked. For the purposes of the Working Time Regulations 1998 applicable to the Host Company, you agree to opt out of the 48 hour maximum working hours per week.
|
8.
|
PLACE OF WORK
|
8.1
|
Your normal place of work while assigned to the Host Company will be Titanium House, Hanzard Drive, Wynyard Park, Stockton-on-Tees, TS22 5FD, UK. Your normal place of work upon the end of your assignment will be 10003 Woodloch Forest Dr., The Woodlands, Texas. The Company may not change your normal place of work to a location other than a location within England without your prior written consent.
|
9.
|
NOTICE AND SEVERANCE
|
9.1
|
The length of prior written notice that you must give the Company in order to terminate your employment is 3 months. The length of prior written notice that the Company must give you in order to terminate your employment is 3 months
.
|
9.2
|
You continue to participate in the Severance Plan, the terms of which shall continue to apply to your employment, except that, as an additional term, a breach of this Agreement by the Company or its affiliate shall be deemed to be a sufficient cause for a “Termination for Good Reason” under the Severance Plan. For the avoidance of doubt the 30-day remedy provision set out Clause 2.13 of the Severance Plan shall also apply to any breach of this Agreement.
|
9.3
|
The Company may, at its absolute discretion, require you not to attend at work and/or not to undertake all or any of your duties hereunder during any period of notice (whether given by the Company or you), provided always that the Company shall continue to pay your salary and contractual benefits. For the avoidance of doubt, there is no obligation on the Company to provide you with any work during any period of notice and you will not be entitled to work on your own account or on account of any other person, firm or company during that period without the Company’s prior written consent.
|
10.
|
HOLIDAYS AND HOLIDAY PAY
|
10.1
|
Your entitlement to paid vacation days and customary public holidays is as provided in the Assignment Letter.
|
10.2
|
The Company’s holiday year runs from 1st January to 31st December and holiday entitlement (other than customary public holidays) will accrue pro rata on a monthly basis through the holiday year.
|
10.3
|
If your employment ends part way through the holiday year your holiday entitlement for that year will be assessed on a pro rata basis.
|
10.4
|
On termination of your employment you will be entitled to pay in lieu of any holidays which have accrued to you in the holiday year in which the termination takes place but which you have not taken at that time. The Company may require you to take unused holidays during your notice period.
|
11.
|
HEALTHCARE AND ABSENCE FROM WORK DUE TO SICKNESS OR INJURY
|
12.
|
RETIREMENT, LIFE INSURANCE AND OTHER BENEFITS
|
12.1
|
The Company will provide you with retirement benefits in accordance with the 401(k) Plan and the Supplemental Savings Plan as applicable to employees credited with your years of continuous service.
|
12.2
|
In addition, you are entitled to Company-paid life insurance and other benefits provided to the Company’s employees under its benefit plans and written policies, as may be amended from time to time.
|
13.
|
CONFIDENTIALITY
|
(a)
|
divulge or communicate to any person;
|
(b)
|
use for your own purposes or for any purposes other than those of the Company or, as appropriate, any of its customers; or
|
(c)
|
through any failure to exercise due care and diligence, cause any unauthorised disclosure of;
|
14.
|
COVENANT-NOT-TO-COMPETE AND OTHER RESTRICTIONS
|
14.1
|
In the course of your employment you will be exposed to Confidential Information and will acquire other proprietary knowledge relating to the Company’ and its affiliates’ current and planned operations. Therefore, you will not during the period of your employment with the Company and for a period of twelve months after the termination of your employment, either directly, or indirectly through any other person, firm or other organisation (any a “
Person
”):
|
(a)
|
solicit, entice or induce any Person which at any time during the last year of your employment with the Company (that period referred to as the “
Relevant Period
”) was a supplier of the Company or any of its affiliates (and with whom you or one of your direct reports was actively involved during that time or in respect of which you are in possession of material Confidential Information) to reduce the level of business between the supplier and the Company or its affiliates and you will not approach any supplier for that purpose or authorise or approve the taking of such actions by any other person;
|
(b)
|
solicit business which is of the same or similar nature as the business with which you were materially concerned at any time during the Relevant Period or in respect of which you are in possession of Confidential Information as a result of your employment during the Relevant Period (such business referred to as the “
Business
”) from any Person which at any time during the Relevant Period was a customer of the Company or any of its affiliates (and with whom you or one of your direct reports was actively involved during that time or in respect of which you are in possession of material Confidential Information) and you will not approach any customer for that purpose or authorise or approve the taking of such actions by any other Person. For the purposes of this restriction, the expression “customer” shall include all Persons from whom the Company or any of its affiliates has received inquiries for the provision of goods or services where such inquiries have not been concluded;
|
(c)
|
employ or engage or otherwise solicit, entice or induce any person who, during the Relevant Period, was an employee, consultant or contractor of the Company or any of its affiliates who was employed during that period in a senior sales, marketing, financial, managerial, professional or equivalent capacity to become employed or engaged by you or any other Person and you will not approach any such person for such purpose or authorise or approve the taking of such actions by any other Person; and
|
(d)
|
within the Restricted Area, be employed or engaged in that part of a business which is involved in the business of researching, developing, manufacturing, distributing, selling, supplying or otherwise dealing with Restricted Products, if the business or person is or seeks to be in competition with the Company. For the purposes of this sub- clause, acts done by you outside the Restricted Area shall nonetheless be deemed to be done within the Restricted Area where their primary purpose is to distribute, sell, supply or otherwise deal with Restricted Products in the Restricted Area. For the purposes of this sub-clause, “
Restricted Area
” shall mean any country in the world where, on the date you cease to be employed by the Company, the Company researches, develops, manufactures, supplies, markets, distributes or sells Restricted Products, and “
Restricted Products
” shall mean (i) Titanium Dioxide pigments and commercial co- products and (ii) Iron Oxide pigments.
|
14.2
|
If the Company suspends any of your duties under Clause 9.3 during any period after notice of termination has been given by the Company or you, the aggregate of the period of the suspension and the period after the end of your employment with the Company during which the restrictions in this Clause 14 shall apply shall not exceed 12 months and, if the aggregate of the two periods would exceed 12 months, the period after the end of your employment during which the restrictions shall apply shall be reduced accordingly.
|
14.3
|
The restrictions in this Clause 14 are separate and severable restrictions and are considered by the parties to be reasonable in all the circumstances. It is agreed that if any such restrictions by themselves, or taken together, shall be adjudged to go beyond what is reasonable in all the circumstances for the protection of the legitimate interests of the Company but would be adjudged reasonable if part or parts of the wording were deleted, the relevant restriction or restrictions shall apply with such deletion(s) as may be necessary to make it or them valid and effective.
|
14.4
|
You agree that money damages would not be a sufficient remedy for any breach of the restrictions in this Clause 14 and that the Company shall be entitled to seek equitable relief, including an injunction and specific performance, as a remedy for any such breach. Such remedies shall not be deemed to be the exclusive remedies for any such breach, but shall be in addition to all other remedies available at law or in equity.
|
15.
|
DATA PROTECTION
|
16.
|
PREVIOUS CONTRACTS
|
16.1
|
This Agreement and the Incorporated Documents constitute the entire agreement and understanding of the parties and supersede and extinguish all previous agreements, promises, assurances, warranties, representations and understandings between the parties, whether written or oral, relating to the subject matter of this Agreement; provided, however, for the avoidance of doubt, that this Agreement shall not supersede, extinguish or otherwise affect the Indemnification Deed For Officers And Directors between you and Venator Materials PLC.
|
16.2
|
Each party acknowledges that in entering into this Agreement it does not rely on, and shall have no remedies in respect of, any statement, representation, assurance or warranty (whether made innocently or negligently) that is not set out in this Agreement.
|
17.
|
GOVERNING LAW AND VENUE FOR ANY DISPUTES
|
17.1
|
Notwithstanding anything in the Incorporated Documents to the contrary, this Agreement and all acts and transactions pursuant hereto and the rights and obligations of the Parties shall be construed and interpreted in accordance with and governed by the laws of the State of Texas and applicable U.S. federal law, without giving effect to the conflict of law principles thereof, and the Parties hereto submit irrevocably to the exclusive jurisdiction of the courts of the State of Texas for resolution of any dispute arising hereunder.
|
1.
|
TERMS OF EMPLOYMENT
|
1.1
|
The terms set out in this Agreement, together with any documents incorporated into this Agreement by reference as set out in clause
1.2
(each referred to as an
“Incorporated Document”
), govern your employment relationship with the Company and bind the parties to this Agreement. If there is any conflict between the terms of this Agreement and the terms of an Incorporated Document, the terms of this Agreement will prevail.
|
1.2
|
Except as stated otherwise in this Agreement, the terms of each of the following documents are incorporated by reference into this Agreement and are made a part hereof:
|
(a)
|
the Venator Materials PLC Amended and Restated Executive Severance Plan adopted on November 14, 2017 (the “
Severance Plan
”);
|
(b)
|
the Venator Materials PLC 2017 Stock Incentive Plan adopted August 1, 2017, and all Award Agreements thereunder (together, the “
Stock Incentive Plan
”);
|
(c)
|
the Venator Materials PLC 2018 Short Term Incentive Plan adopted April 23, 2018;
|
(d)
|
the Venator Materials PLC Incentive Repayment Policy (or “
Clawback
”), as may be amended from time to time;
|
(e)
|
the Venator 401(k) Plan, as may be amended from time to time;
|
(f)
|
the Venator Executive Elective Deferral Plan adopted February 13, 2018, as may be amended from time to time;
|
(g)
|
the letter-agreement sent to you from the VP Human Resources of Venator Materials PLC detailing the terms of your temporary assignment to the UK dated June 19, 2017 (the
“Assignment Letter”
);
|
(h)
|
the letter-agreement sent to you from the President and CEO of Venator Materials PLC dated June 15, 2017 regarding an Agreement Concerning Retiree Medical Benefit (the “
Retiree Medical Benefit Letter
”); and
|
(i)
|
the letter-agreement sent to you from Huntsman P&A UK Limited dated 15 September 2017 regarding your lease of a home while on your Assignment in the UK.
|
2.
|
JOB TITLE AND DUTIES
|
2.1
|
You are employed as Senior Vice President, General Counsel and Chief Compliance Officer of Venator Materials PLC and its subsidiaries, with effect from June 21, 2017. You are credited
|
2.2
|
Your duties in your role are the global substantive and administrative responsibilities for the Legal, Compliance, Human Resources and Corporate Communications functions of Venator Materials PLC and its subsidiaries.
|
2.3
|
Whilst employed by the Company you must:
|
(a)
|
during your hours of work devote the whole of your time, attention and abilities to the business of the Company and carry out your duties with due care and attention;
|
(b)
|
not, without the Company’s prior written consent, be in any way directly or indirectly engaged or concerned with any other business (other than managing your personal investments) or employment whether during or outside your hours of work for the Company;
|
(c)
|
use your best efforts to promote and protect the interests of the Company and observe the utmost good faith towards the Company; and
|
(d)
|
comply with the Company’s rules, regulations and policies from time to time in force.
|
3.
|
REMUNERATION
|
3.1
|
Your gross base salary is US $455,000.00 (or such higher sum as may be determined by the Compensation Committee from time to time). The salary will be paid after deduction of required or estimated withholding for income taxes and for any benefit plan contributions you elect, and is payable no less frequently than in equal monthly instalments on or around the last day of each month into your nominated bank account.
|
3.2
|
Your salary will be reviewed for increase at regular annual intervals.
|
3.3
|
For the purposes of the Employment Rights Act 1996, sections 13-27, you agree that the Host Company may deduct from your remuneration any sums due from you to the Company including, without limitation, any overpayments, loans or advances made to you by the Company.
|
4.
|
ANNUAL BONUS
|
4.1
|
Your target bonus for each calendar year is a sum equal to 70% (or such higher percentage as may be determined by the Compensation Committee from time to time) of your annual base salary in effect at the end of that calendar year. The actual amount of bonus to be paid to you for a particular year will be determined by the Company by reference to your performance against individual performance targets and the performance of Venator Materials PLC for that year against objective performance targets set for the executive leadership team of Venator Materials PLC each year, with an opportunity each year to earn up to two (2) times your bonus target upon achievement of the maximum performance targets set for that year. For 2018, the objective performance targets are as described in the Venator Materials PLC 2018 Short Term Incentive Plan adopted April 23, 2018, as adjusted by the Compensation Committee on November 14, 2018.
|
4.2
|
The bonus will be paid to you in cash no later than the end of the month following the month in which the Company’s auditors have completed their audit of the financial statements of the Company. To be eligible to receive a bonus, except as provided in the Severance Plan, you must be in employment with the Company at the time of payment of the bonus.
|
5.
|
LONG TERM INCENTIVE
|
5.1
|
You continue to participate in the Stock Incentive Plan and your Awards under the Stock Incentive Plan are governed by the terms thereof, except that, as an additional term, upon a “Termination for Good Reason” under the Severance Plan following a Change of Control all Replacement Awards shall become fully vested in accordance with Section 6(j)(ix)(B) of the Stock Incentive Plan.
|
5.2
|
For each of the next three calendar years (and thereafter if renewed by the Compensation Committee) you will receive an Award under the Stock Incentive Plan, comprising stock options, restricted share units and/or performance share units (or such other type of Award as may be allowed under the Stock Incentive Plan as determined by the Compensation Committee of Venator Materials PLC), having a value on the date of grant of at least the amount of your grant on February 13, 2018. Each Award will vest in such increments over the next three years after the date of each Award as are determined by the Compensation Committee and, except as provided herein, will be subject to the terms of the Stock Incentive Plan and the Award Agreement pursuant to which the Award is made. Capitalised terms used in this clause but not defined in this clause have the meaning given to them in the Stock Incentive Plan.
|
5.3
|
In the event that Venator Materials PLC terminates the Stock Incentive Plan during the next three calendar years (or thereafter during any period renewed by the Compensation Committee as described in clause 5.2), you will be entitled thereafter during each year of your employment by the Company or an affiliate during such three calendar years or renewal thereof to receive in lieu of an Award under the Stock Incentive Plan an annual grant of performance units or similar long term incentive compensation, in each case having a grant value of at least the amount of your grant on February 13, 2018, and which will vest in such increments over the next three years after the date of each such grant as are determined by the Compensation Committee.
|
6.
|
EXPENSES
|
7.
|
NORMAL HOURS OF WORK
|
7.1
|
Your normal hours of work will be Monday to Friday 9am – 5pm. You acknowledge that your duties may require you to work additional hours as required from time to time and that you are not entitled to any additional remuneration for any such additional hours worked. For the purposes of the Working Time Regulations 1998 applicable to the Host Company, you agree to opt out of the 48 hour maximum working hours per week.
|
8.
|
PLACE OF WORK
|
8.1
|
Your normal place of work while assigned to the Host Company will be Titanium House, Hanzard Drive, Wynyard Park, Stockton-on-Tees, TS22 5FD, UK. Your normal place of work upon the end of your assignment will be 10003 Woodloch Forest Dr., The Woodlands, Texas. The Company may not change your normal place of work to a location other than a location within England without your prior written consent.
|
9.
|
NOTICE AND SEVERANCE
|
9.1
|
The length of prior written notice that you must give the Company in order to terminate your employment is 3 months. The length of prior written notice that the Company must give you in order to terminate your employment is 3 months
.
|
9.2
|
You continue to participate in the Severance Plan, the terms of which shall continue to apply to your employment, except that, as an additional term, a breach of this Agreement by the Company or its affiliate shall be deemed to be a sufficient cause for a “Termination for Good Reason” under the Severance Plan. For the avoidance of doubt the 30-day remedy provision set out Clause 2.13 of the Severance Plan shall also apply to any breach of this Agreement.
|
9.3
|
The Company may, at its absolute discretion, require you not to attend at work and/or not to undertake all or any of your duties hereunder during any period of notice (whether given by the Company or you), provided always that the Company shall continue to pay your salary and contractual benefits. For the avoidance of doubt, there is no obligation on the Company to provide you with any work during any period of notice and you will not be entitled to work on your own account or on account of any other person, firm or company during that period without the Company’s prior written consent.
|
10.
|
HOLIDAYS AND HOLIDAY PAY
|
10.1
|
Your entitlement to paid vacation days and customary public holidays is as provided in the Assignment Letter.
|
10.2
|
The Company’s holiday year runs from 1st January to 31st December and holiday entitlement (other than customary public holidays) will accrue pro rata on a monthly basis through the holiday year.
|
10.3
|
If your employment ends part way through the holiday year your holiday entitlement for that year will be assessed on a pro rata basis.
|
10.4
|
On termination of your employment you will be entitled to pay in lieu of any holidays which have accrued to you in the holiday year in which the termination takes place but which you have not taken at that time. The Company may require you to take unused holidays during your notice period.
|
11.
|
HEALTHCARE AND ABSENCE FROM WORK DUE TO SICKNESS OR INJURY
|
12.
|
RETIREMENT, LIFE INSURANCE AND OTHER BENEFITS
|
12.1
|
The Company will provide you with retirement benefits in accordance with the 401(k) Plan and the Supplemental Savings Plan as applicable to employees credited with your years of continuous service.
|
12.2
|
In addition, you are entitled to Company-paid life insurance and other benefits provided to the Company’s employees under its benefit plans and written policies, as may be amended from time to time.
|
13.
|
CONFIDENTIALITY
|
(a)
|
divulge or communicate to any person;
|
(b)
|
use for your own purposes or for any purposes other than those of the Company or, as appropriate, any of its customers; or
|
(c)
|
through any failure to exercise due care and diligence, cause any unauthorised disclosure of;
|
14.
|
COVENANT-NOT-TO-COMPETE AND OTHER RESTRICTIONS
|
14.1
|
In the course of your employment you will be exposed to Confidential Information and will acquire other proprietary knowledge relating to the Company’ and its affiliates’ current and planned operations. Therefore, you will not during the period of your employment with the Company and for a period of twelve months after the termination of your employment, either directly, or indirectly through any other person, firm or other organisation (any a “
Person
”):
|
(a)
|
solicit, entice or induce any Person which at any time during the last year of your employment with the Company (that period referred to as the “
Relevant Period
”) was a supplier of the Company or any of its affiliates (and with whom you or one of your direct reports was actively involved during that time or in respect of which you are in possession of material Confidential Information) to reduce the level of business between the supplier and the Company or its affiliates and you will not approach any supplier for that purpose or authorise or approve the taking of such actions by any other person;
|
(b)
|
solicit business which is of the same or similar nature as the business with which you were materially concerned at any time during the Relevant Period or in respect of which you are in possession of Confidential Information as a result of your employment during the Relevant Period (such business referred to as the “
Business
”) from any Person which at any time during the Relevant Period was a customer of the Company or any of its affiliates (and with whom you or one of your direct reports was actively
|
(c)
|
employ or engage or otherwise solicit, entice or induce any person who, during the Relevant Period, was an employee, consultant or contractor of the Company or any of its affiliates who was employed during that period in a senior sales, marketing, financial, managerial, professional or equivalent capacity to become employed or engaged by you or any other Person and you will not approach any such person for such purpose or authorise or approve the taking of such actions by any other Person; and
|
(d)
|
within the Restricted Area, be employed or engaged in that part of a business which is involved in the business of researching, developing, manufacturing, distributing, selling, supplying or otherwise dealing with Restricted Products, if the business or person is or seeks to be in competition with the Company. For the purposes of this sub- clause, acts done by you outside the Restricted Area shall nonetheless be deemed to be done within the Restricted Area where their primary purpose is to distribute, sell, supply or otherwise deal with Restricted Products in the Restricted Area. For the purposes of this sub-clause, “
Restricted Area
” shall mean any country in the world where, on the date you cease to be employed by the Company, the Company researches, develops, manufactures, supplies, markets, distributes or sells Restricted Products, and “
Restricted Products
” shall mean (i) Titanium Dioxide pigments and commercial co- products and (ii) Iron Oxide pigments.
|
14.2
|
If the Company suspends any of your duties under Clause 9.3 during any period after notice of termination has been given by the Company or you, the aggregate of the period of the suspension and the period after the end of your employment with the Company during which the restrictions in this Clause 14 shall apply shall not exceed 12 months and, if the aggregate of the two periods would exceed 12 months, the period after the end of your employment during which the restrictions shall apply shall be reduced accordingly.
|
14.3
|
The restrictions in this Clause 14 are separate and severable restrictions and are considered by the parties to be reasonable in all the circumstances. It is agreed that if any such restrictions by themselves, or taken together, shall be adjudged to go beyond what is reasonable in all the circumstances for the protection of the legitimate interests of the Company but would be adjudged reasonable if part or parts of the wording were deleted, the relevant restriction or restrictions shall apply with such deletion(s) as may be necessary to make it or them valid and effective.
|
14.4
|
You agree that money damages would not be a sufficient remedy for any breach of the restrictions in this Clause 14 and that the Company shall be entitled to seek equitable relief, including an injunction and specific performance, as a remedy for any such breach. Such remedies shall not be deemed to be the exclusive remedies for any such breach, but shall be in addition to all other remedies available at law or in equity.
|
15.
|
DATA PROTECTION
|
16.
|
PREVIOUS CONTRACTS
|
16.1
|
This Agreement and the Incorporated Documents constitute the entire agreement and understanding of the parties and supersede and extinguish all previous agreements, promises, assurances, warranties, representations and understandings between the parties, whether written or oral, relating to the subject matter of this Agreement; provided, however, for the avoidance of doubt, that this Agreement shall not supersede, extinguish or otherwise affect the Indemnification Deed For Officers And Directors between you and Venator Materials PLC.
|
16.2
|
Each party acknowledges that in entering into this Agreement it does not rely on, and shall have no remedies in respect of, any statement, representation, assurance or warranty (whether made innocently or negligently) that is not set out in this Agreement.
|
17.
|
GOVERNING LAW AND VENUE FOR ANY DISPUTES
|
17.1
|
Notwithstanding anything in the Incorporated Documents to the contrary, this Agreement and all acts and transactions pursuant hereto and the rights and obligations of the Parties shall be construed and interpreted in accordance with and governed by the laws of the State of Texas and applicable U.S. federal law, without giving effect to the conflict of law principles thereof, and the Parties hereto submit irrevocably to the exclusive jurisdiction of the courts of the State of Texas for resolution of any dispute arising hereunder.
|
1.
|
TERMS OF EMPLOYMENT
|
1.1
|
The terms set out in this Agreement, together with any documents incorporated into this Agreement by reference as set out in clause
1.2
(each referred to as an
“Incorporated Document”
), govern your employment relationship with the Company and bind the parties to this Agreement. If there is any conflict between the terms of this Agreement and the terms of an Incorporated Document, the terms of this Agreement will prevail.
|
1.2
|
Except as stated otherwise in this Agreement, the terms of each of the following documents are incorporated by reference into this Agreement and are made a part hereof:
|
(a)
|
the Venator Materials PLC Amended and Restated Executive Severance Plan adopted on November 14, 2017 (the “
Severance Plan
”);
|
(b)
|
the Venator Materials PLC 2017 Stock Incentive Plan adopted August 1, 2017, and all Award Agreements thereunder (together, the “
Stock Incentive Plan
”);
|
(c)
|
the Venator Materials PLC 2018 Short Term Incentive Plan adopted April 23, 2018;
|
(d)
|
the Venator Materials PLC Incentive Repayment Policy (or “
Clawback
”) adopted February 13, 2018, as may be amended from time to time:
|
(e)
|
the Venator UK Management Car Scheme, as may be amended from time to time; and
|
(f)
|
the Retirement Benefit Profile effective August 1, 1996, provided to you by Tioxide Group Limited.
|
2.
|
JOB TITLE AND DUTIES
|
2.1
|
You are employed as Senior Vice President, White Pigments, of Venator Materials PLC. You began your employment in this role on June 21, 2017, and you are credited with continuous employment with the Company (including its predecessors) since February 1, 1985.
|
2.2
|
Your duties in your role are the global substantive and administrative oversight of the White Pigments Business Unit of Venator Materials PLC.
|
2.3
|
Whilst employed by the Company you must:
|
(a)
|
during your hours of work devote the whole of your time, attention and abilities to the business of the Company and carry out your duties with due care and attention;
|
(b)
|
not, without the Company’s prior written consent, be in any way directly or indirectly engaged or concerned with any other business (other than managing your personal investments) or employment whether during or outside your hours of work for the Company;
|
(c)
|
use your best efforts to promote and protect the interests of the Company and observe the utmost good faith towards the Company; and
|
(d)
|
comply with the Company’s rules, regulations and policies from time to time in force.
|
3.
|
REMUNERATION
|
3.1
|
Your gross base salary is the GBP equivalent of US $460,000.00 (or such higher sum as may be determined by the Compensation Committee from time to time). The salary will be paid after deduction of required or estimated withholding for income taxes, for national insurance and for any benefit plan contributions you elect, and is payable no less frequently than in equal monthly instalments on or around the last day of each month into your nominated bank account.
|
3.2
|
Your salary will be reviewed for increase at regular annual intervals.
|
3.3
|
For the purposes of the Employment Rights Act 1996, sections 13-27, you agree that the Company may deduct from your remuneration any sums due from you to the Company including, without limitation, your pension contributions (if any) and any overpayments, loans or advances made to you by the Company.
|
4.
|
ANNUAL BONUS
|
4.1
|
Your target bonus for each calendar year is a sum equal to 70% (or such higher percentage as may be determined by the Compensation Committee from time to time) of your annual base salary in effect at the end of that calendar year. The actual amount of bonus to be paid to you for a particular year will be determined by the Company by reference to your performance against individual performance targets and the performance of Venator Materials PLC for that year against objective performance targets set for the executive leadership team of Venator Materials PLC each year, with an opportunity each year to earn up to two (2) times your bonus target upon achievement of the maximum performance targets set for that year. For 2018, the objective performance targets are as described in the Venator Materials PLC 2018 Short Term Incentive Plan adopted April 23, 2018, as adjusted by the Compensation Committee on November 14, 2018.
|
4.2
|
The bonus will be paid to you in cash no later than the end of the month following the month in which the Company’s auditors have completed their audit of the financial statements of the Company. To be eligible to receive a bonus, except as provided in the Severance Plan, you must be in employment with the Company at the time of payment of the bonus.
|
5.
|
LONG TERM INCENTIVE
|
5.1
|
You continue to participate in the Stock Incentive Plan and your Awards under the Stock Incentive Plan are governed by the terms thereof, except that, as an additional term, upon a “Termination for Good Reason” under the Severance Plan following a Change of Control all Replacement Awards shall become fully vested in accordance with Section 6(j)(ix)(B) of the Stock Incentive Plan.
|
5.2
|
For each of the next three calendar years (and thereafter if renewed by the Compensation Committee) you will receive an Award under the Stock Incentive Plan, comprising stock options, restricted share units and/or performance share units (or such other type of Award as may be allowed under the Stock Incentive Plan as determined by the Compensation Committee of Venator Materials PLC), having a value on the date of grant of at least the amount of your grant on February 14, 2018. Each Award will vest in such increments over the next three years after the date of each Award as are determined by the Compensation Committee and, except as provided herein, will be subject to the terms of the Stock Incentive Plan and the Award
|
5.3
|
In the event that Venator Materials PLC terminates the Stock Incentive Plan during the next three calendar years (or thereafter during any period renewed by the Compensation Committee as described in clause 5.2), you will be entitled thereafter during each year of your employment by the Company or an affiliate during such three calendar years or renewal thereof to receive in lieu of an Award under the Stock Incentive Plan an annual grant of performance units or similar long term incentive compensation, in each case having a grant value of at least the amount of your grant on February 14, 2018, and which will vest in such increments over the next three years after the date of each such annual grant as are determined by the Compensation Committee.
|
6.
|
EXPENSES
|
7.
|
NORMAL HOURS OF WORK
|
7.1
|
Your normal hours of work will be Monday to Friday 9am – 5pm. You acknowledge that your duties may require you to work additional hours as required from time to time and that you are not entitled to any additional remuneration for any such additional hours worked. For the purposes of the Working Time Regulations 1998 you agree to opt out of the 48 hour maximum working hours per week.
|
8.
|
PLACE OF WORK
|
8.1
|
Your normal place of work will be Titanium House, Hanzard Drive, Wynyard Park, Stockton- on-Tees, TS22 5FD, UK. The Company may not change your normal place of work to a location other than a location within England without your prior written consent.
|
9.
|
NOTICE AND SEVERANCE
|
9.1
|
The length of prior written notice that you must give the Company in order to terminate your employment is 3 months. The length of prior written notice that the Company must give you in order to terminate your employment is 12 months
.
|
9.2
|
You continue to participate in the Severance Plan, the terms of which shall continue to apply to your employment, except that, as an additional term, a breach of this Agreement by the Company or its affiliate shall be deemed to be a sufficient cause for a “Termination for Good Reason” under the Severance Plan. For the avoidance of doubt the 30-day remedy provision set out Clause 2.13 of the Severance Plan shall also apply to any breach of this Agreement.
|
9.3
|
The Company may, at its absolute discretion, require you not to attend at work and/or not to undertake all or any of your duties hereunder during any period of notice (whether given by the Company or you), provided always that the Company shall continue to pay your salary and contractual benefits. For the avoidance of doubt, there is no obligation on the Company to provide you with any work during any period of notice and you will not be entitled to work on your own account or on account of any other person, firm or company during that period without the Company’s prior written consent.
|
10.
|
HOLIDAYS AND HOLIDAY PAY
|
10.1
|
Each holiday year, you are entitled to 32 working days paid holiday and all customary public holidays recognised by the Company in that particular holiday year.
|
10.2
|
The Company’s holiday year runs from 1st January to 31st December and holiday entitlement (other than customary public holidays) will accrue pro rata on a monthly basis through the holiday year.
|
10.3
|
If your employment ends part way through the holiday year your holiday entitlement for that year will be assessed on a pro rata basis.
|
10.4
|
On termination of your employment you will be entitled to pay in lieu of any holidays which have accrued to you in the holiday year in which the termination takes place but which you have not taken at that time. The Company may require you to take unused holidays during your notice period.
|
11.
|
HEALTHCARE AND ABSENCE FROM WORK DUE TO SICKNESS OR INJURY
|
12.
|
PENSION, RETIREMENT AND LIFE INSURANCE BENEFITS
|
12.1
|
You are a member of the following pension plans and subject to the rules thereof: (1) the Tioxide Pension Fund (in which you have deferred member status); (2) the U.K. Defined Contribution Scheme (in which you have deferred member status); (3) the AECI Pension Fund in South Africa (in which you have deferred member status); and (4) the Huntsman Global Pension Scheme (the “HGPS”) (in which you have active deferred status). Because you have met the applicable lifetime contribution limit and are therefore not receiving any additional contributions from the Company into your U.K. Defined Contribution Scheme account in which you have deferred member status, the Company will provide you with a monthly cash payment approximately equivalent to the amount you would have been eligible to receive as a contribution to your plan account had you not met the lifetime limit, which is 15% of your base salary.
|
12.2
|
Pursuant to the operation of the HGPS, an illustration of how your pension benefit is calculated is described in the document titled “MM Pension Benefit Calculation 2016.”
|
12.3
|
Pursuant to Company policy, the Company will provide you with a “top up” payment to the HGPS should you wish to withdraw your funds from this pension scheme, in an amount sufficient to enable the HGPS Trustee to transfer a fully funded (unreduced) account value attributable to your years of service in accordance with the terms of the HGPS.
|
12.4
|
Pursuant and subject to the terms of the Venator UK Life Assurance Scheme, the Company will provide you with a Death in Service Benefit of eight times (8x) your annual salary at the time of your death, and an additional seven times (7x) your annual salary at the time of your death if your death is the result of a work-related accident, up to a maximum benefit of £5 million unless a higher amount is approved by the Company’s underwriter.
|
13.
|
CONFIDENTIALITY
|
(a)
|
divulge or communicate to any person;
|
(b)
|
use for your own purposes or for any purposes other than those of the Company or, as appropriate, any of its customers; or
|
(c)
|
through any failure to exercise due care and diligence, cause any unauthorised disclosure of;
|
14.
|
COVENANT-NOT-TO-COMPETE AND OTHER RESTRICTIONS
|
14.1
|
In the course of your employment you will be exposed to Confidential Information and will acquire other proprietary knowledge relating to the Company’ and its affiliates’ current and planned operations. Therefore, you will not during the period of your employment with the Company and for a period of twelve months after the termination of your employment, either directly, or indirectly through any other person, firm or other organisation (any a “
Person
”):
|
(a)
|
solicit, entice or induce any Person which at any time during the last year of your employment with the Company (that period referred to as the “
Relevant Period
”) was a supplier of the Company or any of its affiliates (and with whom you or one of your direct reports was actively involved during that time or in respect of which you are in possession of material Confidential Information) to reduce the level of business between the supplier and the Company or its affiliates and you will not approach any supplier for that purpose or authorise or approve the taking of such actions by any other person;
|
(b)
|
solicit business which is of the same or similar nature as the business with which you were materially concerned at any time during the Relevant Period or in respect of which you are in possession of Confidential Information as a result of your employment during the Relevant Period (such business referred to as the “
Business
”) from any Person which at any time during the Relevant Period was a customer of the Company or any of its affiliates (and with whom you or one of your direct reports was actively involved during that time or in respect of which you are in possession of material Confidential Information) and you will not approach any customer for that purpose or authorise or approve the taking of such actions by any other Person. For the purposes of this restriction, the expression “customer” shall include all Persons from whom the
|
(c)
|
employ or engage or otherwise solicit, entice or induce any person who, during the Relevant Period, was an employee, consultant or contractor of the Company or any of its affiliates who was employed during that period in a senior sales, marketing, financial, managerial, professional or equivalent capacity to become employed or engaged by you or any other Person and you will not approach any such person for such purpose or authorise or approve the taking of such actions by any other Person; and
|
(d)
|
within the Restricted Area, be employed or engaged in that part of a business which is involved in the business of researching, developing, manufacturing, distributing, selling, supplying or otherwise dealing with Restricted Products, if the business or person is or seeks to be in competition with the Company. For the purposes of this sub- clause, acts done by you outside the Restricted Area shall nonetheless be deemed to be done within the Restricted Area where their primary purpose is to distribute, sell, supply or otherwise deal with Restricted Products in the Restricted Area. For the purposes of this sub-clause, “
Restricted Area
” shall mean any country in the world where, on the date you cease to be employed by the Company, the Company researches, develops, manufactures, supplies, markets, distributes or sells Restricted Products, and “
Restricted Products
” shall mean (i) Titanium Dioxide pigments and commercial co- products and (ii) Iron Oxide pigments.
|
14.2
|
If the Company suspends any of your duties under Clause 9.3 during any period after notice of termination has been given by the Company or you, the aggregate of the period of the suspension and the period after the end of your employment with the Company during which the restrictions in this Clause 14 shall apply shall not exceed 12 months and, if the aggregate of the two periods would exceed 12 months, the period after the end of your employment during which the restrictions shall apply shall be reduced accordingly.
|
14.3
|
The restrictions in this Clause 14 are separate and severable restrictions and are considered by the parties to be reasonable in all the circumstances. It is agreed that if any such restrictions by themselves, or taken together, shall be adjudged to go beyond what is reasonable in all the circumstances for the protection of the legitimate interests of the Company but would be adjudged reasonable if part or parts of the wording were deleted, the relevant restriction or restrictions shall apply with such deletion(s) as may be necessary to make it or them valid and effective.
|
14.4
|
You agree that money damages would not be a sufficient remedy for any breach of the restrictions in this Clause 14 and that the Company shall be entitled to seek equitable relief, including an injunction and specific performance, as a remedy for any such breach. Such remedies shall not be deemed to be the exclusive remedies for any such breach, but shall be in addition to all other remedies available at law or in equity.
|
15.
|
DATA PROTECTION
|
15.1
|
The Company will hold, collect and otherwise process certain personal data as set out in the Company’s privacy notice, which is on the intranet. All personal data will be treated in accordance with applicable data protection laws and regulations.
|
16.
|
PREVIOUS CONTRACTS
|
16.1
|
This Agreement and the Incorporated Documents constitute the entire agreement and understanding of the parties and supersede and extinguish all previous agreements, promises, assurances, warranties, representations and understandings between the parties, whether written or oral, relating to the subject matter of this Agreement; provided, however, for the avoidance
|
16.2
|
Each party acknowledges that in entering into this Agreement it does not rely on, and shall have no remedies in respect of, any statement, representation, assurance or warranty (whether made innocently or negligently) that is not set out in this Agreement.
|
17.
|
GOVERNING LAW AND VENUE FOR ANY DISPUTES
|
17.1
|
Notwithstanding anything in the Incorporated Documents to the contrary, this Agreement and all acts and transactions pursuant hereto and the rights and obligations of the Parties shall be construed and interpreted in accordance with and governed by the laws of England, without giving effect to the conflict of law principles thereof, and the Parties hereto submit irrevocably to the exclusive jurisdiction of the English courts for resolution of any dispute arising hereunder.
|
1.
|
TERMS OF EMPLOYMENT
|
1.1
|
The terms set out in this Agreement, together with any documents incorporated into this Agreement by reference as set out in clause
1.2
(each referred to as an
“Incorporated Document”
), govern your employment relationship with the Company and bind the parties to this Agreement. If there is any conflict between the terms of this Agreement and the terms of an Incorporated Document, the terms of this Agreement will prevail.
|
1.2
|
Except as stated otherwise in this Agreement, the terms of each of the following documents are incorporated by reference into this Agreement and are made a part hereof:
|
(a)
|
the Venator Materials PLC Amended and Restated Executive Severance Plan adopted on November 14, 2017 (the “
Severance Plan
”);
|
(b)
|
the Venator Materials PLC 2017 Stock Incentive Plan adopted August 1, 2017, and all Award Agreements thereunder (together, the “
Stock Incentive Plan
”);
|
(c)
|
the Venator Materials PLC 2018 Short Term Incentive Plan adopted April 23, 2018;
|
(d)
|
the Venator Materials PLC Incentive Repayment Policy (or “
Clawback
”) adopted February 13, 2018, as may be amended from time to time; and
|
(e)
|
the Venator UK Management Car Scheme, as may be amended from time to time.
|
2.
|
JOB TITLE AND DUTIES
|
2.1
|
You are employed as Vice President, Innovation and Technology of Venator Materials PLC. You began your employment in this role on May 01, 2017, and you are credited with continuous employment with the Company (including its predecessors) since November 01, 1994.
|
2.2
|
Your duties in your role are the global substantive and administrative oversight of the Innovation function of Venator Materials PLC and its subsidiaries.
|
2.3
|
Whilst employed by the Company you must:
|
(a)
|
during your hours of work devote the whole of your time, attention and abilities to the business of the Company and carry out your duties with due care and attention;
|
(b)
|
not, without the Company’s prior written consent, be in any way directly or indirectly engaged or concerned with any other business (other than managing your personal investments) or employment whether during or outside your hours of work for the Company;
|
(c)
|
use your best efforts to promote and protect the interests of the Company and observe the utmost good faith towards the Company; and
|
(d)
|
comply with the Company’s rules, regulations and policies from time to time in force.
|
3.
|
REMUNERATION
|
3.1
|
Your gross base salary is the GBP equivalent of US $250,000.00 (or such higher sum as may be determined by the Compensation Committee from time to time). The salary will be paid after deduction of required or estimated withholding for income taxes, for national insurance and for any benefit plan contributions you elect, and is payable no less frequently than in equal monthly instalments on or around the last day of each month into your nominated bank account.
|
3.2
|
Your salary will be reviewed for increase at regular annual intervals.
|
3.3
|
For the purposes of the Employment Rights Act 1996, sections 13-27, you agree that the Company may deduct from your remuneration any sums due from you to the Company including, without limitation, your pension contributions (if any) and any overpayments, loans or advances made to you by the Company.
|
4.
|
ANNUAL BONUS
|
4.1
|
Your target bonus for each calendar year is a sum equal to 40% (or such higher percentage as may be determined by the Compensation Committee from time to time) of your annual base salary in effect at the end of that calendar year. The actual amount of bonus to be paid to you for a particular year will be determined by the Company by reference to your performance against individual performance targets and the performance of Venator Materials PLC for that year against objective performance targets set for the executive leadership team of Venator Materials PLC each year, with an opportunity each year to earn up to two (2) times your bonus target upon achievement of the maximum performance targets set for that year. For 2018, the objective performance targets are as described in the Venator Materials PLC 2018 Short Term Incentive Plan adopted April 23, 2018, as adjusted by the Compensation Committee on November 14, 2018.
|
4.2
|
The bonus will be paid to you in cash no later than the end of the month following the month in which the Company’s auditors have completed their audit of the financial statements of the Company. To be eligible to receive a bonus, except as provided in the Severance Plan, you must be in employment with the Company at the time of payment of the bonus.
|
5.
|
LONG TERM INCENTIVE
|
5.1
|
You continue to participate in the Stock Incentive Plan and your Awards under the Stock Incentive Plan are governed by the terms thereof, except that, as an additional term, upon a “Termination for Good Reason” under the Severance Plan following a Change of Control all Replacement Awards shall become fully vested in accordance with Section 6(j)(ix)(B) of the Stock Incentive Plan.
|
5.2
|
For each of the next three calendar years (and thereafter if renewed by the Compensation Committee) you will receive an Award under the Stock Incentive Plan, comprising stock options, restricted share units and/or performance share units (or such other type of Award as may be allowed under the Stock Incentive Plan as determined by the Compensation Committee of Venator Materials PLC), having a value on the date of grant of at least the amount of your grant on February 14, 2018. Each Award will vest in such increments over the next three years after the date of each Award as are determined by the Compensation Committee and, except as provided herein, will be subject to the terms of the Stock Incentive Plan and the Award Agreement pursuant to which the Award is made. Capitalised terms used in this clause but not defined in this clause have the meaning given to them in the Stock Incentive Plan.
|
5.3
|
In the event that Venator Materials PLC terminates the Stock Incentive Plan during the next three calendar years (or thereafter during any period renewed by the Compensation Committee as described in clause 5.2), you will be entitled thereafter during each year of your employment by the Company or an affiliate during such three calendar years or renewal thereof to receive in lieu of an Award under the Stock Incentive Plan an annual grant of performance units or similar long term incentive compensation, in each case having a grant value of at least the amount of your grant on February 14, 2018, and which will vest in such increments over the next three years after the date of each such annual grant as are determined by the Compensation Committee.
|
6.
|
EXPENSES
|
7.
|
NORMAL HOURS OF WORK
|
7.1
|
Your normal hours of work will be Monday to Friday 9am – 5pm. You acknowledge that your duties may require you to work additional hours as required from time to time and that you are not entitled to any additional remuneration for any such additional hours worked. For the purposes of the Working Time Regulations 1998 you agree to opt out of the 48 hour maximum working hours per week.
|
8.
|
PLACE OF WORK
|
8.1
|
Your normal place of work will be Titanium House, Hanzard Drive, Wynyard Park, Stockton- on-Tees, TS22 5FD, UK. The Company may not change your normal place of work to a location other than a location within England without your prior written consent.
|
9.
|
NOTICE AND SEVERANCE
|
9.1
|
The length of prior written notice that you must give the Company in order to terminate your employment is 3 months. The length of prior written notice that the Company must give you in order to terminate your employment is 3 months
.
|
9.2
|
You continue to participate in the Severance Plan, the terms of which shall continue to apply to your employment, except that, as an additional term, a breach of this Agreement by the Company or its affiliate shall be deemed to be a sufficient cause for a “Termination for Good Reason” under the Severance Plan. For the avoidance of doubt the 30-day remedy provision set out Clause 2.13 of the Severance Plan shall also apply to any breach of this Agreement.
|
9.3
|
The Company may, at its absolute discretion, require you not to attend at work and/or not to undertake all or any of your duties hereunder during any period of notice (whether given by the Company or you), provided always that the Company shall continue to pay your salary and contractual benefits. For the avoidance of doubt, there is no obligation on the Company to provide you with any work during any period of notice and you will not be entitled to work on your own account or on account of any other person, firm or company during that period without the Company’s prior written consent.
|
10.
|
HOLIDAYS AND HOLIDAY PAY
|
10.1
|
Each holiday year, you are entitled to 32 working days paid holiday and all customary public holidays recognised by the Company in that particular holiday year.
|
10.2
|
The Company’s holiday year runs from 1st January to 31st December and holiday entitlement (other than customary public holidays) will accrue pro rata on a monthly basis through the holiday year.
|
10.3
|
If your employment ends part way through the holiday year your holiday entitlement for that year will be assessed on a pro rata basis.
|
10.4
|
On termination of your employment you will be entitled to pay in lieu of any holidays which have accrued to you in the holiday year in which the termination takes place but which you have not taken at that time. The Company may require you to take unused holidays during your notice period.
|
11.
|
HEALTHCARE AND ABSENCE FROM WORK DUE TO SICKNESS OR INJURY
|
12.
|
PENSION, RETIREMENT AND LIFE INSURANCE BENEFITS
|
12.1
|
You are a member of the following pension plans and subject to the rules thereof: (1) the Tioxide Pension Fund (in which you have deferred member status); (2) the U.K. Defined Contribution Scheme (in which you have active deferred status); (3) the AECI Pension Fund in South Africa (in which you have deferred member status); and (4) the Huntsman Global Pension Scheme (the “HGPS”) (in which you have active deferred status).
|
12.2
|
Pursuant to Company policy, the Company will provide you with a “top up” payment to the HGPS should you wish to withdraw your funds from this pension scheme, in an amount sufficient to enable the HGPS Trustee to transfer a fully funded (unreduced) account value attributable to your years of service in accordance with the terms of the HGPS.
|
12.3
|
Pursuant and subject to the terms of the Venator UK Life Assurance Scheme, the Company will provide you with a Death in Service Benefit of eight times (8x) your annual salary at the time of your death, and an additional seven times (7x) your annual salary at the time of your death if your death is the result of a work-related accident, up to a maximum benefit of £5 million unless a higher amount is approved by the Company’s underwriter.
|
13.
|
CONFIDENTIALITY
|
(a)
|
divulge or communicate to any person;
|
(b)
|
use for your own purposes or for any purposes other than those of the Company or, as appropriate, any of its customers; or
|
(c)
|
through any failure to exercise due care and diligence, cause any unauthorised disclosure of;
|
14.
|
COVENANT-NOT-TO-COMPETE AND OTHER RESTRICTIONS
|
14.1
|
In the course of your employment you will be exposed to Confidential Information and will acquire other proprietary knowledge relating to the Company’ and its affiliates’ current and planned operations. Therefore, you will not during the period of your employment with the Company and for a period of twelve months after the termination of your employment, either directly, or indirectly through any other person, firm or other organisation (any a “
Person
”):
|
(a)
|
solicit, entice or induce any Person which at any time during the last year of your employment with the Company (that period referred to as the “
Relevant Period
”) was a supplier of the Company or any of its affiliates (and with whom you or one of your direct reports was actively involved during that time or in respect of which you are in possession of material Confidential Information) to reduce the level of business between the supplier and the Company or its affiliates and you will not approach any supplier for that purpose or authorise or approve the taking of such actions by any other person;
|
(b)
|
solicit business which is of the same or similar nature as the business with which you were materially concerned at any time during the Relevant Period or in respect of which you are in possession of Confidential Information as a result of your employment during the Relevant Period (such business referred to as the “
Business
”) from any Person which at any time during the Relevant Period was a customer of the Company or any of its affiliates (and with whom you or one of your direct reports was actively involved during that time or in respect of which you are in possession of material Confidential Information) and you will not approach any customer for that purpose or authorise or approve the taking of such actions by any other Person. For the purposes of this restriction, the expression “customer” shall include all Persons from whom the Company or any of its affiliates has received inquiries for the provision of goods or services where such inquiries have not been concluded;
|
(c)
|
employ or engage or otherwise solicit, entice or induce any person who, during the Relevant Period, was an employee, consultant or contractor of the Company or any of its affiliates who was employed during that period in a senior sales, marketing, financial, managerial, professional or equivalent capacity to become employed or engaged by you or any other Person and you will not approach any such person for such purpose or authorise or approve the taking of such actions by any other Person; and
|
(d)
|
within the Restricted Area, be employed or engaged in that part of a business which is involved in the business of researching, developing, manufacturing, distributing, selling, supplying or otherwise dealing with Restricted Products, if the business or person is or seeks to be in competition with the Company. For the purposes of this sub- clause, acts done by you outside the Restricted Area shall nonetheless be deemed to be
|
14.2
|
If the Company suspends any of your duties under Clause 9.3 during any period after notice of termination has been given by the Company or you, the aggregate of the period of the suspension and the period after the end of your employment with the Company during which the restrictions in this Clause 14 shall apply shall not exceed 12 months and, if the aggregate of the two periods would exceed 12 months, the period after the end of your employment during which the restrictions shall apply shall be reduced accordingly.
|
14.3
|
The restrictions in this Clause 14 are separate and severable restrictions and are considered by the parties to be reasonable in all the circumstances. It is agreed that if any such restrictions by themselves, or taken together, shall be adjudged to go beyond what is reasonable in all the circumstances for the protection of the legitimate interests of the Company but would be adjudged reasonable if part or parts of the wording were deleted, the relevant restriction or restrictions shall apply with such deletion(s) as may be necessary to make it or them valid and effective.
|
14.4
|
You agree that money damages would not be a sufficient remedy for any breach of the restrictions in this Clause 14 and that the Company shall be entitled to seek equitable relief, including an injunction and specific performance, as a remedy for any such breach. Such remedies shall not be deemed to be the exclusive remedies for any such breach, but shall be in addition to all other remedies available at law or in equity.
|
15.
|
DATA PROTECTION
|
15.1
|
The Company will hold, collect and otherwise process certain personal data as set out in the Company’s privacy notice, which is on the intranet. All personal data will be treated in accordance with applicable data protection laws and regulations.
|
16.
|
PREVIOUS CONTRACTS
|
16.1
|
This Agreement and the Incorporated Documents constitute the entire agreement and understanding of the parties and supersede and extinguish all previous agreements, promises, assurances, warranties, representations and understandings between the parties, whether written or oral, relating to the subject matter of this Agreement; provided, however, for the avoidance of doubt, that this Agreement shall not supersede, extinguish or otherwise affect the Indemnification Deed For Officers And Directors between you and Venator Materials PLC.
|
16.2
|
Each party acknowledges that in entering into this Agreement it does not rely on, and shall have no remedies in respect of, any statement, representation, assurance or warranty (whether made innocently or negligently) that is not set out in this Agreement.
|
17.
|
GOVERNING LAW AND VENUE FOR ANY DISPUTES
|
17.1
|
Notwithstanding anything in the Incorporated Documents to the contrary, this Agreement and all acts and transactions pursuant hereto and the rights and obligations of the Parties shall be construed and interpreted in accordance with and governed by the laws of England, without giving effect to the conflict of law principles thereof, and the Parties hereto submit irrevocably to the exclusive jurisdiction of the English courts for resolution of any dispute arising hereunder.
|
6.
|
Expiration of Restrictions and Risk of Forfeiture
.
|
7.
|
Termination of Services or Change of Control
.
|
9.
|
Tax Related Items
.
|
1.
|
The Company and the Committee may process certain Personal Data (whether provided in any documents that you may complete in order to participate in the Plan or sourced from your employment with your employer), in connection with the Plan and an Award For the purpose of this Annex B, references to the “Company” shall include your employer. This Annex B sets out:
|
(a)
|
the Personal Data that the Company and the Committee will hold; and
|
(b)
|
the purposes for which the Company and the Committee will hold and use that Personal Data.
|
2.
|
A Participant shall be required to disclose Personal Data in order to receive an Award. Disclosure may occur pursuant to an Award Agreement or in connection with the administrative processes used by the Company in order to populate the Award Agreement and administer the Award. If a Participant does not disclose the Personal Data which is required by the Company or the Committee in order to comply with the Plan, the Company and the Committee may not be able to grant an Award to the Participant.
|
3.
|
The Company and the Committee may collect, use and process your Personal Data in order to administer or otherwise give effect to the Plan including for the following purposes:
|
(a)
|
to correspond with you and discuss the Plan with you;
|
(b)
|
to carry out your obligations arising from any contracts entered into between you, the Committee and/or the Company;
|
(c)
|
holding, administering and maintaining your records, including, but not limited to, details of your Awards;
|
(d)
|
to support and assist any third parties with whom the Committee or the Company may share your Personal Data to manage and administer the Plan;
|
(e)
|
to manage and administer the relationship between you and the Committee and the Company;
|
(f)
|
to comply with legal obligations of the Company and the Committee and to comply with instructions the Company and the Committee may receive from any regulatory bodies and tax authorities;
|
(g)
|
to provide information to the Company, the Committee, trustees of any employee benefit trust, registrars, brokers or any administrators of the Plan; and
|
(h)
|
to provide information to bona fide prospective purchasers or merger partners of the Company (including advisers to such prospective purchasers or merger partners), or the business in which you work.
|
4.
|
The Company and the Committee may, in order to administer or otherwise give effect to the Plan, from time to time share your Personal Data with:
|
(a)
|
any Company Affiliate or any Subsidiary of the Company that does not employ you;
|
(b)
|
advisers, brokers or registrars engaged by the Company, the Committee, and any Company Affiliate and/or any Subsidiary of the Company that does not employ you; and/or
|
(c)
|
any third parties that provide services to the Company, the Committee, and any Company Affiliate and/or any Subsidiary of the Company that does not employ you.
|
5.
|
The Company and the Committee will process your Personal Data in order to:
|
(a)
|
pursue their legitimate interests of administering, or otherwise giving effect to, the Plan; and/or
|
(b)
|
fulfill their respective obligations as necessary for the performance of a contract with you (or another Person), or in preparation of entering into a contract with you (or another Person).
|
6.
|
The Committee will not retain any of your Personal Data relating to the Plan. Any of your Personal Data relating to the Plan will be stored by the Company until termination of the Plan.
|
7.
|
Where the Company and/or the Committee share your Personal Data with, or transfer it to, any person and that person is located outside the European Economic Area, the Company and/or the Committee will ensure that there are in place adequate safeguards for such information, including, entering into model contract clauses which have been approved by the European Commission. Copies of such agreements can be obtained by request from Nina Nandelstaedt at the Company.
|
8.
|
The privacy compliance manager for the Company (and contact details) are:
[redacted]
).
|
9.
|
You have a number of rights in respect of the use by the Company and the Committee of your Personal Data. These include:
|
(a)
|
the right to object to direct marketing;
|
(b)
|
the right (subject to certain exclusions) to receive a copy of Personal Data held by the Committee and the Company; and
|
(c)
|
from 25 May 2018, the following rights:
|
(i)
|
the right to be forgotten;
|
(ii)
|
the right to restrict the use of your Personal Data by the Company and the Committee;
|
(iii)
|
the right to object to the way your Personal Data is used; and
|
(iv)
|
the right to object to profiling and automated decision making.
|
10.
|
If you would like any further information about your rights or how to exercise them, you should contact Nina Nandelstaedt.
|
11.
|
If you are unhappy about the use of your Personal Data by the Company or the Committee, you may make a complaint to the Information Commissioner. Further information can be found at
https://ico.org.uk
.
|
Subsidiary
|
Jurisdiction
|
Venator Australia Pty Ltd
|
Australia
|
Venator Pigments Pty Ltd
|
Australia
|
Venator Belgium BVBA
|
Belgium
|
Venator Representação Comercial Brasil Ltda.
|
Brazil
|
Venator Group Canada Inc.
|
Canada
|
Venator Investments Ltd
|
Cayman Islands
|
Changshu Rockwood Pigments Co., Ltd.
|
China
|
Venator Pigments Taicang Company Ltd
|
China
|
Venator Shanghai Company Limited
|
China
|
Venator Far East Limited
|
Hong Kong, China
|
Venator Pigments Hong Kong Limited
|
Hong Kong, China
|
Venator P&A Finland Oy
|
Finland
|
Venator Chemicals France SAS
|
France
|
Venator France SAS
|
France
|
Venator International France SAS
|
France
|
Venator Pigments SAS
|
France
|
Silo Pigmente GmbH
|
Germany
|
Venator Germany GmbH
|
Germany
|
Venator Holdings Germany GmbH
|
Germany
|
Venator Pigments GmbH & Co. KG
|
Germany
|
Venator Pigments Holding GmbH
|
Germany
|
Venator Uerdingen GmbH
|
Germany
|
Venator Wasserchemie GmbH
|
Germany
|
Venator Wasserchemie Holding GmbH
|
Germany
|
Nuodex Italiana S.r.l
|
Italy
|
Venator Italy S.r.l.
|
Italy
|
Venator Pigments S.p.A.
|
Italy
|
Venator Finance S.à r.l.
|
Luxembourg
|
Pacific Iron Products Sdn Bhd
|
Malaysia
|
Venator Asia Sdn. Bhd.
|
Malaysia
|
Venator Africa Pty Limited
|
South Africa
|
Venator South Africa Proprietary Limited
|
South Africa
|
Mineral Feed, S.L.
|
Spain
|
Oligo S.A.
|
Spain
|
Venator P&A Spain S.L.U.
|
Spain
|
Venator Pigments España S.A.U.
|
Spain
|
Creambay Limited
|
U.K.
|
Excalibur Realty UK Limited
|
U.K.
|
Inorganic Pigments Limited
|
U.K.
|
Venator Group
|
U.K.
|
Venator Group Services Limited
|
U.K.
|
Venator Holdings UK Limited
|
U.K.
|
Venator International Holdings UK Limited
|
U.K.
|
Venator Investments UK Limited
|
U.K.
|
Venator Materials International UK Limited
|
U.K.
|
Venator Materials UK Limited
|
U.K.
|
Venator P&A Holdings UK Limited
|
U.K.
|
Venator Pigments UK Limited
|
U.K.
|
Venator Nominees UK Limited
|
U.K.
|
Venator Chemicals LLC
|
USA—North Carolina
|
Louisiana Pigment Company, L.P.
|
USA—Delaware
|
Venator Americas Holdings LLC
|
USA—Delaware
|
Venator Americas LLC
|
USA—Delaware
|
Venator Materials LLC
|
USA—Delaware
|
Viance, LLC
|
USA—Delaware
|
|
|
|
/s/ Simon Turner
|
|
Simon Turner
|
|
Chief Executive Officer
|
|
|
|
/s/ Kurt D. Ogden
|
|
Kurt D. Ogden
|
|
Chief Financial Officer
|
|
|
/s/ Simon Turner
|
|
Simon Turner
|
|
Chief Executive Officer
|
|
February 20, 2019
|
|
|
|
/s/ Kurt D. Ogden
|
|
Kurt D. Ogden
|
|
Chief Financial Officer
|
|
February 20, 2019
|
|